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Chapter 1
1 Atherosclerosis and cardiovascular disease
Atherosclerosis can be defined as a multifactorial, progressive disease of medium 
and large sized arteries which sets off already in childhood1 and is characterized 
by accumulation of lipid material and fibrous components in the artery wall2. 
Atherosclerosis is the pathophysiological cause of the majority of cardiovascular 
disease including myocardial infarction, angina pectoris and stroke. Most clinical 
complications are caused by plaque disruption and subsequent thrombus 
formation3,4. Its onset and progression was seen to associate with both environmental 
risk factors like smoking, high-fat diet and lack of exercise and factors with a strong 
genetic component like hypertension, hyperlipidemia, diabetes and male gender5-8. 
Therapies are mostly based on reducing these risk factors, such as lowering serum 
lipid levels using statins, lowering blood pressure and life style changes or consist of 
surgical intervention such as bypass surgery, percutaneous transluminal coronary 
angioplasty (PTCA) and stenting although the effectiveness of the latter interventions 
is often impaired by the recurrent narrowing of the vessel, a process referred to as 
restenosis9. Despite the available treatments, atherosclerosis continues to be one 
of the main causes of death in the world.
2 Pathogenesis of atherosclerosis
2.1	 Leukocyte	adhesion	and	migration
In the normal, healthy arterial wall the endothelium covers a layer of smooth 
muscle cells and produces various factors controlling vascular tone, cellular 
adhesion, thromboresistance, smooth muscle cell proliferation, inflammation of 
the vessel wall and vascular remodeling10. Atherosclerotic plaques start as fatty 
streaks at specific predilection sites within the arterial tree, such as bifurcations 
and branches1,2. The first step herein lies in dysfunction of the endothelium due to 
increased turbulence or decreased shear stress often combined with aspects of the 
above mentioned risk factors1,2. As a result the expression by endothelial cells of 
adhesion and inflammatory molecules, essential in the recruitment of leukocytes, 
is increased11. The initial tethering and rolling of circulating leukocytes (monocytes 
and lymphocytes) is mediated by selectins, L-selectin expressed on circulating 
leukocytes and P-selectin and E-selectin on the activated endothelium, resulting in 
further leukocyte activation12,13. Subsequently firm adhesion of leukocytes requires 
the engagement of β
1
 and β2 integrins, e.g. VLA4 and CD18/CD11, which interact with 
upregulated intracellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion 
molecule 1 (VCAM-1) expressed by endothelial cells14,15. Functional roles for ICAM-1 
and both E-selectin and P-selectin in atherogenesis have been confirmed by gene 
deletion studies in mouse models for atherosclerosis, the ApoE and LDLr deficient 
mouse16,17. Transmigration of leukocytes into the subendothelial space is the final 
step in plaque initiation, a process also known as diapedesis. Various endothelial 
cell expressed molecules facilitate transmigration, such as platelet/endothelial-cell 
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Figure	 1.	 Atherosclerotic	 plaque	 initiation. 
Selectins mediate the first cell-cell interactions 
enabling capture, tethering and rolling of 
circulating monocytes. Once captured, 
integrins (interacting with ICAM-1 and VCAM-
1) mediate the firm adhesion of monocytes 
to the endothelium after which they migrate 
into the subendothelial space along a 
chemokine gradient. Here they differentiate 
into macrophage under the influence of M-
CSF and increase the expression of scavenger 
receptors. Adapted from Li and Glass175.
adhesion molecule 1 (PECAM1), junctional adhesion molecule A (JAM-A), endothelial 
cell-selective adhesion molecule (ESAM), ICAM2 and CD9918-22. In addition to 
adhesion molecules chemokines are critically involved in the adhesion and migration 
of leukocytes23. Regarding lesion initiation chemokine receptor CCR2 and its ligand 
monocyte chemoattractant protein 1 (MCP1) are considered the most important. 
Deletion of MCP1 in LDLr-/- mice and (leukocyte) CCR2 in ApoE-/- or ApoE3 Leiden 
mice all resulted in significantly reduced atherosclerosis development24-26. Once 
migrated into the intima, monocytes differentiate into macrophages in response 
to macrophage-colony stimulation factor (M-CSF) secreted by endothelial cells and 
vascular smooth muscle cells (vSMC) and contribute to plaque progression2. Figure 
1 shows a schematic overview of the processes described above.
2.2	 Plaque	progression	and	instability
Fatty streaks do not cause clinical symptoms but may progress to more complex 
plaques. They are characterized by continuous influx of inflammatory cells 
(macrophages and lymphocytes) and lipids into the vessel wall. Low-density-
lipoprotein (LDL) within the intima can be modified by oxidation and aggregation27-
29. In turn, these modified LDL particles and entrapped cholesteryl esters can be 
taken up by macrophages which have increased expression of scavenger receptors 
due to M-CSF stimulation30. As a result of this progressive accumulation of lipids, 
macrophages will convert into foam cells. Differentiated macrophages and 
infiltrated T lymphocytes will augment the inflammatory response by secreting 
growth factors and cytokines31. Formation of a more complex fibroatheromathous 
lesion involves the migration of vSMC from the vessel wall into the intima and vSMC 
proliferation under the influence of growth factors secreted by endothelial cells and 
macrophages. VSMC synthesize the bulk of the extracellular matrix such as collagen, 
elastin and proteoglycans within the plaque in response to transforming growth 
factor (TGF) β and platelet derived growth factor (PDGF). VSMC and extracellular 
matrix proteins form a fibrous cap overlying the lipid core32. Augmentation of the 
inflammatory response, vSMC migration and formation of a fibrous cap cause the 
initial fatty streak to develop into an advanced atherosclerotic lesion narrowing the 
12
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Figure	2.Atherosclerotic	plaque	progression	from	
early	 atheroma	 to	 myocardial	 infarction.	 Early 
atheroma can progress into a stable fibrous 
plaque characterized by a small core and thick 
fibrous cap. Alternatively a vulnerable plaque 
develops with a large core containing lipids and 
cell debris, a high inflammatory cell content 
and a thin fibrous cap. Vulnerable plaques may 
rupture resulting in the formation of a thrombus. 
Ruptured plaques can either heal following vSMC 
migration and extracellular matrix production or 
result in myocardial infarction. Adapted from 
Watkins and Farrall176.
vessel lumen.  
As the atherosclerotic plaque progresses a necrotic core is formed consisting of 
accumulated lipids and cell debris derived from apoptotic or necrotic cells. Whereas 
stable advanced lesions have a dense fibrous cap overlying this necrotic core, the 
potentially dangerous plaques, responsible for the majority of clinical manifestations, 
are unstable as a result of cap thinning which makes a plaque vulnerable to 
rupture and thrombus formation33. Several factors contribute to the progressive 
destabilization and thrombogenicity of atherosclerotic plaques. A large lipid core34, 
accumulation of inflammatory cells35, extracellular matrix degradation36,37 and plaque 
cell death38,39 comprise the most important contributors. In addition intraplaque 
hemorrhage has been proposed to be a critical factor in plaque destabilization35. 
Fibrous cap thinning and plaque inflammation in regard to lesion progression and 
destabilization will be discussed in more detail in the following sections.
3 The role of vascular smooth muscle cells in atherosclerosis
Vascular smooth muscle cells (vSMC) are one of the major cellular constituents of the 
atherosclerotic plaque. Evidence shows that intimal vSMC differ from medial vSMC 
in many aspects. Medial vSMC are predominantly of the contractile phenotype while 
most intimal vSMC have characteristics of the synthetic, migratory phenotype. This 
phenotypic switch can be induced by a variety of atherogenic stimuli like cytokines, 
shear stress, reactive oxygen species (ROS) and lipids. Synthetic vSMC migrate and 
proliferate better than contractile vSMC and synthesize more collagen41. VSMC 
migration can be triggered by various growth factors and chemokines secreted by 
13
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macrophages and T cells like platelet derived growth factor (PDGF), fibroblast growth 
factor (FGF) and transforming growth factor (TGF) β, monocyte chemoattractant 
protein (MCP) 1 and stromal cell-derived factor (SDF) 1α1,42,43. 
VSMC, like macrophage, are able to ingest lipids and form foam cells. They 
express several receptors involved in (modified) lipoprotein uptake including 
the LDL receptor, CD36, type I and type II scavenger receptors and SR-PSOX44-47. 
Furthermore, adhesion molecules like vascular cell adhesion molecule 1 (VCAM-
1) and intercellular adhesion molecule 1 (ICAM-1) have been demonstrated to be 
expressed by vSMC, these may enable them to increase monocyte adherence and 
infiltration into the atherosclerotic lesion48. The mechanisms and consequences 
of adhesion of leukocytes to vSMC in vivo however are not well characterized. 
Furthermore, intimal vSMC have been reported to produce a wide variety of growth 
factors and cytokines, including PDGF, TGFβ, MIF and MCP-1, contributing to the 
pro-inflammatory environment of the atherosclerotic lesion41.
VSMC play a crucial role in fibrous cap formation and preserving plaque stability. 
Unstable plaques prone to rupture contain a higher macrophage and lipid content 
and a thinned fibrous cap due to loss of vSMC and extracellular matrix. The strength 
of the fibrous cap seems to depend on a balance between collagen synthesis and 
breakdown and on the type of collagen. Expression of genes promoting collagen 
synthesis by vSMC and of matrix metalloproteinases (MMPs), important in the 
breakdown of extracellular matrix, can be influenced by inflammatory cytokines49. 
For instance, TGFβ enhances the ability of vSMC to produce collagen, while TNFα, 
IL1 and IFNγ suppress collagen content either directly or by inducing MMPs50-52. In 
addition MMP expression was shown to be elevated in atherosclerotic plaque in 
comparison to normal vessels, a result of both inflammatory cytokine production and 
oxidative stress33. MMP activity is balanced by tissue inhibitors of metalloproteinases 
(TIMPs), MMP specific inhibitors expressed by vSMC. Expression of TIMPs can be 
either constitutive or upregulated by TGFβ and PDGF53.
Apart from MMPs, cathepsins which are cysteine proteases, can degrade the 
extracellular matrix54. Cathepsins are secreted by macrophages and their expression 
is increased in atherosclerotic lesions compared to healthy arteries55. Comparable 
with MMPs, cathepsin activity can be inhibited by a family of proteins, the cystatins 
of which cystatin C is best described. As opposed to cathepsins, expression of 
cystatin C is decreased in atherosclerotic lesions55,56.
Another role for vSMC may lay in the healing of fibrous cap breaks that remain 
subclinical. Mediators released at sites of thrombosis, for example PDGF and TGFβ 
released by platelets, can stimulate vSMC migration, mitogenesis and production 
of collagen, thus promoting a fibrous lesion morphology49. A thrombus caused by 
plaque rupture that doesn’t occlude the vessel is reorganized and incorporated 
into the plaque. Recurring incidents of plaque rupture and healing can be visible in 
plaques57,58. 
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4 Inflammation in atherosclerosis
Monocyte infiltration contributes largely to plaque initiation. Stimulation with M-
CSF secreted by endothelial cells and vSMC, causes the infiltrated monocytes to 
differentiate into macrophages and induces expression of scavenger receptors and 
cytokine production59-60. Macrophages are able to take up cell-activating modified 
LDL, mainly oxidized LDL (Ox-LDL) via several scavenger receptors including type 1 
and 2 scavenger receptor A (SRA), CD36, CD86, MARCO (macrophage receptor with a 
collagenous structure), SR-PSOX (scavenger receptor that binds phosphatidylserine 
and oxidized lipoprotein) and lectin-like oxidized low density lipoprotein receptor 1 
(LOX-1)61-65. Uptake of modified lipoproteins by scavenger receptors not only leads to 
the formation of foam cells but also results in macrophage activation. Subsequently, 
activated macrophages produce inflammatory cytokines, growth factors, proteases 
and reactive oxygen species influencing endothelial cell activation, vSMC migration, 
proliferation and collagen production and T cell activation35. Expression of scavenger 
receptors can be influenced by various cytokines present in the plaque including 
TNFα, IFNγ, IL4 and TGFβ66-68. TGFβ was shown to inhibit foam cell formation68.  
Uptake of modified lipoproteins via macrophage scavenger receptors can result in 
MHC restricted antigen presentation to T cells69. T cells are recruited into the lesion 
by mechanisms similar to the recruitment of monocytes. The majority of lesional 
T cells are CD4+ effector cells although CD8+ cells are present as well70. The role of 
lymphocytes in atherosclerosis has been studied using RAG-/- mice lacking T and B 
cells. In ApoE-/- mice lymphocyte deficiency results in the development of smaller 
lesions71,72 while transfer of CD4+ T cells into immunodeficient (scid/scid) ApoE-
/- mice aggravated atherosclerosis73. Several antigens have been associated with 
atherosclerosis. An important group of antigens consists of altered self molecules. 
T cells within the atherosclerotic lesions have been shown to respond to Chlamydia 
pneumoniae related antigens and stress-induced heat shock protein (HSP) 6070. 
Apart from Ox-LDL which is recognized by T cells present in human plaques74 
peptides derived from modified LDL components, for example apolipoprotein B 
and phospholipids can serve as antigens in atherosclerotic plaques70. CD4+ T cells 
can be subdivided in several T helper (Th) cell subsets based on their cytokine 
secretion profile, e.g. Th1 cells (which produce IFNγ and TNFα), Th2 cells (producing 
IL4, IL5 and IL13) and regulatory T cells (IL-10 and TGFbeta)70. Mouse and human 
studies have demonstrated a predominant pro-inflammatory Th1 cytokine pattern 
in atherosclerotic plaques75,76. IL2 and IFNγ were shown to be abundantly present 
whereas only small amounts of Th2 cytokines IL4 and IL5 have been found in 
plaques. Mouse studies have demonstrated that IL12 and IL18, both Th1 inducing 
cytokines, have pro-atherogenic properties77-81 as do Th1 cytokines IFNγ82,83 and 
TNFα 84,85, while the role of Th2 cytokines is less clear. IL4 was demonstrated to be 
atheroprotective78,86 but deficiency of IL5 increased atherosclerosis87.
Production of cytokines by macrophages and lymphocytes in the plaques does 
not only influence inflammatory processes but also modulates smooth muscle 
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cell activity. IFNγ inhibits smooth muscle cell proliferation88 and the production 
of collagen, whereas TGFβ stimulates collagen production89. In addition TGFβ 
downregulates the expression of MMPs, collagen degrading proteins90, while 
macrophages are stimulated to produce MMPs by TNFα and IL191. Finally TNFα 
and IFNγ can promote the uptake of modified lipoproteins by smooth muscle cells 
leading to smooth muscle cell derived foam cells92.
In addition to macrophages and T cells other inflammatory cell types have been 
demonstrated to be involved in atherosclerosis, including B cells, dendritic cells, 
mast cells and neutrophils. Although few B cells are present in the plaque the 
majority is located in the adventitia70. B cell associated immunity was shown to 
be protective in atherosclerosis as splenectomy increased plaque development 
in ApoE-/- mice while transfer of spleen derived B cells counteracted this effect93. 
Dendritic cells are the most potent antigen presenting cells. They are present in 
healthy vessels but accumulate during atherogenesis, being mainly localized in the 
rupture prone shoulder areas94. Skin dendritic cells have been shown to be activated 
by dislipidaemia with surprising inhibition of migration into lymph nodes suggesting 
that they contribute to local inflammation95. However a recent study by Packard et 
al.96 found opposing results. Here, dendritic cells were demonstrated to maintain 
their antigen presenting function and ability to prime CD4+ T cells in vitro under 
hypercholesterolemic conditions96. Mast cells are present in the atherosclerotic 
plaque and were shown to accumulate in the shoulder region97. Activated mast cells 
secrete cytokines and proteases and mast cell derived TNFα and IL6 were shown 
to promote atherosclerosis98. In addition mast cells have been demonstrated to be 
involved in intraplaque hemorrhage, macrophage apoptosis and vascular leakage, 
promoting plaque instability99. Neutrophils are thought to be pro-atherogenic as 
well. They are mainly present in the adventitia and the luminal area of mouse 
plaques100 and in ruptured human coronary artery plaques101. Depletion of circulating 
neutrophils resulted in reduced plaque formation in ApoE-/- mice100. 
5 Apoptotic cell death
5.1	 Signal	transduction	pathways
Removal of defective, damaged or dangerous cells is critical for normal development 
and tissue homeostasis of all organisms102. Death of these cells takes place via a 
process called apoptosis or programmed cell death103. Apoptosis is characterized 
by morphological changes like cell shrinkage, DNA fragmentation, condensation of 
chromatin and membrane blebbing. In contrast, features of passive, traumatic cell 
death or necrosis are cell swelling and loss of membrane integrity104. 
The executers of apoptotic cell death are a family of cysteine proteases known 
as caspases. Caspases proteolytically cleave proteins necessary for maintaining 
cellular structure like lamins105 and focal adhesions kinase (FAK)106 but also proteins 
that protect from cell death such as DFF45 (a nuclease inhibitor)107 and Bcl-2 family 
members108. A cascade of caspases in which a pro-apoptotic signal activates initiator 
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caspases (e.g. caspases 1, 8, 9 and 10) which in turn activate effector caspases 
(caspases 3, 6 and 7) results in cellular breakdown109. There are two signaling 
pathways regulating apoptosis that share the same effector caspases. The extrinsic 
or death receptor mediated pathway is activated in response to ligation of death 
receptors (fig. 3). Binding of specific ligands to the cognate death receptor causes 
formation of a death-inducing signaling complex (DISC) in which various adaptor 
proteins like FADD and TRADD interact with death domains (DD) of the receptors110. 
Initiator caspase 8 is essential for death receptor induced apoptosis111. Death 
receptors belong to the tumor necrosis factor (TNF) receptor family and include 
TNF receptor 1 (TNFR1), FAS, death receptor (DR) 3, DR4 and DR5. Their ligands are 
TNF family members, including Fas ligand, TNFα, TWEAK (TNF-like weak inducer of 
apoptosis) and TRAIL (TNF related apoptosis inducing ligand)110. 
The intrinsic apoptosis signaling pathway requires the involvement of members 
of the Bcl-2 (B cell lymphoma 2) family of apoptosis regulators and mitochondria. 
Apoptotic stimuli activating this pathway include DNA damage, UV radiation, hypoxia 
and growth factor withdrawal112. Apoptosis signaling via the intrinsic pathway 
depends on the release of cytochrome c and other apoptosis regulating proteins 
like Smac/Diablo and apoptosis inducing factor (AIF) from the mitochondria (fig. 
3). Once in the cytosol cytochrome c associates with an adaptor molecule called 
apoptotic protease-activating factor-1 (APAF-1) and pro-caspase 9 forming the so-
called apoptosome. The subsequently activated caspase 9 is then able to activate 
effector caspases113. 
5.2	 Bcl-2	family	of	apoptosis	regulators
The intrinsic apoptosis pathway is mainly regulated by proteins of the Bcl-2 family. 
This family consists of both pro- and anti-apoptotic proteins sharing one or more 
Bcl-2 homology (BH) domains114. Anti-apoptotic proteins contain three or four BH 
domains and include Bcl-2, Bcl-w, Bcl-x
L
, Bfl-1 and Mcl-1. There are two classes of pro-
apoptotic Bcl-2 family proteins: proteins of the multidomain group comprising Bax, 
Bak and Bok which contain BH domains 1-3 and Bcl-2 proteins which carry only the 
BH-3 domain. The latter BH-3 only proteins include Bid, Bad, Bik, Bim, Noxa, Puma, 
Bmf, Blk and Hrk114. BH-3 only proteins initiate the apoptotic cascade115, whereas 
Bax and Bak function downstream of BH-3 only proteins116. Bcl-2 family proteins Bak 
and Bax are thought to form pores in the outer mitochondrial membrane or change 
pore size thereby affecting of the mitochondrial permeability for cytochrome c113. 
Cytochrome c release from mitochondria takes place through these pores. Under 
non-apoptotic circumstances activity of BH3-only proteins is inhibited by Bcl-2 and 
other anti-apoptotic Bcl-2 proteins112. Following an apoptotic stimulus, BH-3 only 
proteins can either directly activate multidomain pro-apoptotic proteins (Bid and 
Bim) or interact with anti-apoptotic Bcl-2 proteins and prevent their binding to 
other pro-apoptotic proteins (Bim). Activity of BH3-only proteins can be regulated 
by phosphorylation (for example Bad and Bim117,118), transcriptional control (Puma 
and Noxa which are p53 targets119,120) or cleavage (Bid121). The pro-apoptotic protein 
17
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Figure	 3.	 Apoptosis	 pathways.	 The 
death receptor (extrinsic) pathway is 
activated by ligation of death receptors. 
Subsequently initiator caspases 
activate effector caspases resulting in 
cell death. BH3-only proteins (e.g. Bim) 
initiate the mitochondrial or intrinsic 
pathway after apoptotic stimuli like 
DNA damage and oxidative stress, 
followed by activation of multidomain 
pro-apoptotic proteins (Bak and Bax) 
which form pores in the mitochondrial 
membrane. Apoptotic signaling is 
regulated by anti-apoptotic bcl-2 
proteins (Bcl-2, Bcl-x
L
, Mcl-1 etc). Cell 
death results from effector caspase 
activation and subsequent release of 
cytochrome c and other regulatory 
proteins from the mitochondria. 
Adapted from Kutuk and Basaga112.
Bid, which functions in the intrinsic pathway, can also be activated by caspase-8 
after stimulation of the extrinsic apoptosis pathway, thereby connecting both 
pathways112. 
5.3	 Apoptotic	cell	clearance
Apoptosis is followed by uptake of cellular remnants by professional phagocytes, 
macrophages, dendritic cells and granulocytes122. A wide range of receptors, ligands 
and adaptor molecules on both apoptotic cells and phagocytes are involved in the 
removal of apoptotic cells. One of the best described molecules in the recognition 
of apoptotic cells is phosphatidylserine (PS), which is translocated from the inner 
to the outer leaflet of the cell membrane early in the apoptotic process123. Other 
molecules implicated in the recognition and engulfment of apoptotic cells include 
scavenger receptors CD36, CD68 and SRA, Mer kinase, CD14 and integrins on the 
phagocyte membrane and bridging molecules such as milk fat globule epidermal 
growth factor 8 (Mfge8) and complement component C1q122,124-127. When removal 
of apoptotic cells is insufficient apoptotic cells may undergo secondary necrosis 
with leakage of cellular content. This may have pathological consequences since 
secondary necrotic cells and their debris can be taken up by antigen presenting cells 
and result in inflammation and autoimmunity128. 
18
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6 Apoptosis and phagocytosis in the atherosclerotic plaque
Apoptosis occurs in atherosclerotic lesions affecting all major cell types, endothelial 
cells, macrophages, T cells and vSMC129. However, apoptosis increases with plaque 
progression, being virtually absent in initial lesions and increasingly present in 
advanced lesions130. Inducers of apoptotic cell death are abundant and include 
modified LDL, reactive oxygen species, cytokines with pro-apoptotic activity, hypoxia 
and death receptor ligation (Fas, TNFR1 and 2, DR4 and DR5)131-137.
6.1 Endothelial cell apoptosis
Endothelial injury and apoptosis are late events in atherosclerosis138. Endothelial 
cells in lesion-prone regions in the vasculature have increased turnover due to 
increased apoptosis139. In endothelial cells in regions predisposed to atherosclerotic 
lesion development NF-κB signal transduction pathway was shown to be primed 
for activation140 and NF-κB activation by various stimuli like hypoxia, IL18 and TNFα 
has been demonstrated to trigger apoptosis in endothelial cells141-143. Apoptosis is 
stimulated by exposure to oxidized LDL and oxidative stress among other factors. 
Nitric oxide (NO) may play a role in endothelial cell apoptosis in atherosclerosis 
as well. In healthy arteries NO derived from endothelial NO synthase (eNOS) 
acts protective against apoptosis144. In atherosclerotic lesion prone regions eNOS 
expression is decreased145. In addition, atherosclerotic plaque macrophages 
produce high amounts of inducible NOS (iNOS) which can generate peroxynitrite 
contributing to oxidative stress146 which in turn can induce DNA damage and 
subsequent apoptosis in endothelial cells138. EC injury and apoptosis can have 
various consequences. Induction of EC apoptosis may promote thrombus formation 
followed by plaque erosion and leukocyte infiltration147,148.
6.2 Vascular smooth muscle cell apoptosis
Apoptosis of vSMC has been shown to occur after injury in a rabbit balloon angioplasty 
model149, in human abdominal aortic aneurisms150 and in atherosclerotic lesions21. 
Surprisingly apoptosis of vSMC in atherosclerotic plaques can induce inflammation 
as shown in vivo in rat carotid arteries151 where it triggered IL8 and MCP-1 expression 
together with massive macrophage infiltration after vSMC death. In ApoE-/- mice in 
which apoptosis was specifically induced in vSMC by diphtheria toxin (SM22α-hDTR 
/ ApoE-/- mice) increased inflammation was observed after vSMC apoptosis as well152. 
Furthermore, vSMC apoptosis has been shown to lead to thrombin generation153 
and calcification154 in vitro. In human atherosclerotic lesions apoptosis of both vSMC 
and macrophages was demonstrated to be elevated only in advanced lesions while 
in early lesions apoptosis was minimal130. In addition, human vSMC derived from 
coronary atherosclerotic plaques were shown to be more susceptible to cell death 
than vSMC from healthy coronary arteries in vitro155 and vSMC may exhibit increased 
oxidative stress induced senescence156. VSMC senescence following ROS induced 
19
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DNA damage was shown to be mediated by p53 activation156. Abovementioned 
studies seem to support the general concept that apoptosis of vSMC promotes plaque 
vulnerability by thinning of the fibrous cap and also various studies in mice are in 
agreement with this concept. Induction of apoptosis by targeted overexpression of 
p53 into cap smooth muscle cells in advanced collar induced carotid artery plaques 
in ApoE-/- mice resulted in increased apoptosis of cap cells, reduced cap thickness, 
and in general a vulnerable plaque phenotype which was prone to phenylephrine 
induced rupture157. A comparable, vulnerable plaque phenotype was found after 
adenovirus mediated overexpression of the pro-apoptotic TNF family member 
Fas ligand in cap cells of ApoE deficient mice158. Plaques contained hemorrhage, 
buried caps and iron deposits, also indicating increased vulnerability. Recently, the 
above mentioned SM22α-hDTR / ApoE-/- mice were used to examine the impact 
of vSMC apoptosis on plaque phenotype and disease progression152,159. Induction 
of apoptosis in established atherosclerotic plaques resulted in plaque vulnerability 
as indicated by fibrous cap thinning, loss of collagen, accumulation of cell debris 
and increased inflammation152. In addition, persistent vSMC apoptosis throughout 
plaque development was seen to accelerate atherogenesis159. 
6.3 Macrophage apoptosis
Macrophage apoptosis occurs in both early and late stages of atherosclerosis 
and can be induced by a variety of stimuli including oxidized LDL, oxysterols, free 
cholesterol and hypoxia but also TNFα160. Apoptosis of macrophages has been 
demonstrated to be beneficial in early atherogenesis in several in vivo studies161-
164. Inhibition of macrophage apoptosis due to leukocyte p53 deletion in ApoE3 
Leiden transgenic mice161 or LDLr-/- mice162 and leukocyte Bax deletion in LDLr-/- 
mice163, both pro-apoptotic factors, resulted in increased atherosclerotic lesion size. 
In addition deletion of pro-survival factor AIM (apoptosis inhibitor expressed by 
macrophages) in LDLr-/- mice led to increased macrophage apoptosis and decreased 
lesion area164. The consequences of macrophage apoptosis in advanced lesions 
are less clear. In advanced human lesions clearance of apoptotic cells was shown 
to be defective165, suggesting that macrophage apoptosis will lead to secondary 
necrosis and accumulation of cell and lipid debris. This will translate in necrotic 
core expansion and elicit a pro-inflammatory response which could result in 
promotion of plaque instability160. However, others did not find such pronounced 
effects of macrophage apoptosis in advanced atherosclerotic plaques. For instance, 
Stoneman et al.166 developed a model in which in ApoE-/- mice apoptosis could be 
induced specifically in macrophages with diphtheria toxin (DT), the CD11b-hDTR 
/ ApoE-/- mouse166. Induction of apoptosis during early atherogenesis resulted in 
decreased plaque development together with reduced collagen content and 
necrotic core formation, confirming the atheroprotective effects of macrophage 
apoptosis in aforementioned studies regarding early atherogenesis. However in 
established plaques DT treatment induced macrophage apoptosis but this did not 
result in alterations in plaque size, cell composition or inflammation. In another 
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study macrophage apoptosis was achieved by LysM cre induced deletion of Bcl-2 
in ApoE-/- mice167. Increased macrophage apoptosis was observed after 10 weeks 
of western type diet feeding but this resulted in a slight increase of 25% in necrotic 
core size only in female mice. No other characteristics of enhanced plaque instability 
were observed.
6.4	 Phagocytosis	of	apoptotic	cells
Phagocytosis of apoptotic cells in the atherosclerotic plaque limits plaque 
progression, inflammation and plaque instability as has been demonstrated by 
several gene deletion studies. Deficiency of leukocyte transglutaminase 2 (TG2) in 
LDLr-/- mice was seen to increase aortic valve lesion size and intimal macrophage 
infiltration168. LDLr-/- mice deficient in milk fat globule-EGF factor 8 (Mfge8) show 
accelerated atherosclerosis with increased necrotic core size and an elevated 
inflammatory status169. Finally, deletion of leukocyte Mer kinase in LDLr-/- mice 
led to increased accumulation of apoptotic cells, increased macrophage area and 
lymphocyte infiltration resulting in accelerated lesion development170. 
As mentioned in the previous section, phagocytic clearance of apoptotic cells is 
impaired at later stages of plaque progression165. Several mechanisms for defective 
phagocytosis have been proposed. First, Ox-LDL shares molecules involved in 
recognition by macrophages with apoptotic cells and as a result may compete with 
apoptotic cells for ingestion171,172. In addition auto-antibodies directed against Ox-LDL 
have been demonstrated to bind to apoptotic cells and inhibit their phagocytosis by 
macrophages173. Finally oxidative stress may inhibit the phagocytosis of apoptotic 
cells by macrophages as has been demonstrated in vitro for the oxidative stress 
mediators hydrogen peroxide (H2O2)174 and peroxynitrite165. 
7 Thesis outline
In this thesis the role of several apoptosis regulating proteins in the development of 
atherosclerosis and atherosclerotic plaque stability is investigated. As many of these 
proteins also display immune-modulating features, we have particularly investigated 
effects of modulation of apoptosis regulating proteins on plaque and systemic 
inflammation. In chapter 2 current knowledge on pro- or anti-apoptotic proteins 
and their effects on inflammation in both murine and human atherosclerosis as well 
as the influence of pro- or anti-inflammatory mediators on apoptotic processes are 
reviewed. 
Chapter 3 describes a study in which gene expression profiles of thin cap 
fibroatheroma are compared to those of thick cap fibroatheroma by micro-array 
technology in order to identify genes or pathways that are associated with plaque 
vulnerability. Two different mouse models for thin cap fibroatheroma are used to 
increase the significance of the findings.
In chapter 4 the relevance of Bim (Bcl-2 interacting mediator of cell death), a pro-
apoptotic member of the Bcl-2 family identified as upregulated in both models in 
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the previous chapter, for atherosclerosis is investigated in LDLr-/- mice. Bim has been 
previously demonstrated to be an important regulator of B and T cell homeostasis. 
Therefore, apart from apoptotic processes relevant for atherosclerosis, we also 
assessed the role in disease associated innate and adaptive immunity. The pro-
apoptotic activity of Bim is partly regulated by Mcl-1 (myeloid cell leukemia 1), 
an anti-apoptotic member of the Bcl-2 family. Mcl-1 is amongst others involved 
in proliferation and differentiation of monocytes and neutrophils and has been 
implicated in lipid accumulation by macrophages. In chapter 5 we therefore studied 
the impact of Mcl-1 deletion on cell death, lipid accumulation and inflammatory 
status of LDLr-/- mice.
Chapter 6 describes a study addressing the role of focal adhesion kinase (FAK), a 
kinase not only involved in cell death and proliferation, but particularly important 
in cell adhesion and migration, in atherosclerosis development and progression in 
ApoE-/- mice. Recently, FAK was shown to be involved in oxidized LDL mediated CD36 
signaling. Thus,  in chapter 6 the role of FAK in plaque apoptosis, inflammatory 
status and lipid metabolism in Western type diet fed ApoE-/- mice was investigated.
To conclude, in chapter 7 the main findings of the studies described in this thesis are 
summarized and discussed in relation to possible therapeutic approaches.
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Abstract
Inflammation and apoptosis are regarded key processes in the development, pro-
gression and instability of atherosclerotic plaques. Although originally considered 
anti-inflammatory, recent insights promote the notion that apoptosis may under 
conditions prevalent in atheromathous tissue promote inflammation. Vice versa 
several pro-inflammatory mediators that contribute to atherogenesis can have pro- 
or anti-apoptotic effects. In this review we shall describe recent advances in our 
understanding of the crosstalk between apoptotic and inflammatory signaling pa-
thways in the context of atherosclerosis.
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1 Introduction
Immunoregulatory	effects	of	cell	death
Cells can die through two major processes, traumatic cell death (“necrosis”) 
and or programmed cell death (“apoptosis”). Features of necrotic cell death are 
cell swelling and loss of membrane integrity, whereas apoptosis is characterized 
by a completely different repertoire of morphological changes including cell 
shrinkage, DNA fragmentation and membrane blebbing1. Necrosis will elicit a 
pro-inflammatory response. In contrast, apoptotic cells maintain their membrane 
integrity and in addition are readily taken up by phagocytes including macrophages 
and dendritic cells. Both measures will prevent the release of cell contents and as 
a result, apoptotic death generally does not cause an inflammatory response. In 
fact, apoptotic cells and phagocytes ingesting apoptotic remnants both can act anti-
inflammatory by secreting transforming growth factor β1 (TGFβ1), interleukin (IL) 10 
and prostaglandin E2 (PGE2) and by decreasing the secretion of pro-inflammatory 
cytokines such as TNF-α, IL1 and IL122,3,4,5. However, recent studies have shown that 
apoptosis not always acts inflammation-neutral or anti-inflammatory (for reviews 
see 6 and 7). For example, various inducers of apoptosis, among which Fas, can 
influence cytokine secretion or immune cell behaviour8. Adequate elimination of 
apoptotic remnants to prevent secondary necrosis and the ensuing pro-inflammatory 
response is therefore of great importance. 
Inflammation	and	apoptosis	in	atherogenesis
Atherosclerosis, a chronic inflammatory disease, is initiated by endothelial 
dysfunction and accumulation of lipoprotein and low-density lipoprotein (LDL) 
derived lipids in the vessel wall. Expression of adhesion molecules in the endothelium 
results in adherence and migration of T lymphocytes and monocytes into the intima, 
after which monocytes differentiate into macrophages9. Intimal leukocytes release 
a whole range of pro- and anti-inflammatory cytokines, chemokines and growth 
factors10. Moreover reactive oxygen species (ROS) are generated in the intima, 
which act pro-apoptotic on the one hand and modify (phospho)lipids and LDL 
promoting foam cell formation on the other hand11. Modified LDL can also cause 
further endothelial activation and dysfunction10. Furthermore lesional vSMC are 
also able to take up lipids to form foam cells and secrete adhesion molecules and 
cytokines, thereby contributing to inflammation12.	
The relevance of apoptosis to plaque progression and instability has been established 
in numerous studies. Clearly, both rate and consequences of apoptotic cell death 
are dependent on the actual cell type and on lesion stage. VSMC apoptosis increases 
with plaque progression. Differences in expression patterns of pro- or anti-apoptotic 
proteins and survival cytokines like decreased insulin-like growth factor 1 (IGF-1) 
and increased p53 levels and alterations in expression of Bcl-2 family members 
may cause increased sensitivity of intimal vSMC to apoptosis compared to medial 
vSMC13. In murine atherogenesis persistent apoptosis of vSMC was seen to result in 
accelerated lesion development14 and both persistent vSMC apoptosis and induction 
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of vSMC apoptosis in established lesions leads to plaque vulnerability as indicated 
by increased necrotic core and fibrous cap thinning14,15. In addition, in established 
lesions increased intimal inflammation was detected15. 
Macrophage death occurs at all stages of atherosclerotic lesion development16, 
although in human lesions macrophage death was elevated mainly in advanced 
lesions compared to healthy vessels17. Apoptosis of macrophages can be induced 
by various stimuli present in the plaque including reactive oxygen species (ROS), 
oxidized LDL (ox-LDL), free cholesterol, TNF-α and Fas ligand16. Experimental 
studies in mice revealed that macrophage apoptosis may be beneficial in early 
atherosclerosis, limiting lesion size and cellularity. On the contrary in late stage 
atherosclerosis macrophage death leads to increased lesion size and necrotic core 
expansion. The latter is possibly attributable to insufficient removal of apoptotic 
cells and resulting secondary necrosis. Apoptosis of the various plaque cell types in 
atherosclerosis and its consequences for lesion progression and stability has been 
extensively reviewed elsewhere13,16,18. Recent studies, which be will reviewed here, 
suggest that several apoptotic proteins are involved in inflammatory processes 
while inflammatory mediators can influence apoptosis and that the association of 
apoptosis and inflammation might be of great significance in atherosclerotic lesion 
progression and stability. This review will discuss this link between apoptosis and 
inflammation in the context of atherosclerosis elaborating on pro-inflammatory 
effects of plaque cell apoptosis on the one hand and on pro- or anti-apoptotic 
effects of the foremost inflammatory mediators in atherosclerotic lesions on the 
other hand.
2 Immunomodulatory effects of intraplaque apoptosis
2.1	Inflammatory	consequences	of	apoptotic	protein	activity
2.1.1	Apoptosis	inducing	TNF	family	proteins
Fas/Fas ligand
Fas (CD95) is a death receptor of the TNF receptor super family that stimulates cells 
to undergo apoptosis after ligation of Fas ligand. The Fas /Fas ligand system is key 
to the elimination of immune cells (T cells) and thus in the regulation of adaptive 
immune responses. In fact lpr en gld mice, which have inactivating mutations in Fas 
and Fas ligand respectively, both develop autoimmune disease very reminiscent of 
lupus erythematosis with overt lymphadenopathy and splenomegaly19,20. 
In several studies Fas triggered apoptosis has been implicated in neointima formation 
and atherogenesis. Adenoviral Fas ligand gene delivery inhibit neointima formation 
in balloon-injured rat carotid arteries21, while in advanced atherosclerotic lesions 
it reduced the number of vSMC in the cap inducing intraplaque hemorrhage and 
buried cap formation. Moreover overexpression in carotid artery plaques was seen 
to promote leukocyte adhesion, endothelial leakage and intraplaque bleeding22. 
Several other studies have explored the impact of Fas function in atherosclerosis on 
inflammatory status. Yang et al23 describe that Fas induced apoptosis of endothelial 
cells has anti-inflammatory properties. Transgenic mice overexpressing Fas ligand 
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on vascular endothelial cells showed decreased plaque macrophage and CD8+ T cell 
content and overall decreased aorta lesion size23. Conversely Fas signaling in vSMC 
had rather pro-inflammatory effects. Overexpression of inducible Fas-associated 
death domain (FADD), a downstream signal transducer of Fas, in a rat vSMC line 
increased apoptosis23. Seeding of these FADD overexpressing vSMC on rat carotid 
arteries led to Fas ligand induced intimal vSMC apoptosis resulting in MCP-1 and IL-8 
secretion and monocyte recruitment to adventitia and neointima. The link between 
auto-immune disease and atherosclerosis has been addressed in Fas ligand defective 
gld mice, backcrossed to ApoE-/- mice. gld.ApoE-/- double transgenics not only had 
increased atherosclerotic lesion size and apoptotic cell content compared to Apo- 
E-/- mice, but also increased lymphadenopathy, splenomegaly and formation of auto-
antibodies compared to gld mice25, implying that autoimmune effects associated 
with Fas ligand deficiency is exacerbated by the proinflammatory milieu in Apo- 
E-/- mice. Finally, Fas has been implicated in oxidative stress and ox-LDL induced cell 
death26. Ox-LDL induced apoptosis of T lymphocytes has been demonstrated to be 
preceded by an increased expression of Fas and membrane associated and soluble 
Fas ligand, and apoptosis could be inhibited by blocking of the Fas/Fas ligand dyad26. 
The relevance of Fas signaling for oxidative apoptosis in atherosclerosis is illustrated 
by colocalisation of TUNEL positive apoptotic cells in human carotid plaques with 
Fas expression on T cells and that of Fas ligand on macrophages. Interestingly both 
cell types showed increased iNOS expression, implicating Fas in iNOS induced cell 
death27.
The above mentioned studies identify Fas as an important factor in atherosclerotic 
lesion apoptosis, including Ox-LDL and ROS induced cell death, of several cell types 
while both pro- and anti-inflammatory effects have been reported.
TRAIL
TNF related apoptosis inducing ligand (TRAIL), another member of the TNF super 
family, was originally described as a protein inducing apoptosis exclusively in 
transformed and infected cells. TRAIL acts by binding to signaling (i.e. death receptors 
or DR’s) and non-signaling receptors (osteoprotegerin and decoy receptors) and 
displays both pro-apoptotic and immunoregulatory capacity28. TRAIL expression 
on immune cells is upregulated in response to type I interferons IFNα and IFNβ29. 
IFNα induced TRAIL upregulation on T cells has also been shown in atherosclerotic 
lesions via colocalization. The enhanced TRAIL expression enabled these T cells 
to induce apoptosis in coronary SMC30. TRAIL colocalizes with CD3 and ox-LDL in 
human stable lesions with increased expression in vulnerable plaques31. Secchiero 
et al32 showed that systemic adenoviral TRAIL delivery reduces atherosclerotic lesion 
size in diabetic ApoE-/- mice, while increasing apoptosis of infiltrating macrophages 
within the lesion and increasing plaque vSMC content.
CD40
CD40 and CD40 ligand (CD154) are expressed by all cell types of human atherosclerotic 
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lesions. CD40 activation acts proliferative and pro-apoptotic and stimulates the 
secretion of pro-inflammatory cytokines and chemokines33. Genetic or antibody 
based CD40 signaling blockage decreased atherosclerotic lesion size in ApoE-/- and 
LDLr-/- mice34,35 and led to a more stable phenotype35. Leukocyte CD40 ligand deletion 
however did not affect lesion size at all36 suggesting that pro-atherogenic activity 
of CD40 ligand can be attributed to non-hematopoietic cells. This is supported by 
the finding that human umbilical vein endothelial cells (HUVECs) stimulated with 
CD40 ligand undergo massive apoptosis along with VCAM-1 and ICAM-1 release37, 
suggesting that stimulation of CD40 on endothelial cells may promote monocytes/
macrophages recruitment and thereby lesion development. 
TWEAK
TNF-like weak inducer of apoptosis (TWEAK) has various biological functions including 
induction of inflammation, activation of cell growth, and stimulation of apoptosis 
upon binding its receptor Fn1438. Fn14 and TWEAK are expressed by macrophages, 
foam cells and smooth muscle cells in human carotid atherosclerotic plaques and 
in human aortic SMC39,40. Fn14 expression is upregulated after stimulation with 
IL1β and IFNγ39, and TWEAK induced pro-inflammatory cytokines IL-6, MCP-1 and 
IL-8 in THP-1 human macrophages40, suggesting that this pro-apoptotic TNF family 
member may function in apoptosis and inflammation in atherosclerotic plaques. 
Experimental proof to support this is lacking to date.
2.1.2	Bcl-2	family
Bcl-2 family members, which can be either pro- or anti-apoptotic, are the major 
regulators of both extrinsic and intrinsic apoptosis signaling pathways. In the 
vasculature these proteins are expressed in all major cell types and regulate 
apoptosis in response to oxidation and inflammation. Expression of Bcl-2 family 
members has been studied in human carotid endarterectomy samples showing 
increased expression of pro-apoptotic Bax and Bak in lipid laden macrophages, 
vSMC and apoptotic cells, absence of anti-apoptotic Bcl-2 and Bcl-XL in apoptotic 
cells and expression of the latter in non-apoptotic vSMC. Expression patterns of Bcl-
2 family members in atherosclerotic lesions have been reviewed in detail by Kutuk 
and Basaga41.
Inhibition of Bcl-XL by antisense oligonucleotides was shown to induce apoptosis 
in intimal cells of rabbit vascular lesions, an effect that was absent in medial SMC 
and in control vessels. Increased apoptosis led to a reduction in intimal lesion size42. 
Bax is another Bcl-2 family member which has been studied in an atherosclerotic 
mouse model. Liu et al showed reduced macrophage apoptosis in hematopoietic 
LDLr-/- chimeras with Bax deficiency leading to an increase in atherosclerotic lesion 
size in the aorta43.
Increasing evidence indicates that Bcl-2 family members are involved in apoptosis 
induced by ROS, Ox-LDL, and inflammation. Ox-LDL induced apoptosis in U937 
human monocytes and in human differentiated endothelial progenitor cells was 
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shown to involve ROS generation with concomitant mitochondrial Bax translocation 
and activation44,45. Translocation of Bax from cytoplasm to mitochondria in these cells 
could be inhibited by Bcl-2 overexpression, which did not prevent ROS generation 
suggesting that Bax acts downstream of ROS44. In endothelial cells Bax activation 
and translocation was mediated by an increase in p5345. Similarly minimally oxidized 
LDL induced apoptosis in human coronary endothelial and vSMC was mediated 
by Fas and TNF receptor domains and, in endothelial cells, accompanied by an 
increase in pro-apoptotic Bad and a decrease in anti-apoptotic Bcl-246. In addition, 
activation of Bim and Bad and downregulation of Bcl-XL was observed in oxysterol 
(25-hydroxycholesterol and 7-ketocholesterol) induced cell death in P388D1 murine 
macrophages, probably by promoting AKT degradation47. Finally Badrichani et al 
showed that Bcl-2 and Bcl-XL overexpression not only protects bovine aortic EC’s 
from TNFα induced apoptosis but also inhibits TNFα dependent upregulation of 
pro-inflammatory genes like E-selectin and IL-8 by inhibiting NF-κB48. 
Bcl-2 family members appear to be involved in apoptosis signaling pathways induced 
by both pro-apoptotic proteins and inflammatory mediators Ox-LDL and ROS and in 
addition are able to affect inflammatory responses in vascular cells.
2.1.3 P53 and p21
Tumor suppressor p53 is a key regulator of cellular homeostasis exerting various 
functions such as cell-cycle arrest, senescence, differentiation and apoptosis. 
Downstream regulators of p53 in apoptosis and survival include Bax, NOXA, 
PUMA, PTEN, Fas, DR5 and p2149. Vascular p53 expression was reported to be 
increased in advanced atherosclerosis. Various studies have been undertaken to 
elucidate the role of p53 in atherosclerosis investigating the effect of (cell type 
specific) p53 deficiency and p53 overexpression on lesion development in animal 
models (reviewed in 50). From these data p53 function in atherosclerotic lesion 
appears to be complex and stage-, context- and cell-dependent. For instance p53 
protected from apoptosis and stimulated proliferation in atherosclerotic lesions in 
one study51, whereas its overexpression in advanced atherosclerosis was seen to 
promote vSMC apoptosis and destabilize plaques52. In macrophages p53 induced 
apoptosis. Generally, deficiency of p53 increased atherosclerotic lesion size50. 
Recently p53 was implicated in Ox-LDL induced apoptosis in endothelial cells via 
the pro-apoptotic Bcl-2 member Bax45. Ox-LDL led to activation and mitochondrial 
translocation of Bax and subsequent apoptosis, processes that could be prevented 
by siRNA induced p53 knockdown. Earlier, induction of apoptosis by mildly oxidized 
LDL in human coronary endothelial and vSMC has also been shown to increase 
p53 expression together with that of multiple other pro-apoptotic proteins53. In a 
human colorectal cancer cell line (DLD-1) p53 induced apoptosis was preceded by 
increased expression of several ROS generating genes54, identifying p53 as a pro-
oxidant factor. In comparison, relatively low levels of p53 were able to protect DNA 
from oxidation and damage by ROS55.
An important p53 target, p21 cyclin-dependent kinase inhibitor, also known as WAF1 
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and CIP1, can upon activation inhibit apoptosis49. Recombinant p21 was reported 
to inhibit lymphocyte proliferation and expression of pro-inflammatory cytokines 
IL2, TNFα and IFNγ56 as well. Adenoviral gene delivery of p21 into balloon injured 
porcine arteries inhibited the development of intimal hyperplasia57. In addition, 
overexpression of a p21 mutant with increased biological activity, reduced restenosis 
in ApoE-/- mice58. This was attributed to attenuated vSMC proliferation and macrophage 
infiltration and increased apoptosis of vascular cells. In contrast, both systemic and 
leukocyte p21 deficiency in ApoE-/- mice protected against atherosclerosis and led 
to increased apoptosis rates. In these mice systemic p21 deficiency reduced VCAM-
1 expression59. Furthermore p21 deficient peritoneal macrophages expressed lower 
levels of pro-inflammatory cytokines such as macrophage inflammatory proteins 
(MIP) 1 and 2 and displayed increased phagocytosis of apoptotic cells. 
The role of p53 in atherosclerotic lesions is stage-, context- and cell-dependent. P53 
is implicated in apoptosis induced by various factors like Ox-LDL and ROS involving 
different Bcl-2 family members as well. Several studies indicate that p53 responsive 
protein p21, like p53, has a complex role in atherogenesis.
2.2	Phagocytosis	of	apoptotic	cells
Apoptotic cell death was originally considered to be immunologically neutral or anti-
inflammatory6. In general apoptotic cells are rapidly removed by phagocytes such 
as macrophages and dendritic cells, which is mediated by dedicated eat-me signals 
including phosphatidyl serine (PS) exposure on the surface of apoptotic cells. 
Various molecules participate in recognition and engulfment of apoptotic cells 
including CD14, TG2, calreticulin, Mer receptor tyrosine kinase, lactadherin, 
complement components (C1q, CR3 and CR4), integrins and scavenger receptors 
CD36, CD68 and SRA60-64. Although considerable redundancy in uptake and signaling 
mechanisms exists, these mechanisms may differ between the various phagocytic 
cells. Moreover inflammatory responses after apoptotic cell recognition and uptake 
may depend on specific receptors and proteins implicated as demonstrated in 
knockout mouse models60,61,65-67.
Anti-inflammatory effects are attributable to the apoptotic cells themselves as 
well as to the remnant ingesting phagocytes61. For example phagocytic DC’s exhibit 
decreased secretion of the pro-inflammatory cytokine TNFα after exposure to 
apoptotic cells68 but secretion of anti-inflammatory mediators like TGFβ, IL10, and IL1 
receptor antagonist is promoted61. In addition apoptotic lymphocytes were shown 
to release TGFβ61.  Apoptotic cell death can also be pro-inflammatory. For example 
Fas induced apoptosis in vivo resulted in hepatic inflammation and neutrophil 
recruitment8. Furthermore, apoptotic cells may undergo secondary necrosis when 
not readily cleared by phagocytes, to subsequently evoke an inflammatory response. 
Figure 1 shows potential immunomodulatory effects of apoptotic cell death.
Defective phagocytosis by plaque macrophages has been demonstrated by Schrijvers 
et al 69. Analysis of human endarterectomy samples revealed a higher ratio of free 
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to phagocytised apoptotic cells when compared with human tonsils69. Tabas has 
postulated the hypothesis that in early lesions phagocytotic capacity is sufficient 
to clear cellular debris implying that macrophage apoptosis will result in decreased 
lesion progression. In more advanced lesions phagocytosis is impaired, which not 
only dampens immunoregulatory feedback normally observed after phagocytosis 
but also favors proinflammatory secondary necrosis promoting lesion progression 
and instability16.
The relevance of phagocytosis to atherosclerosis was subject to various recent 
studies. Aprahamian et al 25 observed that the induced atherogenic response in 
Fas ligand deficient gld.ApoE-/- mice was associated with decreased apoptotic cell 
clearance and increased macrophage and lymphocyte infiltration. Even deficiency of 
ApoE itself may already affect phagocytosis70. In vitro ApoE deficient macrophages 
ingest less apoptotic thymocytes and in ApoE-/- mice apoptotic macrophage content 
is increased in various tissues compared with wild-type mice resulting in a pro-
Figure	1.	Modulation	of	inflammatory	response	through	apoptotic	cells	and	phagocytosis. Phagocytosis 
of apoptotic cells generally results in an anti-inflammatory response via increased release of anti-
inflammatory molecules and inhibition of that of pro-inflammatory molecules by both apoptotic cells 
and phagocytes. However, apoptosis and subsequent phagocytosis can also be pro-inflammatory. A 
number of receptors and factors involved in apoptotic cell recognition and engulfment were shown 
to be associated with activation of pro- as well as with anti-inflammatory pathways, suggesting that 
a shifted pattern of apoptotic cell handling will translate in an altered inflammatory profile. Defective 
engulfment of apoptotic cells may lead to secondary necrosis. In contrast to apoptotic cells necrotic 
cells lose membrane integrity and their cellular content is released resulting in a pro-inflammatory 
response. TGFβ, transforming growth factor β; IL, interleukin; TNFα, tumor necrosis factor α; IL1RA, 
interleukin 1 receptor antagonist; PGE2, prostaglandin E2; PAF, platelet activating factor; NO, nitric 
oxide; DC, dendritic cell.
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inflammatory state as witness the elevated plasma TNFα levels in the former mice.
One of the first macrophage receptors to be implicated in phagocytosis of apoptotic 
remnants is CD36, a class B scavenger receptor61. Ox-LDL, an established substrate 
for this receptor, was suggested to compete with apoptotic cells for ingestion 
by macrophages71,72. In keeping Khan et al 73 reported impaired uptake but not 
binding of apoptotic vSMC and fibroblast by thioglycolate elicited mouse peritoneal 
macrophages in the presence of excess Ox-LDL. In addition, release of IL6 and 
MCP-1, inhibited by phagocytosis without Ox-LDL, was no longer suppressed72. A 
similar apoptotic cell engulfment reducing effect of Ox-LDL was noted in peritoneal 
macrophages by Schrijvers et al 71. Interestingly, minimally modified LDL, although 
not recognized by scavenger receptors, also can inhibit phagocytosis of apoptotic 
cells by binding to CD14, while increasing uptake of Ox-LDL73. Altogether these 
studies suggest partially shared but non-identical recognition sites for Ox-LDL and 
apoptotic cells. A second mechanism underlying the impaired apoptotic cell handling 
in atherosclerosis may involve Ox-LDL targeted auto-antibodies, which are present 
in both human and murine atherosclerotic lesions. These auto-antibodies were 
shown to bind to apoptotic cells and inhibit their phagocytosis by macrophages74. 
The role of several key genes in apoptotic cell removal on vascular disease 
progression has been recently addressed. Deficiency of leukocyte transglutaminase 
2 (TG2), which mediates apoptotic cell uptake and TGFβ secretion by macrophages62, 
in LDLr-/- mice was seen to increase aortic valve lesion size and intimal macrophage 
penetration65. In another study the effect of leukocyte milk fat globule-EGF factor 
8 (also known as Mfge8 or lactadherin) deficiency was assessed on atherogenesis 
in LDLr-/- mice66. Mfge8 binds to PS exposed by apoptotic cells and enhances their 
uptake by macrophages63. Atherosclerosis was accelerated in Mfge8-/-LDLr-/- mice 
and, importantly, lesions showed larger necrotic cores. In addition, Mfge8 deficiency 
appeared to favor proatherogenic Th1 type immune responses, with reduced IL10 
production by spleen and increased IFNγ levels in both spleen and atherosclerotic 
arteries66. Another critical factor involved in phagocytosis of apoptotic cells is Mer 
receptor tyrosine kinase (Mer). Macrophages with dysfunctional Mer had defective 
phagocytosis of apoptotic thymocytes64. Moreover, Mer was shown to be necessary 
for apoptotic cell induced inhibition of NF-kB activation and pro-inflammatory 
cytokine secretion in dendritic cells68. Mer has been implicated in phagocytosis 
in atherosclerosis as well. Apoptosis induced in macrophages by free cholesterol 
loading elicited an inflammatory response in phagocytes, consisting of TNFα and 
IL1β production. This inflammatory response was constrained by Mer as shown 
by the use of Mer deficient phagocytes67. Similar to TG2 and Mfge8, deletion of 
leukocyte Mer in LDLr-/- mice also led to increased accumulation of apoptotic cells, 
increased macrophage area and lymphocyte infiltration resulting in accelerated 
lesion development75.
3 Pro- and anti-apoptotic effects of immunomodulators in atherogenesis
3.1	Pro-inflammatory	cytokines
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IFNγ 
Interferon gamma (IFNγ) is a pro-inflammatory cytokine produced by T and NK cells 
and macrophages. It is highly expressed in atherosclerotic lesions76. IFNγ has been 
shown to induce apoptosis in endothelial cells, SMC and macrophages in culture. 
Several pro-apoptotic proteins were suggested to be responsible for IFNγ induced 
cell death. In microvessel endothelial cells (EC) IFNγ synergizes with TRAIL to induce 
apoptosis, but not in large-vessel EC77. In agreement with the last finding, IFNγ 
lowers expression of death receptors DR4 and DR5 in HUVECs which is accompanied 
by decreased apoptosis78. In contrast, Li et al proposed a key role for Fas rather 
than TRAIL in IFNγ induced apoptosis in HUVECs79. Anti-Fas antibodies were able to 
completely block the pro-apoptotic effects of IFNγ. Likewise pro-apoptotic effects 
of IFNγ in vSMC were attributed to Fas80 as well as to the pro-apoptotic X-linked 
inhibitor of apoptosis associated factor-1 (XAF1) and Bcl-2 family member Noxa81 
while in THP-1 macrophages upregulation of TNFR1 appeared to be implicated in 
IFNγ induced apoptosis82.
Animal studies do support a pro-atherogenic role of IFNγ, but leave unanswered 
whether IFNγ dependent apoptosis could in part be held accountable for this effect. 
In IFNγ deficient ApoE-/- mice atherosclerotic lesion size and T lymphocyte content 
was shown to be reduced83,84 while intraperitoneally administered recombinant 
IFNγ increases lesion size accompanied by an increase in lesional T lymphocytes85. A 
similar, reduced lesion size was observed in LDLr-/- mice lacking IFNγ86. 
Tumor Necrosis Factor alpha
Tumor Necrosis Factor alpha (TNFα) is highly expressed by activated macrophages 
and other immune cells in murine as well as human lesions. It exerts its, mainly 
pro-inflammatory, effects through two receptors, TNFR1 (p55) and TNFR1 (p75). For 
instance TNFα promotes monocyte/macrophage recruitment by inducing expression 
of E-selectin, VCAM-1 and ICAM-1 in endothelial cells via TNFR2 activation87. TNFα 
can induce apoptosis via TNFR1, which in contrast to TNFR2 contains a death 
domain, although TNFR1 is also capable of transducing survival signals88-90. TNFα 
induces apoptosis in endothelial cells and SMC, both on its own account and in 
response to various other pro-inflammatory cytokines like IFNγ and IL1β which 
are able to enhance expression of TNFα91-93. Boyle et al showed that in coculture 
macrophage derived TNFα acts proapoptotic on SMC via TNFR192. Possibly, p73β, 
a protein closely related to p53, may mediate the pro-apoptotic effects of TNFα on 
vSMC as shown for rat aorta SMC by Tang et al 93. The role of TNFα and TNF receptors 
in atherogenesis has been studied in various mouse models. The results are rather 
contradictory, but most data are supportive of a proatherogenic effect76. Two of the 
studies examining the effect of TNFα deletion assessed apoptotic cell content in 
atherosclerotic lesions. In ApoE*3 Leiden transgenic mice TNFα deletion resulted 
in decreased necrosis area but paradoxically an increased number of apoptotic 
cells94. In contrast, in ApoE-/- mice, TNFα deletion led to decreased apoptotic cell 
content95.
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Interleukins
Pro- and anti-inflammatory interleukins are regarded key mediators in vascular 
inflammation and atherogenesis76,96. More recently several interleukins such as IL1β, 
IL4 and IL10 have been shown to affect apoptotic processes as well, while others 
like IL6 and IL12 and IL18 promote proliferation97,98. IL1β can promote apoptosis of 
endothelial cells and SMC, an effect which could in human (HUVEC) and mouse lung 
EC be abrogated by overexpression of the naturally occurring interleukin 1 receptor 
agonist IL1-RA99. IL1β induced vSMC apoptosis however was shown to be TNFα 
dependent91. IL1β expression appears to regulate, and in turn is regulated, by various 
apoptotic proteins, including TWEAK receptor Fn14 and bcl-2 family members Bcl-
2 and Bcl-XL39,100. The role of caspase-1 (Interleukin 1 converting enzyme, ICE) in 
pro-IL1β and pro-IL18 cleavage to their active form101,102 further underlines the 
intertwined relationship between apoptosis and inflammation. Apart from IL1β, 
IL2103 and IL4104 have been implicated in apoptosis of vascular cells, at which the 
former acts in an indirect, TNFα and NO dependent manner. 
Anti-apoptotic properties have been attributed to the anti-inflammatory IL10. 
In THP-1 macrophage IL10 was shown to decrease Ox-LDL induced apoptosis by 
upregulating anti-apoptotic Bcl-2 family members Bfl-1 and Mcl-1105. Interestingly 
plaque targeted and systemic overexpression of IL10 in LDLr-/- mice both inhibited 
atherosclerosis and resulted in decreased apoptosis of lesional macrophages106. An 
anti-apoptotic activity of this cytokine was supported by the finding that in advanced 
human atherosclerotic plaques high IL10 expression was seen to associate with 
decreased macrophage death107.
Macrophage inhibitory factor
The pro-inflammatory macrophage inhibitory factor (MIF), which is increasingly 
expressed during atherogenesis, has recently been identified as an important 
contributor to inflammation in atherosclerotic lesions. MIF deletion in LDLr-/- mice 
resulted in reduced aortic atherosclerosis108 while in ApoE-/- mice MIF blockade by 
neutralizing antibodies reduced macrophage infiltration and expression of adhesion 
and inflammatory molecules ICAM-1, MMP-2, TNF, IL-12, and CD40L109. Antibody 
blockade of MIF in LDLr-/- mice led to increased apoptosis in carotid arteries after 
endothelial denudation, pointing to a regulatory role of MIF in apoptosis110. In 
another study the anti-apoptotic properties of MIF in macrophages in culture were 
shown to be caused by inhibition of p53 expression111.
3.2	Oxidative	stress
During atherogenesis reactive oxygen species (ROS) and oxidized LDL (Ox-LDL) 
will accumulate in the vessel wall which leads to progressively increased oxidative 
stress. Ox-LDL, generated by in situ oxidation of extravasated LDL, can be taken up 
by macrophages leading to foam cell formation and promotion of inflammatory 
responses. Moreover, as discussed above, Ox-LDL can induce apoptosis in endothelial 
cells, vSMC and macrophages112 and interfere with apoptotic cell handling, often 
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favoring secondary necrosis. ROS are thought to be pro-atherogenic by, amongst 
others, inducing cell proliferation and apoptosis, recruitment of leukocytes and 
expression of pro-inflammatory cytokines like TNFα, IL1β and IFNγ (reviewed in 
113 and 114). ROS can also cause degradation of cellular components including 
(mitochondrial) DNA, proteins and lipids. Sources of ROS in the vasculature 
include cyclooxygenases, lipoxygenases, NO synthase and NADPH oxidase. Most 
of the atherosclerotic risk factors (hypercholesterolemia, diabetes, hypertension, 
smoking and aging) were seen to increase ROS production114. In inflammatory cells 
and in particular in phagocytes, NADPH oxidase, which is activated by phagocytic 
neutrophils and macrophages114, is the major source of ROS. The importance of 
NADPH oxidase has been established in animal models. ApoE-/- that lack p47phox, 
an essential subunit of NADPH oxidase, showed reduced levels of O2
- production 
and smaller atherosclerotic lesions in the aorta115. A similar protective effect was 
seen after pharmacological inhibition of NADPH oxidase in balloon injured rat 
carotid arteries116. Lipoxygenases (LO) are another class of ROS producing enzymes 
expressed in leukocytes and vSMC. Inhibition of 12/15–LO in vSMC reduces growth 
factor induced migration, proliferation and matrix production117 and 5-lipoxygenase 
pathway products leukotriens are potent vascular inflammation inducing 
mediators118. In ApoE-/- mice 12/15-LO gene disruption led to substantially smaller 
aortic artery lesions together with decreased circulating levels of auto-antibodies 
to Ox-LDL119 while pharmacological inhibition of the receptor for Leukotriene B4, a 
product of the 5-lipoxygenase pathway of arachidonic acid metabolism, in both ApoE-
/- and LDLr-/- mice reduced monocyte infiltration and foam cells in atherosclerotic 
lesions120.
In the vasculature nitric oxide (NO), produced by endothelial NO synthase 
(eNOS) and inducible NO synthase (iNOS), is instrumental in controlling vascular 
tone. At physiological concentrations it is suggested to be anti-apoptotic and 
atheroprotective. Under inflammatory conditions as apparent during atherogenesis, 
catalytically active iNOS will be upregulated and substrate as well as cofactors may 
become rate limiting favoring the production of the pro-oxidant nitroperoxide at the 
expense of a reduced NO production114. This translates in augmented synthesis of 
pro-inflammatory cytokines TNFα, MCP-1 and IFNγ and adhesion molecules VCAM-
1 and ICAM-1, promoting recruitment, infiltration and activation of monocytes and 
macrophages. INOS has been shown to protect EC against apoptosis121. The critical 
importance of a proper NO/ROS balance for endothelial cell function was illustrated 
by a study in which antisense oligonucleotide induced downregulation of iNOS 
expression in EC was seen to lead to endothelial dysfunction and ROS mediated cell 
death118. Furthermore, foam cells show increased iNOS expression resulting in toxic 
levels of NO. Fas associated cell death may be involved in this toxicity122.
Ox-LDL promotes generation of ROS in vascular and atherosclerotic lesion cells, which 
can in turn induce oxidation of LDL. In endothelial cells Ox-LDL stimulates expression 
of adhesion molecules and growth factors leading to monocyte recruitment112. 
Both mildly and extensively oxidized LDL can induce apoptosis of endothelial cells, 
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vSMC and macrophages including foam cells, although exposure of macrophages to 
low concentrations of oxidized LDL also was reported to stimulate proliferation123. 
Mildly oxidized LDL results not only in activation of Fas and TNF receptor signaling 
but also in an increased pro-apoptotic and decreased anti-apoptotic Bcl-2 family 
member expression in human coronary endothelial and SMC53. Furthermore Ox-LDL 
induces various transcription factors involved in oxidative stress pathways including 
p53 and NF-κB. Another mechanism by which oxidative stress influences Ox-LDL 
induced apoptosis and inflammation involves the endothelial oxidized LDL receptor 
LOX-1. Lectin-like oxidized low density lipoprotein receptor (LOX-1) activation by 
Ox-LDL stimulates NF-κB and subsequent adhesion molecule and pro-inflammatory 
gene expression. In endothelial cells Ox-LDL has been shown to reduce eNOS and 
increase LOX-1 expression thereby inhibiting endothelial cell proliferation and 
function124. In keeping, a recent study showed that LOX-1 disruption in LDLr-/- mice 
had reduced aortic atherosclerotic lesion size and pro-inflammatory markers within 
the lesions125. Furthermore LOX-1 expression has been linked to apoptosis in human 
endothelial cells126. Figure 2 gives a summary of the effects of ROS on apoptosis and 
inflammation.
Figure	 2.	 Generation	 of	 reactive	 oxygen	 species	 and	 its	 effects	 on	 inflammation,	 apoptosis	 and	
atherogenesis. During early atherogenesis ROS are generated in the vascular wall, reducing NO 
production and resulting in an unfavorable NO-ROS balance. ROS promotes endothelial activation, 
oxidation of LDL, apoptosis and  inflammation. Ox-LDL in turn promotes generation of ROS and exerts 
pro-apoptotic and pro-inflammatory effects as well. Ox-LDL, oxidized low-density lipoprotein; NO, nitric 
oxide; ROS, reactive oxygen species; EC, endothelial cell; vSMC, vascular smooth muscle cell, TNFα, 
tumor necrosis factor α; MCP-1, monocyte chemoattractant protein 1; IFNγ, interferon γ; VCAM-1; 
vascular cell adhesion molecule 1; ICAM-1, intercellular adhesion molecule 1.
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4 Summary and conclusions
Inflammatory and apoptotic processes in atherogenesis are closely intertwined. 
This notion has been conclusively demonstrated in various recent in vitro studies in 
cell types relevant to atherosclerosis as well as in in vivo studies in atherosclerosis 
prone animal models. First many of the proapoptotic members of the TNF super 
family, Fas, CD40 and Fn14, can promote secretion of inflammatory cytokines like 
MCP-1 and IL8 and/or adhesion molecules accompanying induction of apoptosis. 
Reactive oxygen species and Ox-LDL, accumulating in the vessel wall during plaque 
progression, are able to induce cell death in endothelial cells, vSMC and macrophages 
by upregulating several apoptotic proteins including Fas, TNFα, p53 and Bcl-2 family 
proteins. In addition, several key cytokines present in atherosclerotic lesions, apart 
from being induced in apoptosis, are able to induce apoptosis themselves. Vice versa, 
apoptotic cells were seen to modulate inflammatory responses either on their own 
account by elaborating amongst others cytokines and proteases or after uptake and 
processing by phagocytes. Impaired and altered phagocytosis, as apparent during 
progressive atherosclerosis, will, by eliciting a proinflammatory response and by 
promoting secondary necrosis, further aggravate inflammation leading to lesion 
progression and instability. Although several pro- or anti-apoptotic proteins and 
inflammatory mediators are attractive targets for therapeutic strategies, crosstalk 
between and the complex consequences of inflammatory, apoptotic and phagocytic 
processes have to be accounted for.
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Abstract
While the significance of mouse models for atherosclerotic plaque rupture still is 
subject to discussion, various models have been claimed to display features of en-
hanced plaque vulnerability. Conceivably, models for vulnerable plaque formation 
could share pathways or factors that predispose to plaque rupture. Here we have 
pursued a genomics approach to identify pathways or factors that are operative 
early on in the plaque destabilization process. Total RNA was obtained from col-
lar induced carotid artery plaques of Western type diet fed ApoE-/- mice 7 days af-
ter transduction with adenoviral P53 to generate thin cap fibroatheroma (ThCFA) 
or with AdLacZ (thick cap fibroatheroma control; TkCFA). Brachiocephalic artery 
plaques of the same ApoE-/- mice isolated after 9 weeks of Western type diet fee-
ding served as second model for plaque vulnerability. DNA micro array analysis on 
oligonucleotide arrays (22,000 genes) revealed a total of 57 genes that were sig-
nificantly upregulated in Adp53 (ThCFA) versus AdLacZ overexpressing carotid ar-
tery plaques (TkCFA). 58 Genes were significantly upregulated in brachiocephalic 
(ThCFA) versus non-transduced carotid artery plaques (TkCFA), whereas 87 and 66 
genes were downregulated in the respective models with an overrepresentation of 
gene clusters relevant to cell death.  Five of these genes were found to be upregula-
ted while nine were downregulated in both types of ThCFA. Differential expression 
of several of these genes was confirmed by real-time PCR. In particular neuropep-
tide Y showed increasing gene expression not only with disease progression in both 
mouse models but also in human plaques. In conclusion, mouse models of vulne-
rable plaque formation share various dysregulated genes and gene sets that may 
potentially be relevant to the destabilization process in the human situation.
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Introduction
Rupture of an atherosclerotic plaque generally underlies coronary thrombosis and 
subsequent myocardial infarction and cardiac death1. Although plaque rupture rarely 
occurs in mouse models of atherosclerosis, some studies have demonstrated that 
ApoE and LDL receptor deficient mice do develop complex thin cap fibroatheroma2,3,4. 
At age 42 weeks brachiocephalic artery plaques of chow diet fed ApoE-/- mice show 
overt features of enhanced vulnerability, as amongst others reflected by fibrous 
cap break and intraplaque hemorrhage2. When fed a Western type diet for only 8 
weeks, ApoE-/- mice were even claimed to form complex fibroatheromathous lesions 
with ruptured caps in 62% of cases5. In addition to cap breaks and intraplaque 
hemorrhages, plaques frequently contained buried fibrous caps, possibly remnants 
of a previous plaque rupture, although some debate exists on the significance of 
this finding6-8.
In 2002 we have reported that targeted overexpression of p53 into cap smooth 
muscle cells in advanced collar induced carotid artery plaques resulted in increased 
apoptosis of cap cells, in reduced cap thickness, and in general in a vulnerable 
plaque phenotype which proved prone to phenylephrine induced rupture9.
Several genomics studies have been performed to identify disease related gene 
expression patterns in atherosclerosis in humans and mice10-14 leading to the 
identification of differentially expressed genes or functional groups of genes like 
growth factors, chemokines and other inflammatory and non-inflammatory genes 
resulting from differences in strain, site (atherosclerosis-prone or -resistant), 
age and diet. However transcriptional profiling in established mouse models of 
vulnerable plaque formation, particularly of great importance inducing most clinical 
complications, has not been addressed to date. 
In this study, genome wide profiling is used to identify gene expression patterns 
characteristic of vulnerable thin cap fibroatheroma (ThcFA) compared to more stable 
thick cap fibroatheroma (TkCFA) in ApoE-/- mice. To minimize the impact of patterns 
intrinsic to the models used and thus to increase the significance of our findings we 
have studied two different mouse models at an early stage of the destabilization 
process before vulnerable plaque formation had become manifest. We hypothesize 
that at this stage these models may share pathways or factors that predispose to 
plaque vulnerability.
Methods
Animals and surgery
All animal work was approved by regulatory authority of Leiden and performed in 
compliance with the Dutch government guidelines. ApoE-/- mice were obtained from 
the local animal breeding facility. Starting at 15 weeks of age 18 male ApoE-/- mice 
were fed a Western type diet containing 0.25% cholesterol and 15% cacao butter 
(SDS, Sussex, UK) three weeks before surgery and throughout the experiment. Carotid 
atherosclerotic plaque development was induced by bilateral perivascular collar 
placement as described by Von der Thϋsen et al.15 Five weeks after collar placement 
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right carotid arteries were treated with adenovirus containing a CMV promoter and 
p53 (AdP53, n=9) or β-galactosidase transgene (AdLacZ, n=9) as described by Von 
der Thϋsen et al.9 Contralateral carotid arteries were left untreated. 
Cholesterol levels
Blood samples were taken by tail cut after four weeks and seven weeks of Western 
type diet feeding, and at the time of sacrifice. Total serum cholesterol levels were 
measured spectrophotometrically using enzymatic procedures (Roche Diagnostics, 
Almere, The Netherlands). 
Tissue	harvesting	and	plaque	morphometry	
One week after transduction with either AdP53 or AdLacZ the mice were anesthetized 
and perfused with PBS. AdP53 or AdLacZ transduced carotid arteries and half of 
the non-transduced carotid and brachiocephalic arteries were isolated and snap 
frozen in liquid nitrogen. Mice were subsequently fixated by 4% formaldehyde 
perfusion (4.5 times diluted Zinc Formal-Fixx, Thermo Electron Corporation, Breda, 
The Netherlands). The remaining carotid and brachiocephalic arteries were isolated 
and stored in 4% formaldehyde solution. Cryosections were prepared of carotid 
and brachiocephalic arteries and stained with hematoxylin and eosin and analyzed 
using Leica Qwin image analysis software. 
Micro-array	hybridization	and	analysis
Total RNA was isolated from snap frozen transduced carotid arteries, their non-
transduced contralateral counterparts and brachiocephalic arteries using RNeasy 
Mini Kit (Qiagen, Venlo, The Netherlands) and quality controlled with RNA 6000 
Nano Lab-on-Chip kit (Agilent Technologies, Amstelveen, The Netherlands). RNA of 
brachiocephalic artery and transduced or non-transduced carotid arteries from RNA 
samples of three different mice was pooled, giving three samples per artery, and 
used for cDNA synthesis followed by cRNA amplification with aminoallyl modified 
UTP’s (MessageAmp aRNA Amplification kit, Ambion, Nieuwerker a/d IJssel, 
The Netherlands) and coupling to Cy3 or Cy5 monoreactive dyes (GE Healthcare 
Europe GmbH, Diegem, Belgium). cRNA of carotid artery samples transduced with 
AdP53 and AdLacZ were hybridized together on oligonucleotide arrays containing 
22.000 genes as were cRNA of brachiocephalic artery and non-transduced carotid 
artery in a dyeswap manner. Genepix v6.0 (Axon instruments, Sunnyvale, CA, USA) 
was used for feature extraction. Analysis was performed using Rosetta Resolver 
software (Rosetta Biosoftware, Seattle, WA, USA) and applying the standard 
Rosetta Resolver error model for GenePix. Only spots with significantly higher signal 
(p-value < 10-6) than the surrounding background were considered in the analysis. 
Differences in gene expression between AdP53 transduced carotid artery plaques 
and AdLacZ transduced carotid artery plaques or brachiocephalic artery plaques 
and non-transduced carotid artery plaques were considered significant when 
p<0.001, as determined by a Student’s t-test. The obtained lists of differentially 
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expressed genes were further analyzed using Ingenuity Pathway Analysis (http://
www.ingenuity.com/products/pathways_analysis.html) to determine the biological 
function of differentially expressed genes.
Verification	of	gene	expression	by	realtime	PCR
cDNA was prepared from total RNA samples of mouse brachiocephalic and carotid 
arteries (used for cRNA synthesis). Gene expression was analyzed by realtime PCR 
using ABI PRISM 7700 Sequence Detector (Applied Biosystems) with SYBR-Green 
technology. The different primers and sequences are listed in table 1. HPRT, 18S and 
β-actin were used as standard housekeeping genes.
Table	1. Primer sequences for realtime PCR.
Gene Species Forward Primer (5’-3’) Reverse Primer (5’-3’)
HPRT Mouse TTGCTCGAGATGTCATGAAGGA AGCAGGTCAGCAAAGAACTTATAG
18S Mouse CCATTCGAACGTCTGCCC GTCACCCGTGGTCACCATG
β-actin Mouse AACCGTGAAAAGATGACCCAGAT CACAGCCTGGATGGCTACGTA
Cd5l Mouse GGAGTTGGGACCTCGTTAGAAGA AGGTGGTCAAGCTGTGGACAA
GC Mouse GCAGAACGGCTAAGGACAAAA AGTCCGAGTGTTTCTCCACCAT
Mup3 Mouse CTCGAGGCCCGAGAATGAA TGACGACCAACCTCCTCCTT
Npy Mouse TTTTCCAAGTTTCCACCCTCAT AGTGGTGGCATGCATTGGT
Fabp5 Mouse GGAAGGAGAGCACGATAACAAGA GGTGGCATTGTTCATGACACA
HPRT Human TGACACTGGCAAAACAATGCA GGTCCTTTTCACCAGCAAGCT
Cyclophilin Human CCCACCGTGTTCTTCGACAT CCAGTGCTCAGAGCACGAAA
Npy Human TGGTGATGGGAAATGAGACTTG TGGATTCTCGTTTTACACGATGA
Expression	profiling	in	human	atherosclerotic	carotid	artery	plaques
For gene expression profiling in human stable and unstable plaques RNA was 
obtained from the AtheroExpress Biobank16. Gene expression was analyzed as 
described for verification of gene expression with mouse RNA with primers listed 
in table 1. Hypoxanthine-guanine phosphoribosyltransferase (HPRT) and cyclophilin 
were used as standard housekeeping genes. For immunohistochemical analysis of 
neuropeptide Y expression paraffin embedded sections of plaques corresponding 
with the RNA samples used for gene expression analysis were obtained from the 
AtheroExpress Biobank. Antibodies used were rabbit anti-NPY (Abcam, Cambridge, 
UK) and goat anti-rabbit HRP conjugated secondary antibody (Dako, Heverlee, 
Belgium).
Neuropeptide	Y	gene	expression	during	plaque	development
In a separate experiment 20 male LDLr-/- mice, obtained from the local animal breeding 
facility, were fed a Western type diet two weeks prior to surgery and throughout the 
experiment. Atherosclerotic carotid artery plaques were induced by perivascular 
collar placement as described before. From 0 to 8 weeks after collar placement 
every two weeks a subset of 4 mice was sacrificed. The mice were anaesthetized 
and perfused with PBS after which both carotid arteries were isolated, snap-frozen 
in liquid nitrogen and stored at -80ºC. Two or three carotid arteries were pooled 
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per sample and total RNA was isolated using Trizol reagent (Invitrogen, Breda, The 
Netherlands). Gene expression was analyzed as described before using the (mouse) 
PCR primers listed in table 1.
Statistics	expression	analysis
Values are expressed as mean ± SEM or presented as mean + upper limit of the 
SEM. For analysis of relative mRNA expression data t-test was performed on ΔCt 
values. For these experiments statistical significance was set at p<0.05.
Results
Animal	and	atherosclerotic	plaque	characteristics
In the present study we have pursued a genomics approach to identify pathways 
or factors involved in atherosclerotic plaques vulnerable to rupture early on in 
the plaque destabilization process. Collar induced carotid artery plaques of ApoE-
/- mice fed a Western type diet for eight weeks were transduced with either AdP53 
or AdLacZ and carotid and brachiocephalic arteries were isolated one week later. 
Serum total cholesterol levels did not differ significantly between the two groups 
of mice transduced with either AdP53 or AdLacZ at the time of sacrifice, 1468 ± 
229 mg/dl and 1226 ± 193 mg/dl respectively. Total body weight was comparable 
between both groups as well (26.8 ± 4.8 g for AdP53 transduced mice and 27.5 
± 2.7 g for AdLacZ transduced mice). Carotid and brachiocephalic arteries of 
ApoE-/- mice isolated after nine weeks of Western type diet feeding and six weeks 
after collar placement were sectioned and stained with hematoxylin and eosin. The 
average size of carotid artery plaques was 2.97 ± 1.27 x 104 μm2 and the average 
size of brachiocephalic artery plaques was 1.03 ± 0.27 x 105 μm2. Representative 
micrographs of non-transduced carotid and brachiocephalic artery plaques are 
shown in figure 1. At the time of isolation, brachiocephalic artery plaques had 
progressed to cap fibroatheromas; cap breaks however were not evident at this 
stage. Morphological characteristics are depicted in table 2.  
                 
        Brachiocephalic artery                      Carotid artery
Table	2. Morphological characteristics of carotid and brachiocephalic arteries.
Carotid artery Brachiocephalic artery
Plaque size (μm2) 2.97 ± 1.27 x 104 1.03 ± 0.27 x 105
Media size (μm2 *104) 3.97 ± 0.99 8.36 ± 1.24
Intima/Media ratio 0.79 ± 0.42 1.25 ± 0.36
Intima/Lumen ratio 0.34 ± 0.16 0.55 ± 0.11
Brachiocephalic artery arotid artery
Figure 1. Representative pictures of 
brachiocephalic (left) and carotid 
(right) artery plaques stained with 
hematoxylin and eosin.
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Microarray analysis
To identify pathways or factors shared between the two different mouse models of 
ThCFA and potentially predisposing to plaque rupture we performed genome wide 
analysis using microarray technique. Carotid artery plaques transduced with AdP53 
(ThCFA), were compared with control TkCFA (AdLacZ transduced) carotid artery 
plaques and brachiocephalic artery plaques (ThCFA) were compared with non-
transduced carotid artery plaques (TkCFA). For differential gene expression analysis 
we applied a student’s t-test using a p-value < 0.001 as treshold. In this analysis 87 
genes appeared to be significantly down- and 57 genes upregulated in AdP53 vs LacZ 
transduced carotid artery plaques. Comparison of brachiocephalic artery plaques to 
non-transduced carotid artery plaques showed 66 genes to be down- and 58 genes 
to be upregulated. Comparison of both microarray experiments revealed that 10 
(out of 143) downregulated and 5 (out of 110) upregulated genes, listed in table 
3, were dysregulated in both models of unstable plaque formation. Importantly, of 
the five genes upregulated in both microarrays, three appeared to be involved in 
apoptosis, Cd5l,	Plagl1	and Bim.
Table	3. Genes differentially expressed in two models of unstable atherosclerotic plaque formation as 
identified by micro-array analysis and/or genes verified by realtime PCR.
Fold change
GenBank 
Accession nr.
Gene
AdP53 vs AdLacZ 
transduced Carotid 
Artery
Brachiocephalic 
vs carotid artery
NM009538 Pleiomorphic adenoma gene-like 1 (Plagl1) 2.86 ↑ 9.77 ↑
NM009690 CD5 antigen-like (CD5l) 3.18 ↑ 7.70 ↑
NM009754 BCL2-like 11 (Bim) 2.08 ↑ 3.43 ↑
AK002310 RIKEN cDNA 0610008A10 gene 1.67 ↑ 1.58 ↑
AK019647 RIKEN cDNA 4930478K11 gene 1.49 ↑ 1.95 ↑
AF327059 Apolipoprotein A-V (ApoA5) 2.81 ↓ 41.25 ↓
U89889 Hemopexin (Hpxn) 2.70 ↓ 5.69 ↓
NM010168 Coagulation factor (F2) 2.42 ↓ 16.06 ↓
AK004470 RIKEN cDNA 1190003J15 gene 2.38 ↓ 10.98 ↓
AB039380 Cytochrome P450, family 3, subfamily a, 
polypeptide 44 (Cyp3a16)
2.34 ↓ 39.34 ↓
L04150 Apolipoprotein C-III (ApoC3) 2.33 ↓ 2.70 ↓
M55413 Group specific component (GC) 2.16 ↓ 24.01 ↓
M27608 Major urinary protein 3 (Mup3) 2.07 ↓ 16.08 ↓
L13622 Methionine adenosyltransferase I, alpha 
(Mat1a)
2.04 ↓ 10.70 ↓
AJ011413 Albumin 1 (Alb1) 2.02 ↓ 30.40 ↓
NM010634 Fatty acid binding protein 5, epidermal 
(Fabp5)
4.20 ↑
AF273768 Neuropeptide Y (Npy) 2.28 ↑
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In order to rule out the possibility that differential gene expression is caused by 
differences in plaque macrophage, smooth muscle cell, endothelial cell or T 
lymphocyte content, several cell type specific markers were verified for gene 
expression. The majority of these genes were not differentially regulated (table 4).
Table	4. Expression of cell type specific markers.
Innominate vs.  carotid AdP53 vs. AdLacZ
Cell type Accession nr.
Gene 
name
Fold 
change
P-value
Fold 
change
P-value
Smooth muscle 
cells
AK019969 Myh10 1.31 ↑ 0.0620 1.14 ↑ 0.1262
AK020381 Myh10 1.03 ↓ 0.3179 1.19 ↑ 0.7684
NM_009922 Cnn1 1.32 ↑ 0.0564 1.05 ↑ 0.8895
NM_007725 Cnn2 1.71 ↑ 0.2912 1.35 ↓ 1
Macrophages NM_009853 Cd68 1.99 ↑ 0.4650 1.35 ↑ 0.0593
NM_032465 Cd96 1.09 ↑ 0.9240 1.40 ↓ 0.0059
Endothelial cells NM_008816 Pecam1 1.03 ↓ 0.3463 1.33 ↓ 1
NM_011345 E-selectin 1.17 ↓ 0.8508 1.99 ↓ 0.8278
T-lymphocytes NM_007648 Cd3e 1.41 ↓ 0.0035 1.22 ↓ 0.3214
NM_013487 Cd3d 1.13 ↑ 0.4174 1.07 ↓ 0.5757
NM_031162 Cd3z 1.14 ↑ 0.4439 1.09 ↑ 0.5043
NM_009850 Cd3g 1.14 ↑ 0.8235 1.29 ↓ 0.0962
NM_009858 Cd8b1 1.11 ↑ 0.0619 1.05 ↑ 0.1087
AJ131778 Cd8a 1.17 ↓ 0.3207 1.17 ↑ 0.1979
M12052 Cd8a 1.22 ↑ 0.7407 1.30 ↑ 0.5904
Dendritic cells AF065893 Cd80 1.53 ↓ 0.1476 1.04 ↑ 0.8488
NM_019388 Cd86 1.07 ↓ 0.7801 1.21 ↑ 0.3581
Involvement	of	differentially	expressed	genes	in	functional	groups
Ingenuity Pathway Analysis was performed to identify the underlying pathways 
and processes dysregulated in both models of ThCFA. Processes with particular 
overrepresentation of dysregulated genes, shared by both models included cell 
death (43 and 30 genes differentially regulated in AdP53 versus AdLacZ treated 
carotid artery plaques (p=0.01) and brachiocephalic versus carotid artery plaques 
(p=0.01) respectively, lipid metabolism (21 [p=0.02] and 22 [p=0.01] genes), small 
molecule biochemistry (28 [p=0.01] and 26 [p=0.01] genes), metabolic disease (21 
[p=0.008] and 16 [p=0.01] genes), cellular growth and proliferation (9 [p=0.01] 
and 27 [p=0.01] genes) and cell-to-cell signaling and interaction (19 [p=0.02] and 
8 [p=0.01] genes). These functional groups remain significantly affected when only 
differentially expressed genes are analyzed that are shared between both models 
of ThCFA.  
Verification	of	differentially	expressed	genes	by	realtime	PCR
Genes differentially expressed in advanced plaques of both models of ThCFA 
compared to TkCFA control plaques and genes differentially expressed in advanced 
plaques of one model with previously reported involvement in atherosclerotic 
61
Gene	expression	profiling	in	atherosclerotic	plaque	vulnerability
plaque development were selected for verification by quantitative realtime PCR 
using the same cRNA samples as originally used for microarray analysis. Differential 
regulation of Cd5 antigen like (Cd5l), Pleiomorphic adenoma gene-like-1 (Plagl1), 
Group specific component (Gc) and Major urinary protein 3 (Mup3) in both 
microarray experiments and Neuropeptide Y (Npy) and Fatty acid binding protein 
5 (Fabp5) in brachiocephalic artery plaques compared to carotid artery plaques 
could be confirmed by realtime PCR (fig. 2).  Bcl-2 like interacting mediator of cell 
death (Bim) showed a tendency towards increased expression in brachiocephalic 
compared to carotid artery plaques (p=0.056). Several other selected genes failed 
to reach statistical significance.
Expression	of	Neuropeptide	Y	in	human	carotid	artery	atherosclerotic	plaques
Expression of the genes that were significantly altered in mouse ThCFA compared 
to TkCFA was assessed in human stable and unstable carotid artery plaques. Plaque 
RNA was obtained from the AtheroExpress Biobank of endartorectomy specimen 
of patients who had undergone endarterectomy of the carotid artery (n=9/12)16. 
Plaques from all patients in this study were previously phenotyped16. Fibrous 
plaques low in inflammatory cell and fat content with strong staining for collagen 
and smooth muscle cells were considered stable, while lesions were categorized 
unstable atheromathous plaques if they had strong staining for macrophages and 
no or minor staining for collagen and smooth muscle cells16. Neuropeptide Y (Npy) 
gene expression appeared to be increased more than twofold (p=0.036) in unstable 
compared to stable human carotid artery plaques (fig. 3a). Immunohistochemical 
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Figure 2. Quantitative PCR assisted validation of genes differentially expressed in mouse stable 
(ACC, common carotid artery) versus unstable plaques (ABC, brachiocephalic artery) as identified by 
microarray analysis.
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analysis was performed on paraffin embedded sections from the same carotid artery 
plaques that served as source for gene expression analysis. Npy was demonstrated to 
be strongly present in de medial layer of carotid arteries in both stable and unstable 
plaques and was virtually absent in the intima (fig. 3b). Immunological analysis did 
not allow establishing quantitative differences in Npy protein expression between 
stable and unstable plaques.
Neuropeptide	Y	gene	expression	during	atherogenesis
Next we have monitored Npy expression during atherogenesis. Carotid arteries 
of western type diet fed LDLr-/- mice equipped with semi-constrictive collars to 
accelerate low shear stress induced plaque formation. Npy expression steadily 
increased with plaque progression from 0 (no plaques) to six weeks after initiation 
of plaque development (t=6, fig. 4). After six weeks of plaque development Npy 
expression leveled off to maintain a high level at least until week eight.
Discussion
In the current study we analyzed gene expression profiles of thick cap fibroatheroma 
and thin cap fibroatheroma in mice in order to identify genes or functional groups 
of genes that predispose the vascular wall to plaque rupture. To increase the power 
of genomic analysis and facilitate the identification of actual stability- rather than 
model-associated pathways we included two different models of ThCFA in our 
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Figure 3. A. Neuropeptide Y expression is increased in unstable versus stable human carotid artery 
atherosclerotic plaques, specimen from the AtheroExpress Biobank. B-H. Representative sections 
of Npy immunohistochemical staining in human unstable (B-E) and stable (F-H) carotid artery 
atherosclerotic plaques. Magnification 100x (B,C and F) and 400x (D,E,G, H).
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Figure 4. Neuropeptide Y expression increases with 
atherosclerotic plaque progression in carotid arteries 
of LDLr-/- mice. Mice underwent surgery to place 
perivascular collars around the carotid arteries and 
were fed a Western type diet. (*p<0.05)
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genomics approach and analyzed them for genes and pathways shared by both 
mouse models. As a first model we considered spontaneous vulnerable plaque 
development in the brachiocephalic artery of ApoE-/- mice fed a Western type diet for 
9 weeks5. As a second model we have used low shear stress induced carotid artery 
plaques in ApoE-/- mice that were further destabilized by adenoviral overexpression 
of P53 in the cap zone9. The impact of factors intrinsic to the models or changes in 
cellular plaque composition was minimized by assessing the early stage vulnerable 
plaque formation in both models. Using this strategy we could identify 87 genes that 
were downregulated and 57 genes that were upregulated in ThCFA AdP53 versus 
AdLacZ transduced carotid artery plaques (TkCFA controls) and 66 downregulated 
and 58 upregulated genes when brachiocephalic artery ThCFA were compared to 
TkCFA. Of these differentially regulated genes 10 downregulated and 5 upregulated 
genes were shared between the two models of ThCFA. In addition, Ingenuity Pathway 
Analysis identified several functional clusters consisting of differentially regulated 
genes that were overrepresented in both models. Cell death, lipid metabolism, 
small molecule biochemistry, metabolic disease, cellular growth and proliferation 
and cell to cell signaling and interaction comprise the functional processes that 
were most significantly affected in ThCFA versus TkCFA. With 43 and 30 regulated 
genes in brachiocephalic and AdP53 transduced carotid artery plaques respectively, 
cell death was the most prominently dysregulated process in our analysis. This 
finding is in line with the observed increase in plaque apoptotic cell content after 
adenoviral p53 overexpression9, and with the reported enhanced rate of apoptosis 
of both macrophages and vascular smooth muscle cells (vSMC) in human type IV 
to VI plaques17. Direct induction of vSMC apoptosis in mouse aortic atherosclerotic 
plaques was recently shown to promote features of plaque vulnerability including 
fibrous cap thinning, loss of collagen, intimal inflammation and increased necrotic 
core size18, and in carotid artery atherosclerotic plaques reduced cap cellularity 
and cap/intima ratio with induction of plaque rupture9. Enhanced macrophage 
apoptosis in mouse plaques results in an increased necrotic core size after 10 weeks 
of Western type diet feeding19. This, together with the fact that phagocytosis of 
apoptotic cells is impaired in advanced human atherosclerotic plaques20, also point 
to a destabilizing effect of increased macrophage apoptosis at later stages of plaque 
development, although more recent studies could not support this notion21. 
In this study, of the five genes that are upregulated in both ThCFA models compared 
to their respective TkCFA counterparts three are regulating cell death, while the 
other two have unknown functions, which confirms the important role of apoptosis 
in plaque vulnerability. Pleiomorphic adenoma gene-like-1 (Plagl1, also called 
Zac-1) and Bcl-2 like interacting mediator of cell death (Bim or Bcl2-like-11) are 
both pro-apoptotic proteins. Plagl1 induces apoptosis and cell cycle arrest22 and, 
importantly, is a cofactor for p5323 the expression of which was seen to be increased 
in advanced human plaques24, as well as in mouse plaques after adenoviral p53 
overexpression. Although contradictory results have been reported on its role in 
atherosclerotic plaque development and progression depending on the cell type 
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affected, generally deficiency of p53 increased atherosclerotic lesion size24. Bim is 
a pro-apoptotic BH3 only member of the Bcl-2 family of apoptosis regulators. Bim 
was found to be involved in negative selection of T lymphocytes and its deficiency 
resulted in expansion of lymphocytes and autoimmunity in mice25-26. To date, an 
involvement of Bim in atherosclerotic plaque development or progression has not 
been reported. CD5 ligand (CD5l, also known as AIM or api6) has been demonstrated 
to possess both pro- and antiapoptotic properties27-29. It inhibits apoptosis of NKT 
and T cells27,28, but induces apoptosis in resting B cells29. CD5l has been implicated 
in atherosclerosis development. First it promoted macrophage survival in response 
to pro-apoptotic stimuli such as oxidized LDL30. Second, plaque macrophages 
have been shown to express CD5l and deletion of CD5l in LDLr-/- mice resulted in a 
marked inhibition of atherosclerotic plaque development30. A possible role for CD5l 
in plaque instability has however not been assessed. We propose that these three 
genes, Cd5l, Bim and Plagl1, may play a role in the transition of TkCFA into a more 
vulnerable plaque phenotype. 
The differential regulation of one of the genes upregulated in brachiocephalic 
artery ThCFA versus perivascular collar induced carotid artery TkCFA in ApoE-/- 
mice, neuropeptide Y, could be verified by realtime PCR. In addition we show that 
in LDLr-/- mice Npy RNA expression gradually increases with plaque progression. 
Interestingly in human unstable carotid atherosclerotic plaques Npy gene expression 
was upregulated as well. Moreover Npy protein was abundantly expressed in 
atherosclerotic plaques, but immunohistochemical detection unfortunately did 
not allow to detect significant differences in protein content between unstable and 
stable plaques probably due to the higher sensitivity of RNA expression profiling 
over immunohistochemistry. Npy is a neurotransmitter involved in regulation 
of both central and peripheral processes mediating its effect through G coupled 
receptors Y1-Y631. In the vasculature Npy proved to be a potent vasoconstrictor32,33 
and to exert pro-angiogenic34,35 and pro-atherogenic36 activities via different 
receptors. In rat ischemic tissue Npy release is stimulated and exogenous Npy 
induces angiogenesis34. This effect of Npy was shown to be mediated by receptors 
Y2 and/or Y5. Furthermore, Npy was shown to act mitogenic on endothelial37 and 
smooth muscle cells38. In a rat model of carotid artery balloon angioplasty vascular 
expression of Npy was seen to be upregulated in response to injury and exogenous 
Npy in the same model aggravated intimal hyperplasia at which atherosclerotic-
like lesions are formed with a high macrophage, matrix and lipid content, an effect 
that was likely mediated by receptors Y1/Y536. Our data suggest that apart from its 
documented pro-angiogenic and pro-atherogenic properties Npy colocalizes with 
vSMC and may be involved in induction of ThCFA. 
In conclusion, comparative transcriptome analysis of two ThCFA models and 
respective TkCFA controls by microarray technique shows that several differentially 
expressed genes and functional gene clusters are shared by both models of 
ThCFA. From our study genes involved in cell death signaling are most prominent, 
confirming the importance of apoptosis in plaque vulnerability. In addition, we have 
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identified neuropeptide Y as a gene potentially involved in plaque vulnerability. 
Further studies are necessary to determine the exact contribution of Npy to plaque 
destabilization.
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Abstract
Proapoptotic Bcl-2 family member Bim is an important regulator of leukocyte apop-
tosis. It is particularly relevant for the deletion of autoreactive and activated T and 
B cells implicating Bim in autoimmunity. As atherosclerosis is regarded as a chronic 
inflammatory process with features of an autoimmune disease, we investigated the 
impact of hematopoietic Bim deficiency on plaque formation in Western type diet 
fed LDLr-/- mice.
Bim-/- bone marrow transplanted LDLr-/- mice displayed marked splenomegaly. The 
pro-inflammatory status of Bim-/- chimeras was also reflected by enhanced T cell ac-
tivation and proliferation, which could be partly attributed to an increased capacity 
of matured Bim-/- DCs to induce T cell proliferation. Moreover, circulating and medi-
astinal lymph node lymphocyte levels were increased while atherosclerotic lesions 
were seen to be enriched in T cells as well. Leukocyte Bim deficiency was accompa-
nied by elevated levels of Ox-LDL specific autoantibodies of the IgG1 but not IgG2a 
isotype, suggestive of a Th2 biased T-cell response. In addition, plaques of Bim-/- but 
not WT transplanted mice contained massive immunoglobulin deposits. Although 
circulating monocyte levels were increased in Bim-/- BM recipients and bone mar-
row derived macrophages proved to be less sensitive for Ox-LDL induced apoptosis, 
Bim deficiency did not translate in altered lesion macrophage content. Surprisingly, 
despite these profound effects and unexpected 30-50% reductions in serum lipid 
levels, atherosclerotic lesion burden in aortic root and descending aorta as well as 
lesion stability were unaffected in Bim-/- BM transplanted mice.
In conclusion, leukocyte Bim deficiency in LDLr-/- mice results in general T cell acti-
vation, increased lesion T cell but not macrophage content, enhanced anti-Ox-LDL 
autoantibody formation and lesional immunoglobulin deposition. Apparently, pro-
inflammatory effects counteract the atheroprotective effect of Bim deficiency on 
serum lipid levels leading to an overall unchanged atherogenic response.
Leukocyte	Bim	Deficiency	Induces	Anti-Ox-LDL	Autoantibody	Formation	and	TCell	and	Ig	Accumulation
71
Introduction
Atherosclerosis is a chronic inflammatory disease characterized by lipid 
accumulation1. With disease progression vascular apoptosis gradually increases2. In 
early atherogenesis apoptosis is regarded a beneficial factor as it dampens plaque 
inflammation and limits lesion expansion3,4. At later stages of atherosclerosis however 
clearance of apoptotic cells has been demonstrated to be insufficient5, and apoptotic 
cell death might here promote necrotic core formation and inflammation. 
The Bcl-2 family of pro- and antiapoptotic proteins regulates apoptosis induced by 
cellular stressors such as DNA damage, UV radiation and oxidative stress6. Proteins 
of this family share one to four Bcl-2 homology (BH) domains6. In vivo studies in 
atherosclerotic mouse models have established a role for various Bcl-2 family 
members in apoptosis of atherosclerotic lesion macrophages7,8. For instance lesions 
of lethally irradiated LDLr-/- mice transplanted with proapoptotic Bax deficient bone 
marrow were seen to contain 53% less apoptotic cells and demonstrated to be 50% 
larger than Bax+/+ transplanted mice7. However in ApoE-/- mice macrophage specific 
deletion of antiapoptotic Bcl-2 did not result in altered lesion size, despite an increase 
in apoptotic cell content8. Bim (Bcl-2 interacting mediator of cell death) is a BH3-
only proapoptotic protein of the Bcl-2 family9,10 and, like other BH3-only proteins, 
binds to antiapoptotic Bcl-2 family members thereby initiating apoptosis11. Studies 
in Bim deficient mice have revealed crucial functions in leukocyte homeostasis. Bim 
deficient granulocytes and lymphocytes are less sensitive to apoptosis induced by 
cytokine deprivation or various apoptotic stimuli12,13. Moreover, Bim deficient mice 
have markedly increased numbers of B and T cells in circulation, spleen and thymus, 
and of circulating monocytes and granulocytes12. Bim deficiency results in auto-
immunity and lymphadenopathy due to defective removal of autoreactive T and B 
cells12,14,15. Bim was also demonstrated to be necessary for appropriate termination 
of immune responses16.
Atherosclerotic lesions contain a large number of inflammatory cell types including 
lymphocytes. Lymphocyte deficiency in mice has previously been demonstrated 
to result in reduced atherosclerotic lesion size17,18 while transfer of CD4+ T cells in 
immunodeficient mice was seen to aggravate atherosclerosis19. Various mediators 
of both innate and adaptive immunity are involved in the pathogenesis of 
atherosclerosis. In fact atherosclerosis exhibits several features of an autoimmune 
disease20-22, at which Ox-LDL derived epitopes and heat shock proteins (HSP) were 
shown to act as autoantigen22. T-cell autoreactivity is generally suppressed by 
regulatory T cells (Tregs), and Treg deficiency can result in autoimmune disease23. 
Concordant with various autoimmune diseases, also in atherosclerosis Treg function 
is impaired23. Likewise functional studies demonstrated that depletion or functional 
impairment of Tregs exacerbated atherosclerosis in ApoE-/- mice24,25. As Bim is 
instrumental in preventing autoimmunity a role for this protein in the pathogenesis 
of atherosclerosis is anticipated. Therefore, in the present study we have investigated 
the role of Bim regulated apoptosis in atherosclerosis-prone LDLr-/- mice. Our study 
shows that leukocyte Bim deficiency in LDLr-/- mice results in increased atherosclerotic 
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lesion T cell content and massive immunoglobulin deposition as well as increased 
circulating anti-oxidized LDL autoantibodies. Furthermore, we demonstrate that 
loss of leukocyte Bim interferes with lipid metabolism. 
Methods
Bone	marrow	transplantation
All animal work was approved by regulatory authority of Leiden and performed 
in compliance with the Dutch government guidelines. LDLr-/- mice were obtained 
from the local animal breeding facility and Bim-/- mice from the Department of 
Biochemistry, Biosciences Research Institute from the University College Cork, 
Ireland. Male LDLr-/- mice (n=12) were housed in sterile individual ventilated cages 
with food and water ad libitum. The drinking water was supplied with antibiotics (83 
mg/l ciprofloxacin and 67 mg/l Polymixin B) and 5 g/l sugar. The mice were exposed 
to a single dose of 9 Gy total body irradiation (0.19Gy/min, 200 kV, 4 mA) using an 
Andrex Smart 225 Röntgen source (YXLON International, Copenhagen, Denmark) 
one day before transplantation. Bone marrow was extracted from femurs and 
tibia of male Bim-/- and wild-type (WT) littermates. Irradiated LDLr-/- mice received 
either 5 x 106 Bim-/- bone marrow cells or 5 x 106 WT bone marrow cells via tail vein 
injection. After a recovery period of eight weeks the diet was changed from normal 
chow (RM3, Special Diet Services, Witham, Essex, UK) to Western type diet (WTD) 
containing 0.25% cholesterol and 15% cacao butter (Diet W, Special Diet Services, 
Witham, Essex, UK) for an additional ten weeks. 
Cholesterol and triglyceride levels
Blood samples were taken by tail bleeding before bone marrow transplantation 
(BMT) and before and five weeks after start of Western type diet feeding and 
at the time of sacrifice. Hepatic lipids were extracted as described by Bligh and 
Dyer26. Total cholesterol, triglyceride and phospholipid content was measured 
spectrophotometrically using enzymatic procedures (Roche Diagnostics, Almere, 
The Netherlands) in serum and hepatic extracts.
Tissue	harvesting	and	analysis
Sixteen weeks after BMT mice were anesthetized and perfused with PBS after 
which heart, aorta, spleen, thymus and mediastinal lymph nodes were isolated 
and stored in 4% formaldehyde solution or snap-frozen in liquid nitrogen and 
stored at -80ºC. Cryosections were prepared of aortic valves, spleen and liver 
and stained with hematoxylin and eosin (HE) and/or Oil Red ‘O. The descending 
aorta was cut open longitudinally for en	 face analysis after staining with Oil Red 
‘O. Immunohistochemical stainings were performed for macrophage (MOMA-2, 
Sigma, Zwijndrecht, The Netherlands) and T cell (CD3, Immunologic, Duiven, The 
Netherlands) content in aortic root lesion, liver and/or spleen sections. Apoptotic 
cell content was quantified using terminal deoxytransferase dUTP nick-end labeling 
(TUNEL) kit (Roche Diagnostics) and presence of immunoglubulins using FITC 
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labeled rabbit anti-mouse Ig (DakoCytomation, Heverlee, Belgium). Lesion size 
and tissue morphology was analyzed using Leica image analysis system, consisting 
of a Leica DMRE microscope with camera and Leica Qwin Imaging software (Leica 
Ltd, Cambridge, UK). Fluorescent immunohistochemistry was analyzed on a Nikon 
Eclipse E600 using ImagePro 4.5 software.
Blood	cell	analysis	and	flow	cytometry
Blood samples were taken by tail bleeding before BMT (week 0), before (week 6) 
and five weeks after start of Western type diet feeding (week 11) and at the time of 
sacrifice (week 16). Peritoneal leukocytes were isolated at the time of sacrifice by 
peritoneal lavage with 10 ml cold PBS. Whole blood and peritoneal lavage samples 
were analyzed on a Sysmex blood cell analyzer (XT-2000i, Sysmex Europe GmbH, 
Norderstedt, Germany). White blood cells (WBC) were isolated after erythrocyte 
lysis of whole blood samples obtained by orbital puncture. For flow cytometry, WBC 
and peritoneal leukocytes or single cell suspensions of spleen and lymph nodes 
were stained with fluorescently labelled antibodies from eBioscience (Halle-Zoersel, 
Belgium; CD3, CD4, CD8, CD11c, CD69, CD71, CD62L, CCR7 and MCH-II) and BD 
Pharmingen (Breda, The Netherlands; CD4, CD8 and CD45). Fluorescence-activated 
cell sorting (FACS) analysis was performed on a FACSCanto with FACSDiva software 
(BD Biosciences).
Macrophage apoptosis
Femurs and tibia were flushed with phosphate buffered saline (PBS) to isolate bone 
marrow. A single cell suspension was obtained by passing the bone marrow through 
a 70 µm nylon cell strainer (BD Falcon, Breda, The Netherlands). Bone marrow cells 
were differentiated into macrophages by culturing in 70% RPMI, supplemented 
with 20% FCS, glutamine, pyruvate, penicillin/streptomycin and non essential 
amino acids, and 30% M-CSF conditioned DMEM (obtained from L929 cells) for 7 
days. Bone marrow derived macrophages (BMDM) were stimulated with 40 ug/
ml Ox-LDL, cultured without growth factors (30% M-CSF conditioned DMEM) or 
in control medium for 24 hours. The macrophages were detached with accutase 
(PAA Laboratories GmbH, Cölbe, Germany), stained with Annexin V (ImmunoTools, 
Friesoythe, Germany) and propidium iodide (Sigma, Zwijndrecht, The Netherlands) 
and subsequently analyzed by flow cytometry using a FACSCalibur with CellQuest 
software (BD Biosciences).
Proliferation	assay
Single cell suspensions from spleens of Bim-/- and WT BM transplanted mice 
were obtained by passing spleen tissue through a 70 µm nylon cell strainer (BD 
Falcon), after which splenocytes were washed with PBS. When indicated T cells 
were isolated from spleen and lymph nodes of LDLr-/- mice fed a Western type 
diet for 2 weeks using a Mouse T Lymphocyte Enrichment Set – DM (“purified T-
cells”; BD Pharmingen, Breda, The Netherlands). Bone marrow cells of Bim-/- and 
Chapter 4
74
WT BM transplanted mice were differentiated into dendritic cells (DCs) by culturing 
in 70% IMDM, supplemented with 8% FCS, 2 mM glutamine, 100 U/ml penicillin/
streptomycin and 20 μM beta-mercaptoethanol, and 30% GM-CSF conditioned 
IMDM (obtained from R1 cells) for ten days. DCs were then stimulated with LPS (1 
μg/ml), Ox-LDL (7.5 μg/ml) or left untreated for 24 h. 
Splenocytes (2 x 105) or purified T-cells (6 x 105) were plated in triplicate in a round-
bottom 96-well plate in RPMI containing 10% FBS, 2 mM glutamine, 100 U/ml 
penicillin, 100 μg/ml streptomycin and 50 μM β-mercaptoethanol and incubated 
for 24 hours in the presence or absence of 2 μg/ml concanavalin A (splenocytes) or 
in the presence of stimulated or nonstimulated DCs (purified T-cells; cell ratio 1:10) 
at 37ºC. [3H]-thymidine (0.5 μCi/well, GE Healthcare, Diegem, Belgium) was added 
and after incubation for another 24 hours samples were washed with PBS and cells 
were lysed in 0.1 M NaOH. [3H]-thymidine incorporation was measured by a liquid 
scintillation analyzer (Tri-Carb 2900R, Packard).
Detection	of	anti-Ox-LDL	antibodies
An EIA/RIA high binding 96-well plate (Corning, Schiphol, The Netherlands) was 
coated with Ox-LDL (5 μg/ml) in a 50 mM Na2CO3/NaHCO3 coating buffer (pH 9.6). 
IgM, IgG1 and IgG2a antibodies against Ox-LDL in serum were measured using an 
enzyme-linked immunosorbent assay (ELISA) Ig detection kit (Zymed Laboratories, 
San Francisco, CA, USA) according to the manufacturer’s protocol.
Statistical	analysis
Values are expressed as mean ± SEM or presented as mean + upper limit of the 
SEM. Analysis to compare two groups was performed by two-tailed Student’s t-test. 
P-values less than 0.05 are considered significant. 
Results
Serum lipid levels are reduced in Bim-/- BM transplanted mice  
The role of leukocyte Bim in atherogenesis was studied in chimeras generated 
by transplanting bone marrow (BM) from Bim-/- and WT littermates to irradiated 
LDLr-/- recipients. First we analyzed whether leukocyte Bim deletion in western 
type diet fed LDLr-/- mice influenced serum total cholesterol (TC) and triglyceride 
(TG) levels. To our surprise TC and TG levels of Bim-/- BM transplanted mice were 
reduced by a very significant 30-48% compared to controls both after 5 and after 
10 weeks of western type diet feeding (p<0.05, fig. 1A and B). The reduction in TC 
was clearly induced by Western type diet since there was no difference between 
groups when mice were fed a chow diet, eight weeks after BMT. However, at this 
time point serum TG levels had already dropped by 35% (p<0.05). Body weight was 
comparable between the two groups of mice (39.4 ± 1.7 g vs. 38.9 ± 1.8 g for WT 
and Bim-/- BM transplanted mice respectively), suggesting that the decreased TC 
and TG levels were not caused by differences in the general metabolic state.
Reduction of serum lipid levels neither did translate in nor was caused by perturbed 
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hepatic lipid handling as we did not observe differences in hepatic lipid content (fig. 
1C and D). Livers of Bim-/- BM transplanted mice did however show an increased 
leukocyte content, consisting for a substantial part of T cells, suggestive of increased 
hepatic inflammation (fig 1E and F).
Figure 1. Serum lipid levels are reduced. Circulating total cholesterol (TC) levels are reduced after 
Western type diet feeding of Bim-/- BM transplanted LDLr-/- mice (A), circulating triglyceride (TG) 
levels are reduced independent of diet (B). The reductions in lipid levels are not caused by changes 
in hepatic TC and TG content (C and D). Livers of Bim-/- chimeras show increased cell influx, consisting 
partly of T cells. Representative picture of a HE (E) and CD3 stained (brown) cryosections (F). (*p<0.05, 
**p<0.01)
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Loss	of	leukocyte	Bim	in	LDLr-/-	mice	affects	T	cell	levels	and	characteristics
As Bim is instrumental in lymphocyte development and T cell response, we assessed 
these characteristics in Bim-/- BM transplanted LDLr-/- mice. The spleen of Bim-/- BM 
recipients was enlarged (+81% in relative weight; p<0.001, fig. 2A) compared to WT 
BM recipients. Thymus weight and mediastinal lymph node (MLN) total cell number 
were unaltered (fig 2B and C). Total white blood cells in Bim-/- BM transplanted 
mice were increased by almost two-fold, which was mainly attributable to a 90% 
increase in circulating lymphocyte numbers (p<0.01, fig. 3A). Next, T cell content 
and activation in spleen and MLN was analyzed. Compared to controls MLN from 
Bim-/- BM recipients were slightly enriched in CD4+ and CD8+ T cells (p<0.01, fig. 3B). 
Relative spleen T cell content was unchanged (fig. 3C), indicating that the different 
leukocyte subsets were enhanced proportionally. However both CD4+ and CD8+ 
T cell subsets were found to be more activated in Bim-/- BM transplanted mice in 
comparison with WT transplanted mice as judged from the enhanced expression of 
activation markers CD69 and CD71 (p<0.05, fig. 3D and E).
In keeping with this finding, basal proliferation of unstimulated splenocytes 
derived from Bim-/- BM recipients, as measured by [3H]-thymidine incorporation, 
was increased by 38% (p<0.05, fig. 4A). Concanavalin A induced proliferation was 
however not affected in Bim-/- splenocytes (fig. 4B), indicating that Bim deficiency 
does not alter the splenocyte proliferation capacity. Next, we examined the ability 
of WT and Bim-/- dendritic cells to stimulate T cell proliferation. Bone marrow cells 
from Bim-/- and WT transplanted mice were differentiated into dendritic cells (DCs) 
by growth factor stimulation. DCs were subsequently matured in the presence of 
lipopolysaccharide (LPS) or Ox-LDL to stimulate antigen presentation. Proliferation 
of T cells isolated from western type diet fed LDLr-/- mice was measured after co-
incubation for 24h with matured DCs. Proliferation of T cells incubated with immature 
WT or Bim-/- DCs was essentially similar as was proliferation of T cells incubated with 
Ox-LDL pulsed DCs (fig. 4C). However Bim-/- DCs stimulated with LPS were able to 
stimulate T cell proliferation to a slightly higher extent than unstimulated Bim-/- DCs 
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Figure	2.	Organ	weights	in	Bim-/- versus Bim+/+	bone	marrow	transplanted	LDLr-/- mice. Spleen weight 
was increased in Bim-/- BM recipients (A), while thymus weight was unaltered (B). Values are expressed 
as organ weight relative to total body weight. (***p<0.001)
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while for WT DCs no significant increase in T cell proliferation was observed after 
LPS stimulation (p<0.05, fig. 4C).
Figure	3.	Effect	of	hematopoietic	Bim-/-	deficiency	on	 lymphoid	organ	T	cell	 content	and	activation. 
Total white blood cell numbers were largely increased in Bim-/- chimeras, mainly due to the large 
increase in lymphocyte counts (A). Both CD4+ and CD8+ T cell levels were elevated in mediastinal 
lymph nodes (MLN; B), but not in spleen (C). However in spleen a larger portion of CD4+ and CD8+ T 
cells were activated as shown by increased CD69 and CD71 expression (D and E). (*p<0.05, **p<0.01, 
***p<0.001)
Figure	4.	Proliferative	capacity	of	Bim	deficient	splenocytes	and	T	cells. Basal proliferation of splenocytes 
is enhanced after leukocyte Bim deletion (A), while that of concanavalin A stimulated splenocytes 
is unchanged (B). Proliferation of T cells isolated from LDLr-/- mice fed a Western type diet for two 
weeks was increased after incubation with Bim-/- dendritic cells (DCs) stimulated with LPS, but not 
after incubation with nonstimulated Bim-/- DCs or DCs stimulated with Ox-LDL as compared to T cells 
incubated with stimulated or nonstimulated WT DCs (C). (*p<0.05)
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Leukocyte	Bim	deficiency	affects	circulating	myeloid	cell	and	lymph	node	DCs
In addition to elevated circulating lymphocyte numbers, monocyte/macrophage 
and neutrophil levels in blood were elevated by 87% and 42%, respectively (p<0.05, 
fig 5A). Mediastinal lymph nodes surprisingly showed a reduced total dendritic cell 
(DC) content (10.0 ± 0.8 % in Bim-/- BM transplanted mice vs. 7.6 ± 0.7% in WT BM 
transplanted mice; p<0.05, fig. 5B). MHCII+ DCs were reduced to the same extent 
as total DCs, suggesting that Bim deficiency does not influence activation of DCs in 
LDLr-/- mice. Relative DC content in spleen remained unchanged (fig. 5C).
Leukocyte	Bim	deficiency	affects	the	humoral	immune	response	in	LDLr-/- mice
Apart from affecting T cell homeostasis, loss of Bim was seen to be associated with 
impaired deletion of autoreactive B cells. The resulting accumulation of these cells 
and derived autoreactive antibodies in vivo15 can promote autoimmunity12. We 
therefore measured Ox-LDL directed autoantibody titers in serum. IgG1 anti-Ox-
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Figure	5.	Consequences	of	Bim	deletion	on	circulating,	splenic	and	MLN	myeloid	cell	content. Circulating 
monocytes/macrophages and neutrophils are increased in Bim deficient LDLr-/- mice fed a Western type 
diet for ten weeks (A). Total DC and MHCII+ DC content is reduced after Bim deletion in mediastinal 
lymph nodes (MLN; B) but not in spleen (C). (*p<0.05)
Figure	6.	Effect	of	 leukocyte	Bim	deficiency	on	humoral	 immune	response. Ox-LDL specific antibody 
titers in serum after 10 weeks of Western type diet feeding were measured by ELISA. IgG1 antibody 
levels were increased while IgM and IgG2a antibody levels were unchanged suggestive of a Th2 shifted 
T-cell response (A). Total immunoglobulin (Ig) deposition in aortic root lesions was massively increased 
in Bim-/- transplanted mice (B). Representative cryosections showing overt staining for total Ig (green); 
nuclei are stained with DAPI (blue) (C). (*p<0.05)
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LDL antibodies were increased by more than two-fold (p<0.05, fig. 6A) in Bim-/- BM 
transplanted mice compared to controls, but no differences in IgM and IgG2a anti-Ox-
LDL auto-antibodies were detected. Consequently the IgG1/IgG2a ratio, a measure 
of Th2/Th1 polarized T-cell response, was sharply increased in Bim-/- chimeras from 
1.19 ± 0.22 for WT BM recipients to 2.84 ± 0.71 for Bim-/- BM recipients (p=0.06). 
Importantly, staining for deposits of total immunoglobulins (Ig) in lesions revealed 
the striking presence of Ig complexes in lesions of Bim-/- chimeras but not littermate 
controls (0.10 ± 0.04 % versus 1.08 ± 0.04%; p<0.05, fig. 6B and C).
Apoptotic	cell	death	is	affected	by	loss	of	leukocyte	Bim
Loss of Bim in bone marrow derived macrophages (BMDM) resulted in decreased 
sensitivity to apoptotic cell death in response to a number of stimuli. Basal apoptosis 
levels were already reduced in Bim-/- compared to WT BMDM (45%, p=0.06, fig. 
7A). While in WT BMDM apoptosis increased from 4.39 ± 0.81% to 22.94 ± 3.61% 
upon growth factor withdrawal, in Bim-/- BMDM apoptosis increased from 2.39 ± 
0.37 to only 8.59 ± 0.70% (p<0.01, fig. 7A). OxLDL induced apoptotic cell death was 
43% less in Bim-/- compared to WT BMDM (p<0.05), but interestingly the relative 
increase over non-stimulated cells was similar in WT and Bim-/- BMDM (fig. 7A). 
Since we observed profound splenomegaly in Bim-/- BM recipients we measured 
apoptotic cell content in spleens, which appeared to be significantly lower in Bim-
/- BM compared to WT BM transplanted mice (3.34 ± 0.43 vs. 1.84 ± 0.29 % of total 
splenocytes for WT and Bim-/- BM transplanted mice respectively, p<0.01, fig. 7B). 
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Figure	 7.	 Apoptotic	 cell	 death	 in	
leukocyte	 Bim	 deficient	 LDLr-/- mice. 
Apoptosis of bone marrow derived 
macrophages is reduced in Bim-/- 
transplanted mice at basal level, after 
growth factor withdrawal, and after 
stimulation with Ox-LDL (40 μg/ml) 
(A). Spleen apoptotic cell content is 
decreased by 45% in Bim-/- chimeras 
(B), but is unaffected in atherosclerotic 
lesions (C). Representative pictures of 
TUNEL stained aortic root cryosection 
(D). (*p<0.05, **p<0.01)
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In striking contrast, apoptotic cell content of atherosclerotic lesions remained 
unchanged (fig. 7C and D).
Atherosclerotic	lesion	size	and	stability	are	not	changed	after	loss	of	leukocyte	Bim
After ten weeks of Western type diet feeding mice were sacrificed and the aortic 
root and descending aorta were isolated and analyzed for size and composition. In 
keeping with elevated T cell levels in circulation and lymphoid organs T cell content 
in the atherosclerotic lesions (intima and adventitia) was increased by 51% from 
10.1 ± 1.2 per section in WT BM recipients to 15.3 ± 1.6 per section in Bim-/- BM 
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Figure	 8.	 Atherosclerotic	 lesion	 size	 and	 composition. Lesion size in aortic root and descending 
aorta were unchanged in LDLr-/- mice with hematopoietic Bim deficiency (A and C respectively, with 
representative pictures [B and D]) as was Moma-2+ macrophage content (E, with representative 
pictures [F]). CD3+ T cell content was increased in Bim-/- transplanted mice (G). Representative picture 
of a CD3 stained (brown) cryosection (H). (*p<0.05)
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transplanted recipients (p<0.05, fig. 8G and H). We did not observe any significant 
differences in lesion size in aortic root between groups (fig. 8A and B). In agreement 
en	face analysis of the descending aorta showed no differences in atherosclerotic 
lesion area as well (fig. 8C and D). Regarding composition, lesional moma-2 positive 
macrophage content in Bim-/- did not differ from that in WT BM transplanted mice 
(fig. 8E and F). Collagen and necrotic core were virtually absent in the early lesions 
of WT and Bim-/- BM transplanted mice.
Discussion 
Bim was demonstrated to be essential for apoptosis of various leukocyte subsets, 
including T and B cells, dendritic cells, macrophages and granulocytes12,13,27. 
As these cell types are all shown to be present in atherosclerotic lesions and to 
contribute to disease development, a role for Bim in lesional leukocyte apoptosis 
and atherogenesis may be anticipated. Therefore we generated LDLr-/- mice with Bim 
deficiency in  hematopoietic cells by bone marrow transplantation and addressed 
effects of Bim deficiency on lesion development. The most profound consequences 
of Bim deficiency following BMT were observed on T cell homeostasis. Lymphocytes, 
although in atherosclerotic lesions less abundantly present than macrophages, are 
importantly involved in regulating immune responses in lesions20,28. Lymphocyte 
deficiency in mice has previously been demonstrated to result in reduced 
atherosclerotic lesion size17,18 and transfer of CD4+ T cells in immunodeficient mice 
was seen to aggravate atherosclerosis19. In keeping with previous studies12 we 
show markedly elevated circulating lymphocyte levels in Bim-/- BM transplanted 
LDLr-/-mice. Furthermore, mediastinal lymph node CD4+ and CD8+ T cell content 
is slightly increased and LDLr-/- mice suffer from considerable splenomegaly after 
leukocyte Bim deletion. Our results are consistent with previous observations that 
systemic Bim deficient mice have enlarged spleens and highly elevated lymphocyte 
content in circulation and lymphoid organs12, although as expected in systemic Bim 
deficiency the above-mentioned differences were more pronounced. As suggested 
by Bouillet and Hildeman and colleagues this overt lymphocytosis may be caused 
by impaired apoptosis of autoreactive thymocytes and activated T cells for which 
Bim has been demonstrated to be essential14,16. In agreement with the latter, both 
CD4+ and CD8+ splenic T cells are more activated in Bim-/- BM recipients than in 
control mice, both at an absolute (% of total splenocytes) and at a relative level (% 
of the respective T cell subset). The observed elevated T cell numbers are reflected 
in increased T cell content in atherosclerotic lesions indicating an enhanced 
infiltration of T cells from circulation into the lesions. Decreased apoptotic cell death 
in spleen was accompanied by a slightly increased basal splenocyte proliferation in 
Bim-/- BM transplanted mice. The proliferation capacity of Bim-/- splenocytes was 
not affected. Although increased proliferation of Bim-/- splenocytes has not been 
described before, Bim interacts with anti-apoptotic Bcl-2 family members, which 
in turn were seen to influence cell cycle entry29,30. Interestingly, T-cell proliferation 
was increased after stimulation with LPS but not Ox-LDL pulsed Bim-/- DCs compared 
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to immature DCs. This effect was absent in WT DCs. Previously loss of Bim in DCs 
was seen to decrease cell death and to promote proliferation of antigen-specific 
T cells27. We extend these findings by showing that pulsed Bim-/- DCs are able to 
enhance proliferation of nonspecific T cells as well. 
In addition to T cell homeostasis and activation Bim was previously reported to be 
necessary for apoptosis of autoreactive B cells15 and to prevent autoimmunity12. 
Atherosclerosis is currently recognized as a lipid driven inflammatory process with 
features of autoimmune disease20-22, implicating T cell responses to auto-antigens, 
such as Ox-LDL and heat shock proteins (HSP)22. In fact, Ox-LDL specific antibodies 
have been detected in atherosclerosis-prone ApoE-/- mice31, in human and rabbit 
serum and in atherosclerotic lesions32. Moreover, a subset of T cells present in human 
lesions was demonstrated to be Ox-LDL specific33. In the present study we observed 
markedly elevated Ox-LDL antibody levels in serum of Bim-/- BM transplanted 
mice. In addition, total immunoglobulin deposition in atherosclerotic lesions of 
Bim-/- BM recipients was dramatically increased. Generally, these auto-antibodies 
directed against Ox-LDL are thought to be atheroprotective as several studies have 
demonstrated decreased lesion formation after immunization with modified LDL34-
37. Furthermore IgG antibodies against modified LDL and oxidized phospholipids 
were increased in immunized LDLr-/- mice and correlated with decreased lesion 
formation37. Furthermore B cell associated immunity was shown to be protective in 
atherosclerosis as splenectomy increased lesion size of ApoE-/- mice which could be 
counteracted by transfer of spleen derived B cells38. The observed increase in anti-
Ox-LDL antibodies in serum of Bim-/- BM recipients is mainly due to elevated anti-
Ox-LDL IgG1 levels, whereas anti-Ox-LDL IgM and IgG2a isotypes were not affected. 
This may point to a shift towards Th2 type immune responses, which may by itself 
influence the progression of atherosclerosis20. Both mouse and human studies have 
demonstrated a predominant Th1 response in atherosclerotic plaques, with Th1 
cytokines such as IFNγ, IL2 and TNFα abundantly present within the lesion39,40. Th2 
cells, in contrast, produce IL4, IL5, IL10 and IL13 which promote antibody formation 
and inhibit pro-inflammatory cytokine expression and are thought to protect against 
atherosclerosis20,21.
In agreement with previous studies12, not only circulating lymphocytes numbers 
but also that of monocyte/macrophages and neutrophils were increased in Bim-/- 
BM transplanted mice. Surprisingly, this does not translate into increased plaque 
macrophage content or elevated relative macrophage and DC content in lymphoid 
organs, except for a slight relative decrease in mediastinal lymph node DCs. Since 
loss of Bim has been demonstrated to increase half life and proliferation of DCs27 
our result may indicate that either trafficking of antigen presenting DCs into lymph 
nodes is impaired or that uptake of antigen by DCs and subsequent DC maturation 
is reduced in Bim-/- BM recipients compared to WT BM recipients.
Absence of Bim decreased spontaneous apoptosis of bone marrow derived 
macrophages as well as apoptosis induced by growth factor withdrawal. These results 
are consistent with previous studies showing decreased apoptosis in Bim deficient 
Leukocyte	Bim	Deficiency	Induces	Anti-Ox-LDL	Autoantibody	Formation	and	TCell	and	Ig	Accumulation
83
T cells12, DCs27 and granulocytes13 in response to various stimuli. In addition we 
identify Bim as a regulator of Ox-LDL induced apoptosis of macrophages. However 
while spleen apoptotic cell content was decreased in Bim-/- BM recipients as 
expected, we did not observe any differences in atherosclerotic lesion apoptotic cell 
content, predominantly representing macrophages and foam cells. Bim dependent 
pro-apoptotic effects on T cells, which are present at much lower numbers in 
atherosclerotic lesions20, are probably not detectable. 
Despite marked effects on T cell levels and characteristics, humoral immune 
response and myeloid subset levels, leukocyte Bim deficiency in LDLr-/- mice 
did not alter atherosclerotic lesion size or stability as assessed at two different 
vascular sites, early atherogenesis in the descending aorta and intermediate 
stage atherosclerosis in the aortic root valves. Apart from an increased lesional 
T cell content no differences were observed in aortic root lesion composition. 
Surprisingly leukocyte Bim deficiency following BMT led to a striking reduction in 
serum lipids, e.g. total cholesterol and triglycerides, in LDLr-/- mice. For triglycerides 
this effects was independent of the diet. Decreased serum lipid levels were not 
caused by differences in hepatic lipid content. To what extent hepatic inflammation 
represented by T-cells which were elevated in livers of Bim-/- BM transplanted mice 
had contributed to the hypolipidemia remains to be determined. Nevertheless, 
such involvement of Bim in hepatic lipid metabolism has not yet been described 
thus far and warrants further study.. 
In conclusion, we show here that leukocyte Bim deficiency in LDLr-/- mice results in 
increased activated T-cell content in circulation, lymphoid organs and atherosclerotic 
lesions, in increased levels of autoreactive antibodies directed against oxidized LDL in 
circulation and in substantial immunoglobulin deposition in atherosclerotic lesions. 
Collectively these pro- and anti-atherogenic effects of leukocyte Bim deficiency, 
summarized in table 1, together with the surprising reduction in serum lipid levels 
likely counterbalance so that atherosclerosis development remains unaffected. 
Table	1. Pro- and anti-atherogenic consequences of leukocyte Bim deficiency in LDLr-/- mice.
Pro-atherogenic Anti-atherogenic
Circulating and lymph node T cell levels ↑ Serum cholesterol ↓
T cell activation ↑ Serum triglycerides ↓
Circulating Monocyte/macrophage 
and neutrophil levels
↑ Ox-LDL antibodies ↑
Apoptosis (depending on cell type) ↓ Apoptosis (depending on cell type) ↓
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Abstract
The anti-apoptotic Bcl-1 family member myeloid cell leukemia 1 (Mcl-1) plays an 
important, in neutrophils essential, role in survival and differentiation of leukocy-
te subsets. Here, we investigated the impact of Mcl-1 deletion in neutrophils and 
macrophages on atherosclerotic plaque development and stability in Western type 
diet fed LDLr-/- mice by a bone marrow (BM) transplantation strategy.
First, Mcl-1 deficient peritoneal macrophages had an increased sensitivity to Ox-LDL 
induced cell death and showed altered expression of several pro-apoptotic Bcl-2 fa-
mily members as compared to WT macrophages. In keeping apoptotic cell content 
in aortic root lesions of Mcl-1-/- chimeras was elevated by 77% compared to WT con-
trols. Second, lipid accumulation by peritoneal Mcl-1-/- macrophages, induced by 
Ox-LDL and VLDL, was enhanced in vitro as well as in vivo. Third, Mcl-1-/- macropha-
ges showed a shift towards a pro-inflammatory M1 phenotype as apparent from 
their cytokine expression pattern and reduced phagocytic capacity. Despite these 
profound pro-atherogenic effects of Mcl-1 deficiency, the atherosclerotic plaque 
development and progression in LDLr-/- mice on a Western-type diet did not differ 
be-tween Mcl-1-/- and WT BM recipients. This seeming paradox can be explained by 
the markedly lower neutrophil numbers and migratory capacity in Mcl-1 deficiency, 
which translates in impaired atherosclerotic lesional neutrophil infiltration thus cor-
roborating the significance of neutrophils for atherogenesis.
In conclusion, myeloid Mcl-1 deletion enhances Ox-LDL induced foam cell forma-
tion and cell death, favors a pro-inflammatory macrophage phenotype and mar-
kedly lowers neutrophil recruitment. The unaffected plaque initiation and growth 
indicates that neutrophil recruitment is essential to translate the pro-inflammatory 
phenotype into increased plaque formation.
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Introduction
Macrophages are critical in the onset and progression of atherosclerotic lesion 
development. Monocyte infiltration with subsequent differentiation into 
macrophages, accumulation of lipids and secretion of various cytokines and growth 
factors all contribute to lesion progression1. Plaque macrophages have been shown 
to undergo apoptosis at all stages2, although apoptosis tends to increase with 
plaque progression3. Macrophages are also the predominant lesional phagocytes4. 
Defective macrophage apoptosis in early lesions has been shown to promote 
lesion development in different atherosclerotic mouse models5-7. In advanced 
lesions, macrophage apoptosis contributes to the formation of large necrotic cores 
consisting mostly of lipids and apoptotic cell debris2. However, studies addressing 
effects of CD11b monocyte/macrophage apoptosis in advanced lesions did not 
reveal any differences in lesion size despite increased apoptotic cell content7,8. In 
human atherosclerotic lesions apoptosis of macrophages appeared to be enhanced 
only in more advanced stages9. This increase may at least in part be due to defective 
apoptotic cell phagocytosis in advanced lesions10. 
Anti-apoptotic Mcl-1 is a member of the apoptosis regulating Bcl-2 family11. It 
directly interacts with proapoptotic BH3-only proteins Bim and Bid and multidomain 
proapoptotic Bak12-14, thereby inhibiting apoptosis. Mcl-1 is expressed in various 
tissues including hematopoietic cells15, in which overexpression delays cell death 
in response to various stimuli16. Deletion of Mcl-1 in mice results in embryonic 
lethality17. A recent in vivo study in conditional knockout mice lacking Mcl-1 in 
neutrophils and macrophages demonstrated that Mcl-1 is necessary for neutrophil 
but not macrophage survival18,19. Mcl-1 induced neutropenia could be prevented by 
combined deletion of pro-apoptotic Bak and Bax19. In synovial fluid macrophages of 
rheumatoid arthritis patients Mcl-1 expression is enhanced and demonstrated to 
be essential for survival since Mcl-1 inhibition largely increased apoptosis20. Mcl-1 
has been implicated in macrophage lipid accumulation. Mcl-1 RNA expression was 
found to be increased in THP-1 macrophages following Il-10 exposure, which also 
augmented Ox-LDL induced foam cell formation 21. Furthermore, silencing Mcl-1 and 
Bfl-1, another anti-apoptotic Bcl-2 family member, in these macrophages prevented 
IL-10 induced lipid accumulation21. The critical importance of macrophage apoptosis 
and foam cell formation in atherosclerosis points to a potential role of this anti-
apoptotic factor in atherosclerosis. 
In the present study we have investigated the role of myeloid Mcl-1 in atherosclerotic 
plaque development and progression using bone marrow transplantation of LDLr-
/- mice with Mcl-1fl/fl LysMcre or control bone marrow, with a specific emphasis on 
neutrophil recruitment as pro-atherogenic factor. 
Materials and Methods
Animals
All animal work was approved by regulatory authority of Leiden and performed in 
compliance with the Dutch government guidelines. LDLr-/- mice were obtained from 
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the local animal breeding facility. Mcl-1fl/fl LysMcre mice were obtained from the 
Department of Immunology, Duke University Medical Center, Durham, NC, USA. 
Mcl-1 gene expression during atherogenesis
To assess Mcl-1 gene expression during atherosclerotic lesion progression 20 male 
LDLr-/- mice were fed a Western type diet (WTD) two weeks prior to surgery and 
throughout the experiment. Atherosclerotic carotid artery lesions were induced by 
perivascular collar placement as described by Von der Thüsen et al.22 and subsets of 
4 mice were sacrificed at 0, 2, 4, 6 and 8 weeks after collar placement for expression 
analysis. The mice were anaesthetized and perfused with phosphate buffered saline 
(PBS, 150 mM NaCl, 1.5 mM NaH2PO4, 8.6 mM Na2HPO4, pH 7.4) after which both 
common carotid arteries were isolated, snap-frozen in liquid nitrogen and stored 
at -80ºC. Two to three carotid arteries were pooled per sample and total RNA was 
isolated using Trizol reagent (Invitrogen, Breda, The Netherlands). Gene expression 
was analyzed by real time PCR using ABI PRISM 7700 Sequence Detector (Applied 
Biosystems) with SYBR-Green technology. The primers used for expression of Mcl-1 
and standard housekeeping gene hypoxanthine-guanine phosphoribosyltransferase 
(HPRT) are listed in table 1.
Bone	marrow	transplantation	and	atherosclerosis	induction
Male LDLr-/- mice (n=10) were housed in sterile ventilated cages with food (RM3, 
Special Diet Services, Witham, Essex, UK) and water ad libitum. The drinking water 
was supplied with antibiotics (83 mg/l ciprofloxacin and 67 mg/l Polymixin B) and 
5 g/l sugar. The mice were exposed to a single dose of 9 Gy total body irradiation 
(0.19Gy/min, 200 kV, 4 mA,) using an Andrex Smart 225 Röntgen source (YXLON 
International, Copenhagen, Denmark) one day before transplantation. Bone 
marrow was extracted from femurs and tibia of male Mcl-1fl/fl LysMcre (hereafter 
Mcl-1-/-) and wild type (WT) littermates. Irradiated LDLr-/- mice received either 2.5 x 
106 Mcl-1-/- bone marrow cells (n=10) or 2.5 x 106 WT bone marrow cells (n=10) via 
tail vein injection. After a recovery period of eight weeks mice were put on a WTD 
containing 0.25% cholesterol and 15% cacao butter (Diet W, Special Diet Services, 
Witham, Essex, UK) for an additional five (plaque initiation) or ten weeks (advanced 
plaque formation).
Cholesterol and triglyceride assay
Blood samples were taken by tail bleeding before bone marrow transplantation 
(BMT), before start of (week 0), after two and six weeks of WTD feeding (week 2 
and week 6) and at the time of sacrifice (week 5 or week 10). Total cholesterol and 
triglyceride levels in serum were measured spectrophotometrically using enzymatic 
procedures (Roche Diagnostics, Almere, The Netherlands). 
Blood	cell	analysis	and	flow	cytometry
Blood samples were taken by tail bleeding immediately before BMT, before start of 
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(week 0) and after four weeks of WTD feeding (week 4) and at the time of sacrifice 
(week 5 or week 10). Peritoneal leukocytes were isolated at the time of sacrifice by 
peritoneal lavage with 10 ml PBS. Whole blood and peritoneal lavage samples were 
analyzed using a Sysmex blood cell analyzer (XT-2000i). White blood cells (WBC) were 
isolated by erythrocyte lysis of whole blood samples obtained by bleeding through 
the orbital sinus. For flow cytometry, WBC and peritoneal leukocytes were stained 
with fluorescently labeled antibodies against F4/80, CD19, CD4, CD71 and CD11b 
(eBioscience, Halle Zoersel, Belgium) and Gr1, CD8 and CXCR4 (BD Pharmingen, 
Breda, The Netherlands). Fluorescence-activated cell sorting (FACS) analysis was 
performed on FACSCalibur with CellQuest software (BD Biosciences).
Tissue	harvesting	and	analysis
Two hours before sacrifice five mice from each group, Mcl-1-/- or WT, received 
intraperitoneal injections of the chemokine KC (200 ng/ml in 1 ml PBS) or PBS 
control. The mice were anesthetized and perfused with PBS. Heart, spleen and 
liver were harvested and stored in 4% formaldehyde solution. Cryosections were 
prepared of the aortic root and of spleen tissue and stained with hematoxylin and 
eosin (HE) or Oil Red O. Lesion size was quantified using Leica image analysis system, 
consisting of a Leica DMRE microscope with camera and Leica Qwin Imaging software 
(Leica Ltd, Cambridge, UK). Immunohistochemical stainings were performed for 
macrophage (MOMA-2, Sigma, Zwijndrecht, The Netherlands) and vSMC (α-smooth 
muscle actin, Sigma) content. Apoptotic cell content was quantified using terminal 
deoxytransferase dUTP nick-end labeling (TUNEL) kit (Roche Diagnostics). 
LDL	and	VLDL	isolation
LDL and VLDL were obtained from human plasma by density gradient 
ultracentrifugation for 20h at 4ºC23. Oxidation of LDL was performed by incubation 
with CuSO
4
 for 24 hours at 37ºC after which the oxidation reaction was terminated 
by addition of EDTA (final concentration 200 µM).
Lipid	loading	of	peritoneal	macrophages
Peritoneal leukocytes were isolated from mice that received an i.p. injection of PBS 
before sacrifice and subsequently combined resulting in 3 pools of Mcl-1-/- and of WT 
peritoneal leukocytes. Cells were plated at 0.25 x 106 cells/well in 8 chamber culture 
slides (BD Falcon, Breda, The Netherlands). Non-adherent cells were removed and 
adherent macrophages were stimulated with 20 μg/ml oxidized LDL (Ox-LDL) or 50 
ug/ml VLDL for 24 hours after which slides were washed with PBS and stained with 
Oil Red O. Lipid loading was quantified as the ratio between the Oil Red O stained 
cell area and total cell surface.
Apoptosis	of	peritoneal	macrophages
Mcl-1-/- and WT peritoneal leukocyte pools (n=3 each) were plated at a density of 0.5 
x 106 cells/well in a 24 well plate. Non-adherent cells were removed and adherent 
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macrophages were stimulated with 40 ug/ml Ox-LDL for 24 hours. The macrophages 
were detached with Accutase (PAA Laboratories GmbH, Cölbe, Germany), stained 
with  FITC labeled Annexin V (ImmunoTools, Friesoythe, Germany) and propidium 
iodide (Sigma) and subsequently analyzed by flow cytometry (FACSCalibur, BD 
Biosciences, Breda, The Netherlands).
Isolation	and	differentiation	of	bone	marrow	derived	macrophages	
Bone marrow cells were isolated by flushing femurs and tibia with PBS and single 
cell suspensions were obtained by passing the suspension through a 70 µm nylon 
cell strainer (BD Falcon). Bone marrow cells were differentiated into macrophages 
by culturing in 70% RPMI, supplemented with 20% FCS, glutamine (2 mM), sodium 
pyruvate (1%), penicillin (100 U/ml), streptomycin (100 μg/ml) and non-essential 
amino acids (1%), and 30% L929 conditioned DMEM for 7 days. Bone marrow 
derived macrophages (BMDM) were used for apoptosis assay. BMDM experiments 
were performed in RPMI containing FCS (10%), glutamine (2 mM) and penicillin 
(100 U/ml) and streptomycin (100 μg/ml).
Phagocytosis assay
Jurkat cells were labeled with CellTracker Orange CMTMR fluorescent dye (Molecular 
Probes, Merelbeke, Belgium). Apoptosis was induced by incubation with 1 μM 
staurosporine (Sigma) for 2 hours. Apoptosis was assessed by flow cytometry after 
FITC labbeled Annexin V and propidium iodide staining of the cells. 70% of Jurkat 
cells were found to undergo apoptosis after incubation with staurosporine. BMDM 
were incubated for 1 hour with apoptotic Jurkat cells or red fluorescent beads (2 
μm Fluospheres, Molecular Probes) at 37ºC. After thorough washing with PBS (5 
times) phagocytosis was analyzed on a FACSCanto with FACSDiva software (BD 
Biosciences).
RNA	isolation	and	realtime	PCR
Murine RAW 264.7 cells or BMDM were incubated for 24 h with or without Ox-
Table	1. Primer sequences 
Gene Forward Primer (5’-3’) Reverse Primer (5’-3’)
HPRT TTGCTCGAGATGTCATGAAGGA AGCAGGTCAGCAAAGAACTTATAG
36B4 GGACCCGAGAAGACCTCCTT GCACATCACTCAGAATTTCAATGG
Mcl-1 TCATTCTGGTAGAGCACCTAACACTT AGCAGGTCAGCAAAGAACTTATAG
Bim GGACTCTAAGAAAATACCCATCAAACC TCCCCATCTGCTGCTAATACTTC
PUMA CCCCATCCATCTCATTGCAT GTGGCTTCCGCCAATATCTC
NOXA GGTTGATGGAAATGCCTGGTAT GAAACTCATTCCTATCTCCTTCATCAT
IL10 TCTTACTGACTGGCATGAGGATCA GTCCGCAGCTCTAGGAGCAT
Arg1 GGTTCTGGGAGGCCTATCTTACA TCTTCACCTCCTCTGCTGTCTTC
TNFα GCCAGCCGATGGGTTGTA AGGTTGACTTTCTCCTGGTATGAGA
p35 CCAAACCAGCACATTGAAGA CTACCAAGGCACAGGGTCAT
iNOS CCTGGTACGGGCATTGCT GCTCATGCGGCCTCCTTT
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LDL (20 or 40 μg/ml). Total RNA was extracted using guanidine thiocyanate (GTC, 
Sigma, according to Chomczynski24). After RT-PCR, gene expression was analyzed 
by quantitative real-time PCR using ABI PRISM 7700 Sequence Detector (Applied 
Biosystems) using SYBR-Green technology and the primers listed in table 1. 
Hypoxanthine-guanine phosphoribosyltransferase (HPRT) and acidic ribosomal 
phosphoprotein P0 (36B4) were used as standard housekeeping genes.
Statistic	analysis
Values are expressed as mean ± SEM or presented as mean + upper limit of the 
SEM. Analysis to compare two groups was performed by two-tailed Student’s t-test. 
For analysis of relative mRNA expression data t-test was performed on ΔCt values. 
Statistical significance was set at p<0.05.
Results
Expression	of	Mcl-1	in	murine	macrophages	and	during	atherogenesis
We first examined whether Mcl-1 has a potential role in atherosclerotic lesion 
development by assessing Mcl-1 gene expression in murine RAW 264.7 macrophages 
and the influence of oxidized LDL (Ox-LDL) on Mcl-1 expression. Mcl-1 is expressed 
in RAW 264.7 cells (fig. 1A). RAW 264.7 derived foam cells, generated by exposure 
to 20 or 40 μg/ml OxLDL for 24h displayed decreased mcl-1 expression (p≤0.05, fig. 
1A). 
Next, we monitored Mcl-1 gene expression in LDLr-/- mice during atherogenesis. 
Mcl-1 gene expression during atherogenesis was measured in carotid artery lesions 
of western type diet fed LDLr-/- mice equipped with semi-constrictive collars to 
accelerate atherosclerotic lesion formation22. Mcl-1 gene expression was gradually 
increased during lesion development and in particular advanced plaques (> six weeks 
after collar induction of atherosclerotic lesion development) displayed a significant 
upregulation of increased Mcl-1 (p<0.05, fig. 1B). These results suggest that Mcl-1 is 
regulated during lesion progression which could contribute to atherosclerotic lesion 
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Figure 1. Regulation of Mcl-1 expression in vitro in RAW 264.7 macrophages and in vivo during 
atherogenesis. A. Mcl-1 was abundantly expressed in non-stimulated RAW 264.7  macrophages but 
downregulated upon exposure to 20 μg/ml or 40 μg/ml Ox-LDL for 24h. B. Vascular Mcl-1 expression 
gradually increased during lesion progression in a model of collar induced carotid artery atherogenesis 
in LDLr-/- mice (*p<0.05).
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development or lesion stability.
Total	cholesterol	levels	and	body	weight
Next we generated LDLr-/- mice with myeloid Mcl-1 deletion by reconstituting lethally 
irradiated LDLr-/- mice with Mcl-1fl/fl LysMCre (hereafter Mcl-1-/-) or wild type (WT) 
bone marrow cells. After a recovery of eight weeks mice were put on a Western 
type diet (WTD) and effects of Mcl1-/- deficiency on lipid levels were monitored 
by measuring serum total cholesterol (TC) and triglyceride (TG) levels throughout 
the experiment. Average TC and TG levels did not differ between Mcl-1-/- and WT 
transplanted animals.  Mcl-1 deletion did not affect total body weight.
Myeloid	Mcl-1deletion	increases	lesional	apoptotic	cell	content	but	does	not	affect	
atherosclerotic	lesion	size
Five (early plaque formation) or ten weeks (advanced plaque formation) after WTD 
feeding aortic roots were isolated, sectioned and analyzed. Apoptotic cells content 
appeared to be increased by 71% (NS) and 77% (p=0.002) in atherosclerotic lesions 
of Mcl-1-/- fed a WTD for 5 and 10 weeks, respectively, compared to WT transplanted 
mice (Fig. 2A,B). However, despite its profound impact on apoptosis, myeloid Mcl-
1 deletion did neither alter early atherogenesis (5.97 ± 2.62 *104 μm2 and 4.73 ± 
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Figure	2.	Effect	of	myeloid	Mcl-1	deficiency	on	atherosclerotic	lesion	size	and	composition. A. Plaque 
apoptotic cell content is increased in Mcl-1-/- BM transplanted mice after 10 weeks of WTD feeding. 
B. Representative micrographs of TUNEL-stained aortic root sections (100x and 650x magnification 
(insert)). C. Plaque necrotic core size however is unchanged in Mcl-1 deficiency. D. Atherosclerotic lesion 
size is unaffected by myeloid Mcl-1 deficiency both at early and at late stages of disease progression. E. 
representative micrographs of Oil Red O stained aortic root sections. F. Moma-2 positive macrophage 
content of plaques was unaffected by myeloid Mcl-1 deficiency as well. (*p<0.05)
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2.29 *104 μm2 for Mcl-1-/- and WT reconstituted mice respectively, 5 weeks of WTD) 
nor advanced lesion formation (3.31 ± 1.66 *105 μm2 and 3.44 ± 1.38 *105 μm2, 10 
weeks of WTD) (Fig. 2D) Necrotic core size and lesion macrophage (Moma-2) and 
collagen content were unaffected by myeloid Mcl-1 deletion as well (fig. 2C,E,F). 
Macrophage	sensitivity	to	Ox-LDL	induced	apoptosis	is	increased
Incubation of peritoneal macrophages with 40 μg/ml Ox-LDL for 24 hours showed 
that Mcl-1-/- macrophages have an increased sensitivity towards Ox-LDL induced 
cell death compared to WT macrophages (Fig. 3A). Mcl-1 deletion also appeared to 
decrease cell survival in non-stimulated macrophages. Gene expression of several 
BH3-only proapoptotic Bcl-2 family proteins was assessed in Mcl-1-/- and WT bone 
marrow derived macrophages (BMDM). The expression of Bim, PUMA (p<0.01) 
and NOXA (n.s.), proapoptotic proteins that all were seen to interact with Mcl-125-
27, appeared to be decreased in non-stimulated Mcl-1-/- macrophages (fig. 3B-D). 
Exposure to Ox-LDL decreased gene expression of PUMA and NOXA but did not 
change that of Bim in WT macrophages. Conversely, in Mcl-1-/- macrophages Ox-LDL 
incubation resulted in elevated Bim and PUMA expression. 
Macrophage lipid loading is enhanced
Peritoneal foam cell numbers were increased by 2.5 fold (p<0.05) in Mcl-1-/- compared 
Figure	3.	Cell	death	and	ex-pression	of	Bcl-2	family	members	in	peritoneal	and	bone	marrow	derived	
macrophages. A. Mcl-1 deficiency leads to enhanced cell death of unstimulated and Ox-LDL (40 μg/
ml) stimulated peritoneal macrophages. B-D. Bim, PUMA and NOXA gene expression was affected by 
Mcl-1 deletion (black bars) in both unstimulated and Ox-LDL (40 μg/ml) stimulated BMDM. (*p<0.05, 
**p<0.01)
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to WT transplanted mice (Fig. 4A). Total peritoneal macrophage numbers were 
unchanged. This finding led us to examine the lipid loading capacity of peritoneal 
macrophages in vitro. Macrophages were incubated for 24h with 20 µg/ml Ox-
LDL or 50 µg/ml VLDL and stained with Oil Red O. In agreement with the elevated 
peritoneal foam cell counts in vivo, lipid accumulation in non-stimulated Mcl-1-/- 
macrophages was markedly increased (fig. 4B,C). Lipid loading in WT macrophages 
remained unchanged after incubation with Ox-LDL for 24h, but was substantially 
enhanced in Mcl-1-/- macrophages (p<0.01). While incubation with VLDL increased 
lipid content in both WT and Mcl-1-/- macrophages, this increase was considerably 
(3,6 fold) higher in the latter cells (p=0.01).  
In addition to enhancing the lipid loading capacity, Mcl-1 deficiency resulted in 
an increased presence of multinucleated giant cells (MGC) within the peritoneal 
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Figure	4.	Mcl-1	deletion	enhances	lipid	loading	of	peritoneal	macrophages. A. Elevated macrophage 
derived foam cell numbers in peritoneum of Mcl-1-/- BM (black bars) compared to WT BM transplanted 
mice (white bars). B. Lipid loading of Mcl-1-/- peritoneal macrophages (black bars) was dramatically 
increased after incubation with Ox-LDL (20 μg/ml) or VLDL (20 μg/ml), whereas WT macrophages (white 
bars) only showed a moderate increase in lipid loading after incubation with VLDL. C. Representative 
micrographs of Oil Red O stained unstimulated and Ox-LDL or VLDL stimulated peritoneal macrophages. 
Multinucleated giant cells are indicated by an arrow. (*p<0.05, **p<0.01) D. Multinucleated giant cell 
levels were largely increased among Mcl-1-/- peritoneal macrophages compared to WT macrophages.
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macrophage population both at baseline and after incubation with Ox-LDL or VLDL 
(p<0.05, Fig. 4C and 4D, MGC are indicated by arrows). 
Mcl-1-/- transplanted LDLr-/- mice display splenomegaly and altered macrophage 
phenotype.   
Relative spleen weight was increased by nearly two-fold (p=0.006) in Mcl-1-/- 
compared to WT transplanted mice (fig. 5B), which in Mcl-1 LysMCre deleted mice 
has been shown to result from increased myeloid cell content in splenic red pulp19.
BM derived macrophages with MCL1 deletion showed features of a pro-
inflammatory M1 phenotype (fig 5D-H). IL10 expression in OxLDL stimulated Mcl-1-
/- macrophages was reduced while that of the M2 marker arginase I was unaltered. 
Conversely, expression of proinflammatory M1 cytokines TNFα, and IL12 subunit 
p35 was upregulated after Ox-LDL stimulation, an effect absent in WT macrophages. 
In agreement with the M1 shift, macrophages exhibited reduced phagocytosis of 
early apoptotic Jurkat cells (fig. 5C), a phenomenon that was reported to be more 
pronounced in M2 than in M1 macrophages28.  
Figure	5.	Myeloid	Mcl-1	deficiency	affects	inflammatory	status	of	LDLr-/- mice. A. Mcl-1-/- BM recipients 
showed more pronounced and progressive splenomegaly after Western type diet feeding as compared 
to WT recipients. B. Baseline phagocytosis of apoptotic Jurkat cells by Mcl-1-/- BMDM was slightly 
decreased. Phagocytosis by Ox-LDL stimulated Mcl1-/- BMDM was however comparable to that by WT 
BMDM, however phagocytosis was decreased compared to unstimulated WT BMDM. C-G. Ox-LDL 
incubation led to a decrease in IL10 gene expression and unaltered expression of arginase-I in Mcl-
1-/- BMDM (black bars). Gene expression of TNFα, and IL12 subunit p35 were increased after Ox-LDL 
stimulation (black bars), an effect absent in WT BMDM (white bars), pointing towards a more pro-
inflammatory M1 phenotype of Mcl-1-/- macrophages. (*p<0.05, **p<0.01)
5 weeks 10 weeks
0
1
2
3
4
5
6
*
**
Ra
tio
 S
pl
ee
n/
Bo
dy
 W
ei
gh
t
   
   
   
   
   
x1
0-
3
IL10
Control Ox-LDL
0.000
0.001
0.002
0.003
0.004
0.005
**
Re
la
tiv
e 
G
en
e 
Ex
pr
es
se
io
n
   
   
   
   
   
  (
A.
U
.)
p35
Control Ox-LDL
0.000
0.025
0.050
0.075
0.100 *
*
TNFα
Control Ox-LDL
0.00
0.25
0.50
0.75
1.00
1.25
1.50
1.75
2.00
*
p=0.08
*
p=0.05
iNOS
Control Ox-LDL
0.000
0.005
0.010
0.015
0.020
0.025
Arg1
Control Ox-LDL
0.00
0.01
0.02
0.03
0.04
Re
la
tiv
e 
G
en
e 
Ex
pr
es
se
io
 (A
.U
.)
D E F G
BA C
Control Ox-LDL
0
5
10
15
20
25
30
35
*
Ph
ag
oc
yt
os
is
 (%
 o
f B
M
D
M
)  
*
Chapter 5
98
Mcl-1	deletion	alters	neutrophil	levels	and	characteristics
Mcl-1 was shown to be essential for neutrophil survival and as a result circulating 
and splenic neutrophils numbers were reduced by 80 and 86%, respectively, in Mcl-
1fl/fl LysMcre mice18. Indeed Mcl1-/- chimeras were almost depleted in circulating 
neutrophils both before WTD feeding and under hyperlipidemic conditions (four 
and ten weeks after WTD feeding) (-82% to 91%, p<0.001, Fig. 6A). Neutrophil 
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Figure	6.	Mcl-1	deletion	affects	neutrophil	levels	and	phenotype. A. Circulating neutrophil levels were 
profoundly reduced in Mcl-1-/- compared to WT transplanted mice and even more so after Western type 
diet feeding. B. Aortic root atherosclerotic lesions of Mcl-1-/- BM transplanted LDLr-/- mice contained 
fewer neutrophils as can also be seen in representative micrographs (right panel, arrows indicate 
neutrophils). C,D. CXCR4 expression on Mcl-1-/- neutrophils is elevated compared to WT neutrophils. E. 
WT BM transplanted mice displayed a massive neutrophil influx into the peritoneal cavity in response 
to i.p. KC injection (white bars) which is almost completely prevented in Mcl-1-/- BM transplanted mice 
(black bars). F. The KC induced increase in circulating neutrophil numbers observed in WT chimeras 
(white bars) was absent in Mcl-1-/- BM transplanted mice as well (black bars). (*p<0.05, **p<0.01, 
***p<0.001)
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content in Mcl-1-/- atherosclerotic lesions was decreased by 72% (0.63 ± 0.31 *10-
5 per μm2 lesion) compared to WT lesions (2.28 ± 0.63 *10-5 neutrophils per μm2 
lesion, p<0.05, Fig. 6B), which might point to an enhanced adhesive capacity of 
residual neutrophils in circulation. 
We therefore examined neutrophil phenotype and function in both groups of 
animals. CXCR4 expression was increased on circulating (2.2 fold, p<0.001) as 
well as on peritoneal (1.7 fold, p<0.05) Mcl-1-/- neutrophils (Fig. 6C,D), suggesting 
altered migratory capacity. Remarkably, Mcl-1-/- neutrophils showed a decreased 
responsiveness to KC, a potent neutrophil chemoattractant. Neutrophil content 
in the peritoneal cavity and circulation was measured 2 hours after i.p. injection 
of KC or PBS. Peritoneal neutrophil influx in response to KC was prominent in 
WT transplanted mice whereas Mcl-1-/- transplanted mice only showed a minor, 
non-significant, increase in peritoneal neutrophils (Fig. 6E,F). Of note, neutrophil 
recruitment was paralleled by a moderate increase in circulating neutrophils in WT 
but not Mcl1-/- mice.
Discussion
In this study we determined the role of Mcl-1 in atherosclerotic plaque initiation and 
progression. Mcl-1 is an anti-apoptotic Bcl-2 family member19 and although several 
members of this family have been investigated in the context of atherosclerosis6,8,29, 
the role of Mcl-1 in disease progression has not been assessed thus far. Here, we 
studied effects of specific deletion of Mcl-1 in lysozyme M expressing myeloid subsets 
such as neutrophils and macrophages on early and advanced atherosclerosis.
First we established Mcl-1 expression in RAW 264.7 macrophages and showed that 
Mcl-1 expression is decreased in response to Ox-LDL. In addition vascular Mcl-1 
expression steadily increases with lesion progression in LDLr-/- mice. Given that 
macrophage content and apoptosis gradually increases with plaque progression3 
and that Mcl-1 was seen to affect macrophage lipid accumulation21 these findings 
suggest that Mcl-1 could be a critical player in atherosclerosis. Therefore we 
investigated the role of Mcl-1 atherosclerotic lesion development and stability, in 
LDLr-/- chimeras with Mcl-1 deficiency in macrophages and neutrophils generated 
by transplantation of Mcl-1fl/fl LysMcre or wildtype (WT) bone marrow.  The use 
Mcl-1 deficiency in lysozyme M expressing cells enabled us to specifically study 
effects of Mcl-1 deficiency in macrophage and neutrophil differentiation and 
apoptosis and their contribution to disease. Mcl-1 was previously demonstrated 
to be involved in cell death of various leukocyte subsets16,18, 30-33. Overexpression 
of Mcl-1 in hematopoietic cells protected from cell death in response to various 
stimuli16 and inhibition of Mcl-1 expression in human neutrophils and macrophages 
resulted in increased apoptosis31,32. In vivo overexpression of Mcl-1 promoted 
survival of lymphocytes and myeloid cells18,30,33. Our data largely correspond with 
these findings in that Mcl-1-/- macrophages displayed decreased survival compared 
to WT macrophages. Additionally, we show that Mcl-1 participates in Ox-LDL 
induced cell death as Mcl-1-/- macrophages were more susceptible to cell death 
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after Ox-LDL incubation. Mcl-1 deficiency was seen to influence the expression of 
other apoptosis regulating Bcl-2 family members, such as Bim, PUMA and NOXA, 
which all were decreased in unstimulated Mcl-1-/- compared to WT macrophages. 
Whereas Ox-LDL stimulation resulted in decreased PUMA and NOXA expression 
in WT macrophages, in Mcl-1-/- macrophages this led to an increase in PUMA 
expression together with increased Bim. Bim, PUMA and NOXA are BH3-only pro-
apoptotic Bcl-2 family members involved in the initiation of apoptosis34, which 
exhibit reduced pro-apoptotic activity upon interaction with Mcl1 and all other pro-
survival Bcl-2 family members (Bim and PUMA) or Mcl-1 and A1 only (NOXA)12,25-27. 
The dysregulated expression of BH3-only proteins in Mcl-1-/- macrophages suggests 
that apart from inhibiting apoptosis by interaction with BH3-only proteins, Mcl-1 
might also exert anti-apoptotic effects at the transcriptional level in response to an 
apoptotic stimulus. 
In line with the in vitro findings apoptotic cell content in advanced aortic root 
lesions (10 weeks of WTD) was increased in mice with myeloid Mcl-1 deficiency, 
indicating that Mcl-1 is a major survival protein in atherosclerotic lesions. However 
despite a 77% increase in apoptosis, atherosclerotic lesion burden was unaltered 
in Mcl-1-/- BM recipients, as were necrotic core size and macrophage and collagen 
content. Similar findings were obtained when studying plaque initiation (five 
weeks of WTD feeding). Our results correspond with those from Thorp et al.8, who 
showed increased macrophage apoptosis but unchanged lesion burden in Bcl-
2
flox
-LysMCre ApoE-/- mice that are deficient in macrophage and neutrophil Bcl-28. 
However macrophage apoptosis in early atherogenesis was demonstrated to be 
beneficial in several studies in LDLr-/- and ApoE-/- mice with deleted expression of 
pro-apoptotic or survival factors5,6,35,36. Two studies assessing apoptosis in advanced 
atherosclerosis presented contradictory results. Stoneman et al.7 observed in CD11b-
hDTR / ApoE-/- mouse that diphtheria toxin induced ablation of CD11b+ monocytes 
and macrophages did not result in any effects on lesion initiation or progression 
although lesion apoptotic cell content  was largely increased. Conversely, in a recent 
study by Gautier et al.37 apoptosis in advanced lesions in ApoE-/- mice was seen to 
aggravate disease progression. Here, we found that macrophage and neutrophil 
specific deletion of Mcl-1 in LDLr-/- mice had additional consequences, both at a 
systemic level and within the lesion itself, which may have masked effects of the 
observed increased lesion apoptosis.
First, apart from an increased sensitivity to Ox-LDL induced cell death Mcl-1-/- 
macrophages showed augmented lipid accumulation after incubation with Ox-LDL 
and VLDL. In keeping we observed elevated foam cell levels in vivo in the peritoneal 
cavity of Mcl-1-/- BM compared to WT BM recipients. These findings seems to 
contrast with those of Halvorsen et al.21, who reported reduced IL-10 induced 
OxLDL loading by THP-1 macrophages in vitro after siRNA mediated silencing of Mcl-
1 and Bfl-1 expression. The authors did not assess effects of Mcl-1 inhibition alone, 
without IL10 stimulation. Based on our data we hypothesize that the apoptosis-
prone phenotype of Mcl-1-/- macrophages facilitates uptake of lipids.  
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Another remarkable characteristic was the high propensity of Mcl-1-/- cells to form 
multinucleated giant cells (MGC). MGC originate from monocyte-macrophage 
lineage and result from aberrant cell fusion38. Although the actual mechanism of 
MGC formation is hitherto unclear, their presence is thought to reflect an elevated 
inflammatory status with a crucial role for the cytokine environment in which they are 
formed38. The latter notion is corroborated by the splenomegaly in Mcl-1-/- chimeras 
and a shifted polarization of Mcl-1-/- macrophages towards a pro-inflammatory M1 
macrophage phenotype39 as judged from their cytokine expression pattern and 
reduced phagocytic capacity28.
Previously Mcl-1 has been proven to be essential for appropriate differentiation of 
hematopoietic stem cells40 and development of lymphocytes12 and neutrophils18, 
whereas monocytes and macrophages display normal development in the absence 
of Mcl-119. Lately, neutrophils are increasingly perceived as important players in 
atherogenesis. Increased neutrophil count is positively correlated with coronary 
artery disease41,42 and in mouse models neutrophils have been demonstrated to 
be present in atherosclerotic lesions and adventitia43,44. Depletion of neutrophils in 
ApoE-/- mice results in reduced atherosclerotic lesion formation43. In our study, Mcl-
1-/- BM transplanted LDLr-/- mice were displaying overt neutropenia, consistent with 
previous findings that Mcl-1 is essential for neutrophil survival18. Impaired neutrophil 
survival translated in a reduced atherosclerotic lesion neutrophil content although 
the decrease was less pronounced than in circulation. The latter finding may be 
explained by an altered migratory capacity of residual neutrophils. Dzhagalov et 
al.18 showed that residual  neutrophils in plain Mcl-1fl/fl LysMcre mice were shown 
to express Mcl-1 and apparently had escaped Cre-mediated Mcl-1 deletion18. In our 
study, both in circulation and in the peritoneal cavity CXCR4+ neutrophil numbers 
were increased in Mcl-1 deficiency, indicative of increased stromal retention and 
decreased release of neutrophils from the bone marrow. Administration of CXCR4 
blocking antibody to mice was reported to reduce retention of circulating neutrophils 
in while increasing their release from bone marrow45. In addition it was shown 
that CXCR2 ligand KC induces desensitization to effects of CXCR4 ligand SDF-1α45. 
Vice versa, SDF-1α is able to attenuate neutrophil response to KC46. In our study, 
circulating neutrophils in Mcl-1-/- BM recipients had a reduced migratory response 
to chemoattractant KC in vivo. This reduced response might be partly attributable 
to enhanced SDF-1α /CXCR4 signaling and partly be a result of the substantially 
reduced neutrophil pool.
In summary, myeloid Mcl-1 deficiency enhanced Ox-LDL induced cell death of 
macrophages ex vivo as well as atherosclerotic lesion apoptosis in BM transplanted 
LDLr-/- mice. Furthermore, mcl-1 deficiency was seen to reduce phagocytic capacity 
and to promote macrophage lipid uptake and macrophage polarization towards 
a pro-inflammatory M1 phenotype. Despite these supposedly pro-atherogenic 
effects of Mcl-1 deficiency, it did not aggravate lesion development or progression. 
This apparent paradox indicates that the markedly lower neutrophil numbers in 
circulation and plaque, contravene the pro-atherogenic capacity of Mcl-1 deficiency, 
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illustrating that neutrophil recruitment is essential to translate a pro-inflammatory 
phenotype into increased atherosclerotic plaque formation.
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Abstract
Focal adhesion kinase (FAK) is a non-receptor protein tyrosine kinase involved in cell 
survival, cell-matrix adhesion, migration and cell proliferation and apoptosis of all 
major cell types involved in atherosclerotic plaque development. While suggestive 
of a role in cellular homeostasis in atherosclerotic plaques, experimental evidence 
to support this hypothesis is lacking to date. The aim of this study was to address 
the role of impaired FAK function on inflammatory status and atherosclerotic lesion 
development in Western type diet fed ApoE-/- mice.
FAK+/-ApoE-/- mice had significantly lower plasma total cholesterol levels, which was 
attributable to decreased hepatic VLDL production rather than an altered intestinal 
cholesterol absorption. Hepatic lipid content was unchanged in FAK+/-ApoE-/-mice. 
Furthermore, FAK+/-ApoE-/- mice displayed splenomegaly (31% increase in weight) 
with a decreased number of white pulp nodules in the spleen and enlarged germi-
nal centres, suggesting perturbed immune function. Macrophage content in spleen 
was found to be decreased whereas the number of lymphocytes was increased. 
In contrast, the peritoneal cavity and the circulation showed increased monocytes 
numbers accompanied by a reduced CD4+ and CD8+ T cell content. Surprisingly, des-
pite these marked effects on lipid homeostasis and immune status, impaired FAK 
expression neither affected size and composition of collar induced carotid artery 
plaques nor that of spontaneous brachiocephalic artery and aortic root plaques.
We conclude that compromised FAK function beneficially affects cholesterol meta-
bolism in Western type diet fed ApoE-/- mice and alters their inflammatory status. 
Despite these marked peripheral effects impaired focal adhesion does not translate 
in an altered atherogenic response.
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Introduction
Focal adhesion kinase (FAK) is a ubiquitously expressed non-receptor protein 
tyrosine kinase and is activated by (auto)phosphorylation upon integrin binding. 
Known targets of FAK include paxillin, Cas and the Src family of kinases1. In addition 
to activation by phosphorylation following integrin binding, FAK phosphorylation 
has been shown to occur in response to growth factor stimulation (VEGF and HGF)2,3. 
Several studies have established a role for FAK in cell-matrix adhesion, cell migration, 
proliferation and apoptosis4. FAK-deficient fibroblast-like cells were shown to have 
an increased number of focal adhesions, most likely to be caused by a decreased 
turnover, and to spread more slowly on extracellular matrix proteins5. Furthermore 
FAK deficient hematopoietic precursor cells display an impaired migratory response 
to chemotactic signals6. FAK is essential in embryonic development in particular of 
the vasculature, since FAK knockout embryo’s die at 8.5 days of age due to perturbed 
vasculogenesis5. 
In the vasculature FAK was found to affect adherence, migration and proliferation of 
vascular smooth muscle cells (vSMC’s)7,8 and endothelial cells9-11. Moreover, study of 
endothelial cells from FAK knockout embryo’s showed that endothelial FAK is required 
for tubulogenesis9. In addition, targeted FAK deletion in embryonic endothelial cells 
resulted in impaired vascular network stability and cell survival10. Consequently, 
FAK knockout embryo’s exhibit severe defects in vascular development. The non-
catalytic carboxyl-terminal protein binding domain of FAK called FRNK (FAK related 
non kinase) is independently and selectively expressed in vSMC’s, acting as an 
endogenous inhibitor of FAK signaling. Following balloon-induced carotid artery 
injury FRNK is strongly upregulated in vSMC’s indicating that following injury vSMC 
migration and adhesion complex turnover may be negatively regulated7. 
These findings combined with the recent observation that FAK is overexpressed 
in VSMC’s in human intimal hyperplasia12 might suggest a role for FAK in cellular 
homeostasis in atherosclerotic plaques. However to date the precise role of FAK in 
atherogenesis has not been addressed. In this study we therefore assessed the effect 
of compromised FAK function in ApoE-/- mice using perivascular collar placement 
around the common carotid arteries to induce atherosclerotic lesion development. 
Although our results surprisingly demonstrated no overt effect on atherosclerotic 
lesion size or composition, lipid metabolism and inflammatory status of these mice 
appeared to be seriously modified in the heterozygote status of FAK expression. 
Materials and Methods
Animals
All animal work was approved by regulatory authority of Leiden and performed in 
compliance with the Dutch government guidelines. FAK+/- mice were obtained from 
the Department of Toxicology (LACDR, Leiden, The Netherlands) and were crossbred 
with ApoE-/- mice, obtained from the local animal breeding facility. 
Chapter 6
110
Carotid	collar	placement
At 16-18 weeks of age carotid atherosclerotic lesion development was induced 
by bilateral perivascular collar placement in female FAK+/-ApoE-/- mice (n=10) and 
FAK+/+ApoE-/- littermates (n=9) as described by Von der Thϋsen et al.13 Starting 4 
weeks before collar placement and throughout the whole experiment mice were 
fed a Western type diet containing 0.25% cholesterol and 15% cacao butter (Diet 
W, Special Diet Services, Witham, Essex, UK).  In a separate experiment bilateral 
perivascular collar were placed in female FAK+/-ApoE-/- mice (n=11) and ApoE-/- 
littermates (n=11) at the age of 12-16 weeks. These mice were fed a regular chow 
diet throughout the experiment.
Cholesterol,	triglyceride	and	phospholipid	assay
Blood samples were taken by tail cut before start of (week 0), after four weeks of 
the Western type diet (week 4), and at the time of sacrifice (week 10). Hepatic 
lipids were extracted as described by Bligh and Dyer14. Total cholesterol, triglyceride 
and phospholipid content was measured spectrophotometrically using enzymatic 
procedures (Roche Diagnostics, Almere, The Netherlands) in serum and hepatic 
extracts. Serum samples were fractionated using Superose 6 column (SMART 
System, Pharmacia Biotech, Uppsula, Sweden) to obtain total cholesterol distribution 
patterns.
Cholesterol	absorption
To analyze cholesterol absorption from the intestine, FAK+/-ApoE-/- mice and ApoE-/- 
littermates (n=5) were intravenously injected with 500 mg Triton WR1339/Tyloxapol 
per kg body weight (Sigma, Zwijndrecht, The Netherlands) to block lipoprotein lipase 
mediated lipolysis after overnight fasting. Subsequently the mice were gavaged 
with 1.2 μCi 14C-cholesterol (GE Healthcare, Diegem, Belgium) and 200 μl unlabeled 
cholesterol (Sigma) in olive oil. Blood samples were taken by tail cut before and 1, 2, 
3 and 4 hours after oral cholesterol administration. After 4 hours the animals were 
anesthetized and gal bladder, small intestine and liver were harvested. 14C content 
was determined in serum, gall bladder, small intestine (20 cm from pylorus) and 
liver sections using a liquid scintillation analyzer (Tri-Carb 2900R, Packard).  
VLDL	production	rate
For analysis of Very Low-Density Lipoprotein (VLDL) production rate, mice were 
intravenously injected with Triton WR1339/Tyloxapol (500 mg per kg body weight, 
Sigma). Blood samples were taken via tail vein before and 1 and 2 hours after 
injection. Serum triglyceride accumulation was measured as described above.
FAK gene and protein expression 
FAK+/-ApoE-/- mice and ApoE-/- littermates (n=4) were anesthetized and blood was 
obtained by bleeding through the orbital sinus. Erythrocytes in whole blood were 
lysed to obtain white blood cells (WBC’s). Various organs including liver, heart 
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and aorta were harvested in liquid nitrogen after perfusion with PBS. Total RNA 
was extracted using guanidine thiocyanate (GTC, Sigma). After RT-PCR, FAK gene 
expression in various organs and expression of genes involved in lipid homeostasis 
in liver were analyzed by quantitative real-time PCR using ABI PRISM 7700 Sequence 
Detector (Applied Biosystems) and SYBR-Green technology. The primer sequences 
are listed in table 1. HPRT, β-actin and/or acidic ribosomal phosphoprotein P0 (36B4) 
were used as standard housekeeping genes. 
Protein expression was analyzed by Western blotting using mouse anti-FAK, clone 
4.47 (Upstate Biotech, Charlottesville, VA, USA) primary antibody and rabbit anti-
mouse-HRP (DakoCytomation, Heverlee, Belgium) secondary antibody. Signal 
intensity was analyzed using ImageJ software (http://rsb.info.nih.gov/ij/).
Tissue	harvesting	and	analysis
Six (for Western type diet fed mice) or ten weeks (for normal chow diet fed mice) after 
collar placement the animals were anesthetized and perfused with PBS followed by 
fixation with 4% formaldehyde (4.5 times diluted Zinc Formal-Fixx, Thermo Electron 
Corporation, Breda, The Netherlands). Carotid arteries, brachiocephalic artery, 
heart, spleen and liver were harvested and stored in 4% formaldehyde solution. 
Cryosections were prepared of carotid and brachiocephalic arteries, aortic valves, 
spleen and liver and stained with hematoxylin and eosin (HE) and/or Oil Red O. Lesion 
size was quantified using Leica image analysis system, consisting of a Leica DMRE 
microscope with camera and Leica Qwin Imaging software (Leica Ltd, Cambridge, 
UK). Immunohistochemical stainings were performed for macrophage (MOMA-
2, Sigma), VSMC (α-smooth muscle actin, Sigma), T cell (CD3, Serotec) and B cell 
(Cd45R/B220, Pharmingen) content. Apoptotic cell content was quantified using 
terminal deoxytransferase dUTP nick-end labeling (TUNEL) kit (Roche Diagnostics, 
Almere, The Netherlands). 
Blood	cell	analysis	and	flow	cytometry
Peripheral blood mononuclear cells, splenocytes and peritoneal leukocytes were 
isolated from FAK+/-ApoE-/- mice and ApoE-/- littermates fed normal chow or Western 
type diet for 4 weeks and analyzed using a Sysmex blood cell analyzer (XT-2000i), or 
stained for cell surface markers and analyzed by flow cytometry. White blood cells 
Table	1. Primer sequences for realtime PCR.
Gene Forward Primer (5’-3’) Reverse Primer (5’-3’)
HPRT TTGCTCGAGATGTCATGAAGGA AGCAGGTCAGCAAAGAACTTATAG
18S CCATTCGAACGTCTGCCC GTCACCCGTGGTCACCATG
β-actin AACCGTGAAAAGATGACCCAGAT CACAGCCTGGATGGCTACGTA
36B4 GGACCCGAGAAGACCTCCTT GCACATCACTCAGAATTTCAATGG
FAK GAGAATCCAGCTTTGGCTGTT GGCTTCTTGAAGGAACTTCT
CD36 GTTCTTCCAGCCAATGCCTTT ATGTCTAGCACACCATAAGATGTACAGTT
FAS GGCATCATTGGGCACTCCTT GTCGCAAGCACAGCCTCTCT
SCD1 TACTACAAGCCCGGCCTCC CAGCAGTACCAGGGCACCA
SREBP-1 GACCTGGTGGTGGGCACTGA AAGCGGATGTAGTCGATGGC
SREBP-2 TGAAGCTGGCCAATCAGAAAA ACATCACTGTCCACCAGACTGC
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were isolated after erythrocyte lysis of whole blood samples obtained by bleeding 
through the orbital sinus, peritoneal leukocytes by peritoneal lavage with 10 ml PBS 
and splenocytes by passing (part of) the spleen through a 70 µm nylon cell strainer 
(BD Falcon). White blood cells were stained with fluorescently labeled antibodies 
against CD4, CD19, CD23, CD69, CD71, CD86, F4/80 and MHCII (eBioscience, San 
Diego, California) and CD8 and CD11b (BD Pharmingen, Breda, The Netherlands). 
Fluorescence-activated cell sorting (FACS) analysis was performed on a FACS-Calibur 
and analyzed with CellQuest software (BD Biosciences). 
Statistical	analysis	
Values are expressed as mean ± SEM. Analysis to compare two groups was performed 
by two-tailed Student’s t-test. For analysis of relative mRNA expression data t-test 
was performed on ΔCt values. Statistical significance was set at p<0.05.
Results
FAK expression
To determine the level of FAK deletion in FAK+/-ApoE-/- mice, gene and protein 
expression was analyzed in heart, aorta, liver and/or spleen of these mice and ApoE-
/- littermates. FAK gene expression appeared to be reduced by 34-45 % in FAK+/-
ApoE-/- mice compared to ApoE-/- littermates as determined by quantitative real-
time PCR (Fig. 1A). In keeping total FAK protein expression was reduced by a similar 
35-50% in these organs as shown by Western blotting and Image J analysis software 
(Fig. 1B and C).
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Figure 1.	 FAK expression in FAK+/-ApoE-/- mice and ApoE-/- littermates. Total RNA was isolated from 
different organs with GTC and used for real-time PCR. Proteins were isolated with protein lysis buffer 
and used for Western Blotting. FAK gene expression in heart and aorta (A) and FAK protein expression in 
heart, liver and spleen (B) are reduced in FAK+/-ApoE-/- mice compared to ApoE-/- littermates. (*p<0.05, 
**p<0.01) 
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Lipid	metabolism
Throughout the study we have monitored lipid levels in FAK+/-ApoE-/- and ApoE-/- mice 
by measuring serum total cholesterol (TC) and triglyceride (TG) levels before and 
after four or ten weeks of Western type feeding. Surprisingly, while total cholesterol 
levels were increased in both groups after Western type feeding, the diet induced 
increase in TC levels in FAK+/-ApoE-/- mice was 18% lower than in ApoE-/- mice (p<0.01, 
Fig. 2A). Triglyceride levels were comparable in both groups as were total cholesterol 
levels when fed a regular chow diet. The reduced hypercholesterolemic response 
to Western type diet was not caused by apparent differences in health status or 
food intake, since total body weight remained unchanged, 30.3 ± 2.1 g for FAK+/-
ApoE-/- mice and 29.8 ± 2.1 g for ApoE-/- mice. As shown in fig. 2B, when serum was 
fractionated by Superose 6 column to analyze the TC distribution over the different 
lipoproteins, the total VLDL cholesterol levels were found to be responsible for the 
decrease in total cholesterol. 
Liver morphology of FAK+/-ApoE-/- mice did not reveal pathological changes or 
features of inflammation. Moreover the reduction in TC levels was not caused by 
changes in hepatic lipid content or cholesterol absorption rate from the intestine 
(fig. 2C-E). However hepatic VLDL production rate appeared to be decreased in 
FAK+/-ApoE-/- mice from 12.71 ± 0.89 mg/dl/h/g body weight in ApoE-/- mice to 8.44 
Figure 2. Lipid metabolism is altered in FAK+/-ApoE-/- mice. Blood samples were taken by tail vein 
puncture before starting the Western type diet (WTD), after four and ten weeks of WTD feeding and 
at the time of sacrifice. Serum total cholesterol levels after high fat diet feeding are reduced (A), 
mainly due to reduced VLDL associated TC. Fractions 2-6 represent VLDL associated TC, fractions 7-13 
represent LDL associated TC (B). This reduction was not caused by altered absorption of cholesterol 
from the intestine (C) or changes in hepatic lipid content (D,E) but is likely due to decreased VLDL 
production rate in FAK+/-ApoE-/- mice compared to ApoE-/- littermates (F,G). 
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± 1.21 mg/dl/h/g body weight (p=0.02, fig. 2F-G), suggesting that decreased total 
cholesterol levels are caused by reduced VLDL production. Remarkably, assessment 
of hepatic gene expression of several genes involved in lipid metabolism by realtime 
PCR revealed an upregulation of key genes in lipogenesis in FAK+/-ApoE-/- mice. 
Figures 3A-E show that expression of stearoyl-coenzyme A desaturase 1 (SCD1, 94% 
p=0.04) and sterol regulatory element-binding proteins (SREBP) 1 and 2 is increased 
(56%, p=0.01 and 32%, p=0.02 respectively) while fatty acid synthase (FAS) shows 
a tendency towards increased gene expression as well (59%, p=0.06). In addition 
CD36 expression was increased by 25% (p=0.003). Expression of several other genes 
involved in lipoprotein metabolism such as acetyl CoA carboxylase α (ACACA), ATP 
citrate lyase (ACLY), microsomal triglyceride transfer protein (MTP), lipoprotein 
lipase (LPL) and its cofactor apolipoprotein C2 (ApoC2) or transcription regulators 
like peroxisome proliferator-activated receptor α (PPARα) and PPARγ coactivator 
(PGC) 1a remained unchanged. 
Spleen	morphology	and	leukocyte	composition
FAK+/-ApoE-/- mice displayed moderate splenomegaly with a 31% increase in organ 
weight after Western type feeding for 10 weeks compared to ApoE-/- littermates 
(p=0.04, Fig. 4A). The spleen/body weight ratio was increased as well. The increase 
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Figure 3. Hepatic expression of various key genes in lipogenesis is upregulated with reduced FAK levels. 
Relative gene expression of SREBP1 (A) and 2 (B), SCD1 (C), FAS (D) and CD36 (E). FAS, fatty acid 
synthase; SCD1, stearoyl-coenzyme A desaturase 1; SREBP, sterol regulatory element-binding protein. 
(*p<0.05, **p<0.01)
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in spleen weight appeared to be at least partly diet dependent, in that spleen 
weight of mice fed a regular chow diet was increased by only 12% (p=0.06, Fig. 
4A). Further pathophysiological analysis revealed a decreased number of white 
pulp nodules in spleen while the germinal centers were enlarged, resulting in an 
increased germinal centre area. The germinal centre expansion was accompanied 
by an altered germinal center organization. As shown in Fig. 4B, germinal centers 
appear to be fused together exhibiting irregular arrangement.
To assess whether the increase in spleen weight was proportional between the 
different cell subsets, splenocytes were isolated and analyzed. In spleen, reduced 
FAK expression resulted in a 23% decreased relative number of monocytes (p=0.01, 
Fig. 4C) while the number of lymphocytes was elevated by 61% (p=0.01, Fig. 4C). 
In contrast, the leukocyte distribution profile in the peritoneal cavity showed the 
inverse pattern with increased monocyte numbers (+18%, p=0.02) and a concomitant 
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Figure 4.	Reduced FAK levels lead to splenomegaly, altered spleen morphology and altered monocyte/
macrophage and (T)-lymphocyte content in spleen, circulation and peritoneal cavity. Spleen size of 
approximately 5 month old FAK+/-ApoE-/- mice (black bars) and ApoE-/- littermates (white bars) after 
normal chow or 10 weeks of Western type diet feeding (A). Cryosections of spleen were prepared 
and stained with hematoxylin and eosin. Spleens of FAK+/-ApoE-/- mice show a decreased number of 
white pulp nodules in the spleen while the germinal centres (arrows) all seem to be enlarged (B). 
Peripheral blood mononuclear cells, splenocytes and peritoneal leukocytes were isolated from FAK+/-
ApoE-/- mice and ApoE-/- littermates fed normal chow or Western type diet for 4 weeks and analyzed by 
Sysmex blood cell analyzer (C,D) or flow cytometry (E,F). In spleen, reduced FAK expression resulted in 
decreased number of monocytes and elevated lymphocyte numbers (C) while the monocyte content 
in the peritoneal lavage was increased in FAK+/-ApoE-/- mice accompanied by a decrease of peritoneal 
lymphocyte numbers (D). Also, reduced FAK expression led to an increase in circulating F4/80+ 
monocytes (E), and a decrease in circulating CD4+ as well as CD8+ T cells (F). (*p<0.05, **p<0.01)
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29% decrease in lymphocyte numbers (p=0.02) (fig. 4D) The changes in peritoneal 
leukocyte profile corresponded with those in circulation, where F4/80+ monocytes 
were up (+31%, p=0.04) and and CD4+ and CD8+ T cells were down by 40% (p=0.04) 
and 28% (p=0.005) respectively (fig. 4E-F). Reduced FAK expression did not affect 
macrophage phenotype and activation, T cell activation, circulating B cell and total 
white blood cell numbers or total peritoneal leukocyte numbers.
Atherosclerotic	plaque	size	and	composition
After ten weeks of high-cholesterol diet feeding and eight weeks after collar 
placement carotid and brachiocephalic arteries and aortic roots were isolated, 
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Figure 5. Reduced FAK expression does not affect atherogenesis. Cryosections were prepared of 
formaldehyde fixed aortic roots, carotid and brachiocephalic arteries and stained Oil Red O or HE. 
Aortic root (A,C), collar aided carotid artery (D,F) and brachiocephalic artery (G) atherosclerotic lesion 
size did not differ between FAK+/-ApoE-/- mice and ApoE-/- littermates fed a Western type or chow diet. 
B, E and H show representative pictures of the lesions. 
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sectioned and stained with hematoxylin and eosin or Oil Red O. Remarkably, 
reduced FAK expression did not alter the atherosclerotic plaque size in collar aided 
carotid artery, brachiocephalic artery or aortic root (Fig. 5). Plaque composition as 
determined by immunohistochemical staining for monocytes/macrophages (MoMa-
2) and vSMC’s (alfa-SM-actin), for collagen (Sirius Red staining) and apoptotic cell 
content (TUNEL staining) at the three different assessed sites was essentially similar 
in FAK+/-ApoE-/- versus ApoE-/- littermates. Moreover, lesion cellularity and necrotic 
core size were unaffected as well (fig. 6).
Because serum total cholesterol levels were reduced in FAK+/-ApoE-/- mice after 
Western type feeding only, we have assessed whether this may have indirectly 
counteracted any pro-atherogenic responses of reduced FAK activity. However 
collar induced carotid artery formation as well as spontaneous brachiocephalic 
artery and aortic root plaque sizes of chow diet fed FAK+/-ApoE-/- mice and Apo-
E-/- littermates were completely comparable (Fig. 5). Apparently differences in 
cholesterol load did not mask pro-atherogenic effects of FAK heterozygousity on 
leukocyte homeostasis.
Discussion
In this study we show that reduction of FAK expression in ApoE-/- mice, as achieved by 
cross breeding FAK+/- with ApoE-/- mice, leads to a reduction of total cholesterol (TC) 
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Figure 6. Atherosclerotic lesion composition is unchanged in FAK+/-ApoE-/- mice. Moma-2+ macrophage 
(A), ASMA+ smooth muscle cell (B) and collagen (C) content, cellularity (D), apoptosis (E) and necrotic 
core size (F) did not differ between FAK+/-ApoE-/- mice and ApoE-/- controls. ASMA, α-smooth muscle-
actin.
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levels in response to Western type diet feeding. This hypocholesterolemic response 
was high fat diet feeding dependent, since it was not observed when mice were 
fed a regular chow diet and suggests an until now unknown involvement of FAK in 
cholesterol metabolism. Closer analysis of the cholesterol distribution over different 
lipoproteins, showed that mainly VLDL associated cholesterol was decreased. 
The absorption rate of cholesterol after oral administration of cholesterol did not 
differ between FAK+/-ApoE-/- mice and ApoE-/- littermates. Hepatic total cholesterol, 
tryglyceride and phospholipid content, was comparable between the two groups 
as well. Thus the decreased TC levels are most likely caused by the observed lower 
hepatic VLDL production rate in FAK+/-ApoE-/- mice. Of note, the hepatic expression 
of critical genes in lipogenesis, SREBP1 and 2, SCD1 and FAS, was increased in FAK+/-
ApoE-/- mice. SREBPs are strongly regulated by a feedback mechanism in cholesterol 
and fatty acid metabolism15 and contribute to the regulation of various effector 
genes in lipogenesis, such as SCD1 and FAS16,17. Hepatic CD36 expression was slightly 
increased in response to FAK reduction as well. In a recent study oxidized LDL 
mediated CD36 signaling was shown to inhibit macrophage migration and stimulate 
cell spreading by continued FAK phosphorylation and activation18, suggesting a role 
for FAK in trapping macrophages in the arterial wall and promoting atherogenesis. 
Thus the elevated hepatic expression of these genes may reflect a compensatory 
mechanism in response to lowered VLDL and TC levels in the case of lipogenesis 
genes and decreased FAK levels in the case of CD36. 
In addition to cholesterol lowering, we found that reduced FAK expression in ApoE-
/- mice leads to splenomegaly accompanied by altered spleen morphology. The 
increase in total spleen weight and in particular germinal centre area suggest an 
aberrant splenocyte composition, with a relative increase in germinal centre B and 
T lymphocytes content and a decrease in monocytes/macrophages numbers. This 
notion was confirmed by further analysis of splenocyte composition. Although initially 
FAK was reported to be absent in monocytes/macrophages19,20, recent publications 
have conclusively proven this to be incorrect21,22. GM-CSF and M-CSF, key regulators 
of myeloid differentiation, were found to induce FAK phosphorylation in monocytes/
macrophages while inhibition of FAK activity by FRNK led to impaired macrophage 
spreading and adhesion21,22. Deletion of FAK in monocytes/macrophages was seen 
to attenuate their migratory capacity, random motility as well as M-CSF, SDF-1α 
and MCP-1 directed migration23. The observed decrease in macrophage content 
in spleen in FAK+/-ApoE-/- mice may likely be attributable to impaired ingress from 
circulation, even despite enhanced circulating monocyte numbers, whereas the 
increased peritoneal macrophage levels may be due to impaired migration from the 
peritoneal cavity. However, no reduction in plaque macrophages was observed.
In contrast to the change in splenocyte composition reduced FAK expression led to 
decreased circulating CD4+ and CD8+ T lymphocyte numbers, however activation of T 
cells or T cell subset numbers were unchanged. FAK is expressed in both human T and 
B lymphocytes24. In the present study we observed an increased spleen lymphocyte 
content in FAK heterozygous mice along with a seemingly paradoxical decrease in 
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relative circulating and peritoneal lymphocyte numbers. In vitro, in T-lymphocytes 
FAK has been shown to have an essential role in β
1
 integrin dependent migration25 
and lymphocyte function-associated antigen-1 (LFA-1 or α
L
β2 integrin) mediated 
T lymphocyte adhesion. FAK dephosphorylation and thus inhibited activity was 
shown to impair LFA-1 mediated adhesion26,27. Furthermore, FAK was indicated in 
chemokine mediated lymphocyte trafficking as FAK phosphorylation and activation 
in T cells is induced by RANTES28. Similarly SDF-1 induced FAK phosphorylation in 
T cells, hematopoietic progenitor cells and pro-B cells appeared to be essential for 
its chemotactic and adhesive responses6,29,30. In agreement with these findings, our 
study seems to point to enhanced retention of lymphocytes in spleen in the case of 
compromised FAK function.  
Despite the previously reported involvement of FAK in migration and proliferation 
of vSMC’s, macrophages and endothelial cells in the vasculature and the impaired 
hypercholesterolemic response to Western type diet and altered inflammatory cell 
distribution pattern in circulation, peritoneal cavity and spleen of FAK+/-ApoE-/- mice 
observed in this study, to our surprise we did not observe any effects of impaired 
FAK function on size or composition of collar aided carotid, brachiocephalic artery 
or aortic root atherosclerotic plaques. The lack of effect of FAK heterozygousity on 
atherogenesis was not due to the observed reduced hypercholesterolemic response 
to high fat diet feeding, which potentially could have masked FAK mediated adverse 
effects on leukocyte trafficking. This suggests that the marked immune effects 
of compromised FAK function per se do not influence atherogenesis. Apparently 
the complex interaction of immune cells in the arterial wall leads to a new 
equilibrium in the FAK+/-ApoE-/- mice culminating into an unchanged development 
of atherosclerotic lesions. It might be concluded that therapeutical approaches to 
diminish atherosclerotic lesions must be focused upon targets which play a more 
unidirectional role in lesion formation.
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Chapter 7
Summary and Discussion
Despite available treatments, be it lipid lowering or blood pressure lowering therapy, 
surgical intervention or life style changes, cardiovascular diseases (CVD) continue 
to be one of the main causes of death in the world1. Most clinical complications 
of CVD can be attributed to atherosclerotic plaque disruption and subsequent 
thrombus formation2,3. Atherosclerosis is a progressive disease of medium and 
large sized arteries characterized by accumulation of lipids in the artery wall4. It 
is a multifactorial process featuring in addition to subendothelial lipid deposition, 
excessive tissue remodeling, inflammation, and oxidative stress5. 
An important process generally considered to contribute to plaque progression and 
instability is apoptotic cell death. Apoptosis, programmed cell death characterized 
by morphological changes like cell shrinkage, DNA fragmentation, condensation 
of chromatin and membrane blebbing6,  occurs in atherosclerotic lesions and 
affects all major cell types relevant to the disease process such as endothelial cells, 
macrophages, T cells and vSMC7. Apoptosis increases with plaque progression, 
being virtually absent in initial lesions and overtly present in advanced lesions8, as 
a result of enhanced apoptosis rates or impaired phagocytosis. Although originally 
considered anti-inflammatory or inflammation-neutral, recent insights support 
the notion that apoptosis may under conditions present in atheromathous tissue, 
promote inflammation9.The consequences of apoptosis also depend on the cell 
type. Apoptosis of vSMC was seen to promote plaque vulnerability10 whereas the 
impact of macrophage apoptosis is less well defined. At early stages macrophage 
apoptosis has been reported to be beneficial11,12, whereas in advanced plaques 
phagocytosis is impaired13 and apoptotic macrophages may undergo secondary 
necrosis, potentially leading to lipid core expansion, plaque inflammation and thus 
progression. On the contrary, others did not observe any effects of macrophage 
apoptosis on plaque size or inflammation in advanced stages of atherosclerosis14. 
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In chapter 2 we review the inflammatory consequences of altered apoptosis and 
effects of plaque inflammation on cell death. Several pro-inflammatory mediators 
that contribute to atherogenesis can have pro- or anti-apoptotic effects. For example, 
proapoptotic members of the TNF super family, Fas, CD40 and Fn14, were also seen 
to promote secretion of inflammatory cytokines like MCP-1 and IL8 and/or adhesion 
molecules15-17. Apoptotic cells modulate inflammatory responses either on their 
own account by inducing amongst others cytokines18 or after uptake and processing 
by phagocytes19. Furthermore, impaired and altered phagocytosis, as apparent 
during progressive atherosclerosis20, elicits a proinflammatory response as a result 
of secondary necrosis thereby further aggravating inflammation leading to lesion 
progression and instability9. Reactive oxygen species and Ox-LDL, accumulating in 
the vessel wall during plaque progression, are able to induce cell death in endothelial 
cells, vSMC and macrophages21-23 by upregulating several apoptotic proteins 
including Fas, TNFα, p53 and Bcl-2 family proteins24-26. In addition, several cytokines 
present in atherosclerotic lesions, including IFNγ27,28, TNFα29,30, IL1β31, IL232, IL433 and 
MIF34,35, are able to induce apoptosis themselves. 
Since most clinical complications of cardiovascular disease are caused by plaque 
rupture in this thesis we first aimed to identify genes or pathways promoting thin cap 
fibroatheroma formation. Thin cap fibroatheroma (ThCFA) can be defined as plaques 
containing a large lipid core with an overlying thin fibrous cap, as opposed to thick 
cap fibroatheroma (TkCFA) which are more fibrous in nature and have as indicated 
by their name a thick cap. ThCFA and TCFA are categorized as type IV and V lesions, 
respectively, according to the classification system of the American Heart Association 
(AHA). ThCFA are considered as the most vulnerable to rupture36. In chapter 3 of this 
thesis we describe a microarray analysis on RNA obtained from mouse TkCFA and 
ThCFA early on in the plaque destabilization process in two different models of thin 
cap fibroatheroma formation. As a first model we chose spontaneous vulnerable 
plaque development in the brachiocephalic artery of ApoE-/- mice, after 9 weeks of 
Western type diet feeding, when plaques were reported to display the first features 
of enhanced vulnerability37. As a second model we considered low shear stress 
induced plaque formation in the carotid artery of ApoE-/- mice that were further 
destabilized by cap overexpression of the tumor suppressor protein p5338. We were 
able to identify several functional clusters consisting of differentially regulated 
genes that were overrepresented in both models of thin cap fibroatheroma. These 
functional gene clusters include lipid metabolism, small molecule biochemistry, 
metabolic disease, cellular growth and proliferation and cell-to-cell signaling and 
interaction. Genes regulating cell death were most significantly dysregulated in thin 
cap fibroatheroma versus thick cap fibroatheroma. Within this functional cluster, 
five upregulated genes were shared between both thin cap fibroatheroma models 
(Cd5l, Plagl1, Bim and two genes of unknown function). This indicates that CD5l, 
Plagl1 and Bim, the differential expression of which was confirmed by realtime PCR, 
may play a role in the transition of thick cap fibroatheroma into a more vulnerable 
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plaque phenotype. 
In addition to the identification of cell death regulating genes possibly involved in 
thin cap fibroatheroma development, one particular gene, Npy, a neurotransmitter 
with both pro- and anti-atherogenic properties39-41, was evident. Apart from an 
upregulation in thin cap fibroatheroma in the brachiocephalic artery compared to 
thick cap fibroatheroma in the carotid artery, Npy expression was shown to increase 
with disease progression not only in murine but also in human plaques. 
Having identified cell death associated genes and gene clusters which were 
differentially regulated in thin cap fibroatheroma versus thick cap fibroatheroma, we 
set out to assess the role of several apoptosis regulating proteins in atherosclerotic 
plaque development and stability in different mouse models. One of the first genes 
of interest was Bim, which as microarray analysis indicated is one the cell death 
regulating factors differentially expressed in thin cap fibroatheroma compared to 
thick cap fibroatheroma. In chapter 4 we have investigated effects of leukocyte Bim 
deficiency on plaque development in LDLr-/- mice. Previous studies in Bim deficient 
mice have already revealed that Bim is a key regulator of leukocyte apoptosis42,43, 
and particularly important in the deletion of autoreactive and activated T and B 
cells42,44-46. T and B cell levels, including autoreactive T and B cell numbers, are 
markedly increased in circulation, spleen and thymus of Bim deficient mice42 
facilitating the development of auto-immunity and lymphadenopathy42,44,45. As 
lymphocytes are important regulators of immune responses in atherogenesis47,48 
and atherosclerosis is considered to have features of an autoimmune disease49,50 
Bim may be of particular relevance in atherosclerosis. 
Deletion of leukocyte Bim in Western type diet fed LDLr-/- mice resulted in an 
increased pro-inflammatory status as demonstrated by marked splenomegaly and 
enhanced T cell activation and proliferation resulting in increased circulating and 
mediastinal lymph node T cell levels. Leukocyte Bim deficiency led to increased 
lesion T cells as well. Leukocyte Bim deficient LDLr-/- mice had increased Ox-LDL 
antibody levels of the IgG1 but not IgG2a isotype in serum and in addition we 
found dramatically increased total immunoglobulin levels in atherosclerotic lesions 
of Bim-/- BM transplanted mice. In atherosclerotic lesions of ApoE-/- mice, human 
and rabbit as well as in serum Ox-LDL specific antibodies have been detected24-26. 
Studies in which mice were immunized with modified LDL resulted in decreased 
lesion formation54-57, suggesting that the Bim deficiency related increase in Ox-
LDL specific auto-antibodies are atheroprotective. Although Bim-/- bone marrow 
derived macrophages were less sensitive to cell death after culturing and growth 
factor withdrawal as well as after stimulation with oxidized LDL, lesion apoptotic 
cell content was not altered in leukocyte Bim deficient LDLr-/- mice. Since apoptotic 
cells in spleen were clearly elevated, the observed lack of effect on apoptosis in 
lesions may be a result of increased resistance of plaque macrophages against 
Bim deficiency associated cell death or of the low T cell content in atherosclerotic 
lesions. Despite these profound effects on lymphocyte homeostasis, inflammatory 
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status and unexpectedly, the reduction in lipid serum levels, atherosclerotic lesion 
burden and stability in both aortic root and descending aorta was unchanged in 
Bim-/- BM transplanted LDLr-/- mice. We hypothesize that the observed pro- and 
anti-atherogenic effects of Bim deletion on inflammatory response, together with 
decreased lipid levels counterbalance, resulting in unaltered atherogenesis. Possibly 
cell-type specific modulation of Bim expression will clarify the contribution of Bim 
functioning in specific cells to atherogenesis.  
Bim activity is in part regulated by the Bcl-2 family member myeloid cell leukemia 
1 (Mcl-1) which directly interacts with Bim, Bid, another pro-apoptotic BH3-only 
protein, and multidomain pro-apoptotic Bak39-41, to inhibit apoptosis. Mcl-1 plays an 
important role in promoting survival and differentiation of leukocyte subsets58,59 being 
essential for neutrophil survival60. In chapter 5 we investigated the consequences 
of modulating macrophage apoptosis on atherosclerotic plaque development and 
stability by deleting Mcl-1 in lysozyme M (lysM) expressing, myeloid cells. Lethally 
irradiated LDLr-/- mice were transplanted with Mcl-1fl/fl LysMcre or wildtype bone 
marrow, followed by Western-type diet feeding to induce atherosclerotic lesion 
development. 
We show that Mcl-1 participates in Ox-LDL induced cell death, and regulates gene 
expression of other apoptosis regulating Bcl-2 family members Bim, PUMA and 
NOXA after Ox-LDL exposure. In atherosclerotic aortic root lesions of Mcl-1-/- bone 
marrow transplanted mice apoptotic cell content was elevated by 77% compared 
to WT controls. However, atherosclerotic plaque size did not differ between Mcl-1-
/- and WT bone marrow recipients as a result of additional effects of myeloid Mcl-
1 deficiency. Mcl-1-/- macrophages exhibited increased lipid uptake and increased 
peritoneal foam cell counts, marked neutropenia and altered neutrophil phenotype 
in Mcl-1-/- bone marrow transplanted mice. Mcl-1fl/fl LysMcre transplanted mice not 
only carry an Mcl-1 deletion in macrophages but also in neutrophils61. In keeping 
with the notion that Mcl-1 is essential for neutrophil survival, neutrophil levels in 
circulation and lesions were sharply decreased in Mcl-1-/- bone marrow transplanted 
mice. The remaining neutrophils, that escaped Cre mediated deletion, displayed a 
decreased response to chemoattractant KC, partly due to reduced responsiveness 
and partly a result of the substantially reduced neutrophil pool Furthermore, 
CXCR4 expressing neutrophil levels in Mcl-1-/- BM transplanted mice were increased 
compared to WT BM recipients, indicative of increased release of neutrophils from 
stroma. 
Finally, myeloid Mcl-1 deficiency resulted in alteration of the inflammatory properties 
of LDLr-/- mice. Isolated peritoneal macrophages from Mcl-1-/- BM recipients contained 
a high amount of multinucleated giant cells as compared to WT macrophages, 
suggestive of an altered apoptotic response and macrophage polarization. Another 
indication for an elevated inflammatory status of Mcl-1-/- BM transplanted mice was 
found in the apparent shift towards a pro-inflammatory M1 macrophage phenotype 
as judged from their cytokine expression patterns and reduced capacity for apoptotic 
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cell clearance. Thus analogous to leukocyte Bim deletion, myeloid Mcl-1 deletion 
in LDLr-/- mice results in several cell death and inflammation related effects but, 
surprisingly, without affecting atherosclerotic plaque size or stability, emphasizing 
the importance of pro-atherosclerotic neutrophil recruitment into plaques. 
In chapter 6 we studied the atherogenic role of focal adhesion kinase (FAK), a kinase 
not only involved in cell death and proliferation, but also in adhesion and migration 
of various cell types62. Plaque initiation starts with adhesion of leukocytes to the 
luminal endothelial cell layer followed by migration into the subendothelial space63. 
After initial tethering and rolling of circulating leukocytes, mediated by selectins, 
adhesion involves the engagement of β-integrins which interact with ICAM-1 and 
VCAM-164,65. FAK is activated by (auto)phosphorylation upon integrin binding, 
resulting in increased turnover of focal adhesions thereby stimulating migration66. 
We generated ApoE-/- mice with heterozygous FAK expression, since FAK deletion is 
embryonically lethal67. Atherosclerosis was induced by Western type diet feeding. 
Reduced FAK levels resulted in an increased inflammatory status in ApoE-/- mice as 
witnessed by splenomegaly and enlarged splenic germinal centers. Furthermore, 
leukocyte composition in spleen, peritoneal cavity and circulation was affected by 
FAK reduction. Macrophage content in spleen was found to be decreased, whereas 
that of lymphocytes was increased. In contrast, peritoneal cavity and circulation 
showed increased monocyte numbers accompanied by reduced CD4+ and CD8+ T 
cell content. These differential leukocyte composition was likely caused by impaired 
monocyte ingress from circulation to spleen even despite enhanced blood monocyte 
counts and enhanced retention of lymphocytes in spleen. FAK+/-ApoE-/- mice had 
significantly lower plasma total cholesterol levels, which was shown to be specifically 
evident upon a Western-type diet and attributable to a decreased hepatic VLDL 
production rather than to an altered intestinal cholesterol absorption. Hepatic lipid 
content was unchanged in FAK+/-ApoE-/- mice. However, hepatic expression of critical 
genes in lipogenesis, SREBP1 and 2, SCD1 and FAS, was increased in FAK+/-ApoE-
/- mice in addition to a slight increase in CD36 expression. OxLDL mediated CD36 
signaling was shown to inhibit macrophage migration and stimulate cell spreading 
by continued FAK phosphorylation and activation68, suggesting a role for FAK in 
trapping macrophages in the arterial wall and promoting atherogenesis.
Surprisingly, despite these marked effects on immune status, impaired FAK 
expression neither affected size and composition of semi-constrictive perivascular 
collar induced carotid artery plaques nor that of spontaneous brachiocephalic 
artery and aortic root plaques. We therefore assessed atherosclerotic lesion size 
in chow fed ApoE-/- mice with reduced FAK expression in order to eliminate the 
impact of reduced lipid levels on atherosclerosis development. However, also here 
atherosclerotic lesion size of FAK+/+ and FAK+/- mice was essentially comparable. 
Thus, FAK reduction beneficially affects lipid metabolism in Western type diet fed 
ApoE-/- mice and alters their inflammatory status without resulting in an altered 
atherogenic response.
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In chapter 6 we show that systemic reduction of FAK activity alters various 
inflammatory parameters. In addition we are the first to show an unexpected effect 
of FAK on hepatic lipid metabolism in mice. The results obtained from the studies 
described in chapter 4 and 5 provide new insights on the role of apoptosis regulating 
Bcl-2 family members in atherosclerosis. We show that both pro-apoptotic Bim 
and anti-apoptotic Mcl-1 have several functions during atherogenesis including 
intraplaque cell death, foam cell formation and lipid metabolism. Moreover, 
modulation of Bim and Mcl-1 expression resulted in major effects on inflammatory 
processes. Apoptosis, and in particular that mediated by Bcl-2 family members, 
is essential in homeostasis and functioning of the immune system69. Deletion of 
autoreactive T and B cells, termination of the immune response and survival of 
activated T and B cells are all regulated by Bcl-2 family member and death receptor 
dependent apoptosis. Dysregulated apoptosis of immune cells may result in 
various pathological conditions including immunodeficiency, autoimmunity, tumor 
growth and infection69. The Bim and Mcl-1 associated modulation of inflammatory 
parameters  observed in our studies correspond with the previously reported role 
of these proteins in immune system homeostasis. We further show that both Bim 
and Mcl-1 regulate specific cell death and inflammatory processes relevant to 
atherosclerosis. However, the key role in systemic immunity and the multifaceted 
mode of action of these proteins involving apoptotic, phagocytic and inflammatory 
processes and lipid metabolism should be taken into account when considering 
therapeutic approaches targeting these apoptosis regulating proteins. In the 
studies described in chapter 4 and 5 we specifically deleted Bcl-2 family proteins in 
total hematopoietic (Bim) or myeloid cells (Mcl-1), whereas in the study described 
in chapter 6 FAK expression was reduced at a systemic level. Local modulation 
of gene expression, for example by targeted gene or drug delivery, or in the case 
of FAK, cell type specific modulation, might be a valuable approach to restrict 
therapeutic effects to the atherosclerotic lesions without affecting the systemic 
immune response. In particular, local intervention in Mcl-1 signaling, to prevent 
pathological consequences of altered systemic immunity, to modify macrophage 
lipid accumulation and plaque apoptosis could potentially be a valuable approach to 
modulate atherogenesis. Further studies are necessary to confirm this hypothesis. 
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Hart- en vaatziekten, zoals hartinfarct of beroerte, hebben meestal atherosclerose, 
ook wel aderverkalking genoemd, als oorzaak. Atherosclerose is een vaak 
progressieve verdikking van de vaatwand in grote en middelgrote slagaders, 
waarvan het ontstaan een proces is dat tientallen jaren in beslag neemt en dat vaak 
al begint in de tienerjaren. De belangrijkste risicofactoren voor de ontwikkeling 
van atherosclerose zijn een vet-rijk dieet, roken, gebrek aan lichaamsbeweging en 
hoge bloeddruk, geslacht en leeftijd. Daarnaast is er een erfelijke component die de 
ontwikkeling van atherosclerose kan beïnvloeden. 
Bij het onstaan van atherosclerose spelen zowel de ophoping van vetten in de 
wand van het bloedvat als het immuunsysteem een belangrijke rol. Een gezonde 
vaatwand bestaat uit endotheelcellen die een gladde spiercellaag bedekken. In 
het eerste stadium van plaque ontwikkeling raakt het endotheel lokaal geirriteerd 
door de chronische blootstelling aan cholesterol in het bloed en hoge bloeddruk, 
en  vindt lekkage door de vaatwand en ophoping van lipidemateriaal zoals 
cholesterol in de vaatwand plaats als gevolg waarvan endotheelcellen geactiveerd 
kunnen raken. Deze brengen vervolgens verschillende eiwitten tot expressie 
die de rekrutering van ontstekingscellen zoals monocyten en T cellen naar de 
vaatwand kunnen bevorderen. In de vaatwand differentieren de monocyten tot 
macrofagen die de opgehoopte lipiden kunnen opnemen leidend tot de vorming 
van zogenaamde schuimcellen. Wanneer de plaque zich verder ontwikkelt 
migreren gladde spiercellen vanuit de vaatwand naar de plaque en vormen een 
beschermend kapsel. In verder gevorderde stadia van atherosclerose heeft de 
plaque zich ontwikkeld tot een forse verdikking met een kern van vetmateriaal, 
schuimcellen en dood celmateriaal. Naarmate het ziekteproces vordert kunnen 
deze groter wordende plaques het bloedvat vernauwen of zelfs afsluiten waardoor 
de bloedtoevoer naar stroomafwaarts gelegen weefsel beperkt wordt. Daarnaast 
134
Nederlandse	samenvatting
kan een atherosclerotische plaque scheuren waarbij plaquemateriaal vrijkomt in 
de bloedbaan waardoor een omvangrijke ontstekingsreactie en vorming van een 
bloedstolsel kan ontstaan. Dit laatste proces kan gepaard gaan met de klinische 
symptomen als een hart- of herseninfarct. 
Behandeling van hart- en vaatziekten is gericht op het verminderen van risicofactoren, 
zoals een verhoogd cholesterolgehalte in het bloed (statines), en chirurgische 
ingrepen zoals dotteren. In een groot aantal patienten hebben deze interventies 
helaas onvoldoende effect en dit legitimeert verder onderzoek naar de ontwikkeling 
van nieuwe, effectievere behandelmethoden. De in dit proefschrift beschreven 
studies zijn uitgevoerd met als uiteindelijke doel om nieuwe aangrijpingspunten 
voor een effectievere therapie te identificeren.
De studies beschreven in dit proefschrift hebben voornamelijk betrekking op 
apoptose oftewel geprogrammeerde celdood. Wanneer een cel stress ondervindt 
als gevolg van bijvoorbeeld DNA schade, infectie door een pathogeen, of binding 
van bepaalde eiwitten aan de cel en reparatie van de schade niet meer haalbaar lijkt 
zal er een programma in werking treden met als uiteindelijke uitkomst celdood. Dit 
proces wordt apoptose genoemd. Apoptose leidt tot afbraak van de cel en opname 
van het restmateriaal door naburige cellen zonder dat de inhoud van de cel vrijkomt. 
In dit laatste aspect onderscheidt apoptose zich van een andere vorm van celdood, 
necrose genoemd, dat een veel willekeuriger verloop heeft en waarbij de celinhoud 
wel vrijkomt, wat een reactie van het immuunsysteem in gang kan zetten. 
Aangetoond is dat alle cellen in de atherosclerotische plaque apoptose kunnen 
ondergaan en dat apoptose toeneemt naarmate een plaque verder ontwikkelt. 
De gevolgen van apoptose voor de ontwikkeling van een plaque hangen af van 
het celtype en het stadium van de plaque. Algemeen wordt aangenomen dat 
apoptose van gladde spiercellen in het kapsel dat de plaque bedekt schadelijk is 
omdat deze daardoor zwakker wordt en de plaque kan gaan scheuren. Apoptose 
van macrofagen in vroege stadia van atherosclerose remt de plaqueontwikkeling 
doordat macrofagen en schuimcellen vroegtijdig worden afgebroken. In late stadia 
wordt macrofaag apoptose echter vaak als pro-atherosclerotisch gezien. Opname 
van apoptotische macrofagen door naburig cellen via een proces dat fagocytose 
wordt genoemd, is dan onvoldoende waardoor de cel necrose ondergaat en de 
celinhoud alsnog vrijkomt. De daarop volgende immuunreactie kan bijdragen aan 
plaque-ontsteking.
Omdat hart- en vaatziekten vaak het gevolg zijn van scheuren van een 
atherosclerotische plaque hebben wij in hoofdstuk 3 genen geidentificeerd, die 
mogelijk betrokken zijn bij de overgang van stabiele plaques naar meer kwetsbare 
plaques. Hierbij hebben we gebruik gemaakt van de zogenaamde micro-array 
techniek, waarbij de mate van aanwezigheid (de expressie) van een grote hoeveelheid 
genen in één meting kan worden bepaald, en van twee muismodellen voor stabiele 
en meer kwetsbare plaques. In onze studie is de expressie van 22.000 genen 
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gemeten. Apolipoproteine E (ApoE) deficiënte muizen, die spontaan atherosclerose 
ontwikkelen, werden na een aantal weken van vetrijk dieet langs operatieve weg 
voorzien van een licht constrictief bandje rond de halsslagaders. Na de vorming van 
de atheroslerotische plaques in de halsslagader is p53 tot overexpressie gebracht in 
het kapsel van de plaque. Dit eiwit induceert apoptose van de gladde spiercellen in 
het kapsel, als gevolg waarvan deze laag zwakker wordt en de kwetsbaarheid van de 
plaque toeneemt. Als controle werd het enzyme beta-galactosidase gebruikt, dat 
geen invloed op de plaque heeft maar goed detecteerbaar is. Het tweede model 
voor kwetsbare plaques is de arteria	bracchiocephalica. Atherosclerotische plaques 
die zich in deze slagader vormen in ApoE deficiënte muizen na een 9 weken durend 
vetrijk dieet hebben van nature een extra dun kapsel en zijn daarmee extra gevoelig 
voor ruptuur. Als controle hiervoor werden stabiele plaques die zich iets verder 
stroomafwaarts in de halsslagader vormen gebruikt. 
Wanneer per model de genexpressie in voor ruptuur gevoelige of kwetsbare plaques, 
(ook wel ThCFA voor thin cap fibro-atheroma genoemd) en meer stabiele plaques 
(TkCFA voor thick cap fibro-atheroma genoemd) wordt vergeleken kan worden 
bepaald welke genen anders gereguleerd zijn in de meer kwetsbare plaques. Deze 
analyse liet zien dat 57 en 58 genen een verhoogde expressie en 87 en 66 genen een 
verlaagde expressie hadden in de twee respectievelijke modellen voor kwetsbare 
plaque vorming ten opzichte van hun stabiele tegenhangers. Van deze genen hebben 
5 een verhoogde expressie in beide modellen en 10 een verlaagde expressie in beide 
modellen. Van de vijf genen met verhoogde expressie in kwetsbare plaques bleken 
er drie een functie te hebben in de regulering van apoptose, nl. Cd5l,	Plagl1	en Bim. 
Vervolgens hebben we gekeken of er nog andere processen waren waarin meerdere 
betrokken genen verhoogd of verlaagd waren in de meer kwetsbare plaque. Hieruit 
bleek dat verschillende processen zoals vetstofwisseling, celgroei en -proliferatie 
en cel-cel communicatie significant beïnvloed waren in de meer kwetsbare plaque. 
Het proces dat in de kwetsbare plaque het meest verschilde van de meer stabiele 
plaque bleek celdood te zijn. 
Verder hebben we in hoofdstuk 3 een ander gen met toegenomen expressie 
aangetoond, nl. het neuropeptide Y (Npy), dat ook in weefsel verkregen uit humane 
plaques een verhoogde productie bleek te hebben in kwetsbare vergeleken 
met stabiele plaques. Npy is een eiwit dat voornamelijk een functie heeft als 
neurotransmitter in het zenuwstelsel. Daarnaast is in diermodellen aangetoond 
dat Npy zowel een schadelijke als een beschermende werking kan hebben in het 
ontstaan van atherosclerose. 
Met deze studie hebben we aangetoond dat in de diverse modellen voor kwetsbare 
plaquevorming een aantal genen waarvan de productie verhoogd of verlaagd 
is in vergelijking met de meer stabiele plaque en die mogelijk bijdragen tot de 
vorming van kwetsbare plaques gemeenschappelijk zijn. Daarnaast hebben wij Npy 
geidentificeerd als mogelijke indicator voor een toegenomen kwetsbaarheid van 
atherosclerotische plaques.
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Na de identificatie van processen en genen die karakteristiek zijn voor de ruptuur-
gevoelige plaque hebben we in de daaropvolgende hoofdstukken de functionele 
rol van enkele bij celdood betrokken eiwitten in de ontwikkeling van atherosclerose 
onderzocht met behulp van dierexperimenteel onderzoek in muismodellen.
In hoofdstuk 4 is het effect van Bim onderzocht, een pro-apoptotisch eiwit en lid 
van de Bcl-2 familie van apoptose regulerende eiwitten, waarvan in hoofdstuk 3 al 
was aangetoond dat het verhoogd aanwezig is in de kwetsbare plaque. 
Eerder is aangetoond dat Bim cruciaal is voor een goede werking van het 
immuunsysteem doordat het mede verantwoordelijk is voor de eliminatie van 
ongewenste T en B cel klonen. In hoofdstuk 3 werden muizen met een defecte LDL 
(lage dichtheids lipoproteine) receptor (LDLr-/-), en die als gevolg daarvan spontaan 
atherosclerose ontwikkelen, bestraald om uit beenmerg afkomstige cellen te 
depleteren. Hierna werd het beenmerg gerepopuleerd door injectie van beenmerg 
uit Bim deficiënte (Bim-/-) of controle donormuizen. Na een herstelperiode van 
acht weken werd de muizen een vetrijk dieet gegeven om de ontwikkeling van 
atherosclerotische plaques te initieren. De LDLr-/- muizen waarin Bim ontbrak in 
de witte bloedcellen bleken een vergrote milt en niet alleen verhoogde aantallen 
maar ook meer geactiveerde T cellen in bloed en lymfeknopen te hebben, hetgeen 
wijst op een verhoogde ontstekingsgraad van deze muizen. Daarnaast bleken ook 
de atherosclerotische plaques van muizen waarin Bim ontbrak in witte bloedcellen 
verhoogde aantallen T cellen te bevatten. Bim zorgt, naast het induceren van 
apoptose in T cellen, ook voor eliminatie van B cellen. Deze B cellen kunnen 
antilichamen of antistoffen produceren die lichaamsvreemde stoffen kunnen 
herkennen om vervolgens andere cellen van het immuunsysteem te stimuleren 
deze stoffen of cellen af te breken. Indien B cellen antilichamen maken tegen 
lichaamseigen stoffen wordt gesproken van auto-immuniteit. Recent onderzoek 
heeft een verhoogde spiegel van antilichamen tegen lichaamseigen stoffen laten 
zien in het bloed van muizen en patienten met hart- en vaatziekten, hetgeen 
suggereert dat atherosclerose deels een auto-immuunziekte is. In onze Bim studie 
zagen we dat het aantal antilichamen in het bloed dat geoxideerd LDL herkent 
aanmerkelijk verhoogd was in muizen waarin Bim ontbrak in witte bloedcellen. 
Van deze antilichamen is aangetoond dat ze een beschermende werking hebben 
in atherosclerose. Verder analyseerden we dat het totaal aantal antilichamen in de 
atherosclerotische plaques in deze muizen sterk was toegenomen. Zoals verwacht 
waren Bim deficiënte macrofagen minder gevoelig voor apoptose dan controle 
macrofagen. Als eerste hebben we nu ook laten zien dat stimulatie van macrofagen 
met geoxideerd LDL, dat in hoge concentraties celdood kan induceren, resulteert in 
minder apoptose in deze macrofagen. 
Ondanks de bovenbeschreven effecten bleken de atherosclerotische plaques in 
Bim deficiënte muizen vergelijkbaar met die in controle muizen wat betreft grootte 
en stabiliteit. Mogelijk is dit het gevolg van het grote aantal verschillende effecten 
veroorzaakt door Bim deficiëntie die elkaar opheffen.
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Mcl-1 behoort, net als Bim, tot de Bcl-2 familie, maar heeft in tegenstelling tot Bim 
een celdood remmende werking. Mcl-1 gaat een interactie aan met pro-apoptotische 
eiwitten, waaronder Bim, waardoor hun apoptose bevorderende werking geremd 
wordt. In hoofdstuk 5 hebben we een vergelijkbare strategie gevolgd als voor Bim, 
om het effect van Mcl-1 deficiëntie op de ontwikkeling van plaques te bestuderen. 
Omdat Mcl-1 vooral een belangrijke rol speelt in de regulatie van apoptose in 
macrofagen en neutrofielen, beide immuuncellen die celresten, bacterien en 
dergelijke kunnen opnemen, hebben we in deze studie gebruik gemaakt van muizen 
waarin Mcl-1 specifiek ontbreekt in deze celtypen. 
Mcl-1 deficiënte macrofagen waren gevoeliger voor de celdood die optreedt na 
incubatie met geoxideerd LDL. Daarnaast bleek de opname van vetmateriaal door 
en de daaropvolgende vorming van schuimcellen uit macrofagen na incubatie 
met geoxideerd LDL of VLDL, sterk verhoogd. In overeenstemming hiermee bleek 
ook het aantal macrofaag afgeleide schuimcellen toegenomen in Mcl-1 deficiënte 
vergeleken met controle muizen. Daarnaast bleek ook dat Mcl-1 deficiënte 
macrofagen meer ontstekingsbevorderend zijn dan controle macrofagen. Ten slotte 
bleek zowel in vroege als in meer geavanceerde atherosclerotische plaques het 
aantal apoptotische cellen verhoogd in Mcl-1 deficiënte muizen. 
Ondanks deze atherosclerose bevorderende effecten van macrofaag Mcl-1 
deficiëntie was de plaquegrootte in Mcl-1 deficiënte en controle muizen in beide 
stadia vergelijkbaar. Dit is mogelijk te wijten aan de sterke afname in het aantal 
neutrofielen, zowel in bloed als in de plaque, en het door ons waargenomen 
veranderde migratiepatroon van dit celtype. Van neutrofielen is aangetoond dat ze 
bijdragen aan de ontwikkeling van atherosclerose, dus door de verlaagde aantallen 
neutrofielen in deze studie is waarschijnlijk die ontwikkeling geremd. 
In hoofdstuk 6 is ten slotte de rol van FAK, een eiwit dat de adhesie en migratie van 
cellen reguleert en daarnaast celdood beïnvloedt, in atherosclerose bestudeerd. 
Adhesie en hechting van cellen aan andere cellen of de vaatwand, en inbedding 
van deze cellen in de weefselmatrix zijn essentiele processen bij het ontstaan van 
plaques. FAK reguleert deze sleutelprocessen in alle in de plaque aanwezige cellen, 
waaronder macrofagen, gladde spiercellen, endotheelcellen en T cellen. Daarom 
is het aannemelijk dat FAK een belangrijke factor is in plaque-ontwikkeling. Een 
volledige verlies van FAK functie is helaas lethaal en daarom  hebben we voor deze 
studie transgene muizen die heterozygoot waren voor FAK (FAK+/-) gebruikt en 
deze gekruist met ApoE deficiënte (ApoE-/-) muizen, die spontaan atherosclerose 
ontwikkelen. Op deze manier werden ApoE deficiënte muizen met verminderde FAK 
functie verkregen. Tot onze verrassing hadden FAK+/-ApoE-/- muizen een verlaagd 
cholesterolniveau in het bloed. Dit werd veroorzaakt door een verminderde 
productie van VLDL deeltjes in de lever. In ApoE-/- deficiënte muizen is cholesterol 
voornamelijk verbonden met VLDL dat in de lever wordt gemaakt en uitgescheiden 
in het bloed. De verlaagde VLDL productie was waarschijnlijk het gevolg van de 
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verminderde expressie van een aantal sleutelgenen in de VLDL productie in de 
lever.
Daarnaast leidde vermindering van FAK tot een veranderde inflammatoire status in 
ApoE deficiënte muizen. Zo was de milt vergroot en bevatte het minder macrofagen 
maar meer T cellen, terwijl in bloed en in de buikholte meer macrofagen en minder 
T cellen aanwezig waren. Deze verschillen werden waarschijnlijk veroorzaakt door 
een verstoorde migratie van monocyten/macrofagen vanuit het bloed naar de milt 
en een verhoogde retentie van T cellen in de milt. 
Ook in deze studie leidt de optelsom van pro- (ontstekings-bevorderend effect) 
en anti-atherogene (verlaagde cholesterol) effecten van verminderde FAK functie 
tot een gelijkblijvende grootte en samenstelling van atherosclerotische plaques in 
verschillende vaten.
Samenvattend kan gesteld worden dat de studies beschreven in dit proefschrift 
laten zien dat celdood-regulerende genen mogelijk bijdragen tot de overgang van 
stabiele naar meer kwetsbare plaques (hoofdstuk 3) en dat uitschakeling van enkele 
van sleutelgenen in de regulatie van apoptose, Bim en Mcl-1, diverse effecten heeft 
op vetmetabolisme en ontsteking (hoofdstuk 4 en 5). Verder blijkt uit hoofdstuk 
6 dat FAK aan de ene kant betrokken is bij VLDL productie in de lever en daaraan 
gerelateerd het cholesterolniveau in het bloed, en aan de andere kant de migratie 
en adhesie van immuuncellen beïnvloedt in ApoE deficiënte muizen. Wanneer 
dus wordt overwogen de hier bestudeerde genen te moduleren zal een celtype 
specifieke of plaque-gerichte aanpak moeten worden gebruikt om gewenste 
effecten te isoleren van ongewenste effecten. Lokale beïnvloeding van de werking 
van bijvoorbeeld Mcl-1 zou bijvoorbeeld de lipide-ophoping in en apoptose van 
macrofagen in de plaque gunstig kunnen beinvoeden hetgeen de ontwikkeling 
van atherosclerose zou kunnen afremmen. Via deze aanpak worden systemische 
effecten op onder andere neutrofielen vermeden. Om deze inzichten te bevestigen 
zullen aanvullende studies nodig zijn.
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Abbreviations
36B4 Acidic ribosomal phosphoprotein P0
ACC Carotid artery
Ad Adenoviral
AIF Apoptosis inducing factor
AIM Apoptosis inhibitor expressed by macrophages
APAF Apoptotic protease-activating factor
ApoE Apolipoprotein E 
Arg1 Arginase 1
ASMA α-smooth muscle actin
Bad Bcl-2-associated agonist of cell death
Bak Bcl-2 antagonist/killer
Bax Bcl-2 associated X protein
BCA Brachiocephalic artery
Bcl-2 B cell lymphoma 2
Bfl-1 Bcl-2-related gene expressed in fetal liver 1
BH Bcl-2 homology
Bid BH3 interacting domain death agonist
Bik Bcl-2 interacting killer
Bim Bcl-2 like interacting mediator of cell death
Blk Bik-like killer protein
BM Bone marrow 
Bmf Bcl-2 modifying factor
BMT Bone marrow transplantation
BMDM Bone marrow derived macrophages
CCR CC chemokine receptor
CD Cluster of differentiation
CMV Cytomegalovirus
Ct Threshold cycle
CXCR CXC chemokine receptor
DC Dendritic cell
DD Death domain
DFF DNA fragmentation factor
DISC Death inducing signaling complex
DMEM Dulbecco’s Modified Eagle Medium
DR Death receptor
DT(R) Dyphtheria toxin (receptor)
EC Endothelial cell
EDTA Ethylene diamine tetra-acetic acid
ELISA Enzyme-linked immunosorbent assay
eNOS Endothelial nitric oxide synthase
ESAM Endothelial cell-selective adhesion molecule
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Fabp Fatty acid binding protein
FACS Fluorescence activated cell sorting
FADD Fas-associated death domain
FAK Focal adhesion kinase 
FAS Fatty acid synthase
FCS Fetal calf serum
FGF Fibroblast growth factor
FRNK FAK related non kinase
GC Group specific component
GM-CSF Granulocyte-macrophage colony stimulating factor
GTC Guanidine thiocyanate
HE Hematoxylin and eosin
HGF Hepatocyt growth factor
HPRT Hypoxanthine-guanine phosphoribosyltransferase
Hrk Harakiri, Bcl-2 interacting protein
HSP Heat shock protein
ICAM Intracellular adhesion molecule
IFN Interferon
Ig Immunoglobulin
IGF-1 Insulin-like growth factor
IL Interleukin
IL1-RA Interleukin 1 receptor antagonist
IMDM Iscove’s Modified Dulbecco’s Medium
iNOS Inducible nitric oxide synthase
LDL(r) Low density lipoprotein (receptor)
LO Lipoxygenase
LOX-1 Lectin-like oxidized low density lipoprotein receptor
LPS Lipopolysaccharide
MARCO Macrophage receptor with a collagenous structure
Mcl-1 Myeloid cell leukemia 1
MCP-1 Monocyte chemoattractant protein 1
M-CSF Macrophage colony stimulating factor
Mfge8 Milk fat globule epidermal growth factor 8
MHC Major Histocompatibility complex
MIF Macrophage migration inhibitory factor
MLN Mediastinal lymph node
MMP Matrix metalloproteinases
Moma-2 Monocyte/macrophage antibody 2
Mup Major urinary protein
NF-κB Nuclear factor κB
NK Natural killer
NO Nitric oxide
Npy Neuropeptide y
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n.s. Non significant
Ox-LDL Oxidized LDL
PAF Platelet activating factor
PBS Phosphate buffered saline
PCR Polymerase chain reaction
PDGF Platelet derived growth factor
PECAM Platelet/endothelial-cell adhesion molecule
PGE2 Prostaglandin E2
Plagl1 Pleiomorphic adenoma gene-like-1
PTCA Percutaneous transluminal coronary angioplasty
Puma P53-up-regulated modulator of apoptosis
RAG Recombination activating gene
ROS Reactive oxygen species
RT-PCR Reverse transcriptase PCR
SCD1 Stearoyl-coenzyme A desaturase 1
SDF-1 Stromal cell derived factor 1
SEM Standard error of the mean
SRA Scavenger receptor 1
SREBP Sterol regulatory element-binding protein
SR-PSOX Scavenger receptor that binds phosphatidylserine and oxidized 
lipoprotein
TC Total cholesterol
TG Triglyceride
TG2 Transglutaminase 2
TGFβ Transforming growth factor β
Th T helper
TNF(R) Tumor necrosis factor (receptor)
TRAIL TNF related apoptosis inducing ligand
TUNEL Terminal deoxytransferase dUTP nick-end labeling
TWEAK TNF-like weak inducer of apoptosis
VCAM Vascular cell adhesion molecule
VEGF Vascular endothelial growth factor
VLA-4 Very late activation antigen 4
VLDL Very low-density lipoprotein
vSMC Vascular smooth muscle cells
WBC White blood cells
WT Wild-type
WTD Western type diet
XAF1 X-linked inhibitor of apoptosis associated factor-1
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